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Summary 
 
The animal pathogenic protozoan, Trypanosoma evansi, leads to a wasting disease in 
equines, cattle and camels, commonly known as Surra. It is extensively distributed 
geographically with a wide range of mammalian hosts and causes great economical loss, 
especially in areas of Africa, Asia and South America. Transmitted mechanically by biting 
flies (tabanids), the most effective form of control for this disease appears to be chemotherapy 
and treatment is currently based on four main drugs: suramin, diminazene aceturate, 
quinapyramine and cymelarsan. However, due to emerging resistance to these drugs, their 
toxicity and a sparse drug repertoire, their effective use is severely threatened, emphasising 
the urgent necessity in finding new alternative drugs. 
Diamidines are dicationic molecules, which bind to the minor groove of DNA at AT-
rich sites and then either inhibit one or more DNA dependent enzymes, or directly impede the 
transcription process. It has been known since the 1940s that these molecules contain anti-
protozoal properties. The diamidine drug, pentamidine, is currently used to treat Pneumocystis 
carinii pneumonia, leishmaniasis and the early stage of African trypanosomiasis. Yet 
pentamidine is impeded by its toxicity, its inability to be absorbed orally and a limited 
understanding of its mode of action. New diamidine compounds were recently synthesised, 
revealing excellent in vitro and in vivo activity against human African trypanosomiasis. 
The overall aim of this project was to explore the possibility of finding new 
diamidines with considerable activity against Trypanosoma evansi and to identify any novel 
diamidine compounds, which possess the potential to act as clinical candidates against this 
infection. Investigations carried out in this thesis using Trypanosoma evansi demonstrated 
outstanding in vitro activities for 181 diamidines, with IC50 values below 30 ng/ml. These 
compounds were further examined within an in vivo mouse model to determine the lowest 
curative dose and to ascertain preliminary toxicity values of the most active diamidines. A 
total of 49 compounds were examined for their in vivo efficacy, of which six were capable of 
curing Trypanosoma evansi infected mice at 0.5 mg/kg doses, given over four consecutive 
days. Additionally, a series of Trypanosoma evansi strains, isolated from various geographical 
locations, were also tested, to establish the effective sensitivity of such chemicals to different 
strains. 
Based on these in vitro and in vivo findings, three novel diamidines (DB 75, DB 867 
and DB 1192) were selected and tested for preliminary acute toxicity within a goat model. 
Several toxicity trials were performed, whereby a single, 4mg/kg dose of each compound was 
 IX
given to goats and a multiple dose was given as four 1 mg/kg drug applications over six 
hours. All drug injections were given to the goats via an intramuscular route of application. 
As well as collecting pharmacokinetic data related to the toxicity trials, the goats were 
additionally observed for any signs of acute toxicity, of which none were seen at a total dose 
of 4 mg/kg for any of the compounds tested. Thereafter, tissue and organ samples were 
collected from each goat and prepared for histological examination.  
Having concluded that DB 75, DB 867 and DB 1192 were considered safe in goats, 
they were furthermore investigated within an experimentally infected Trypanosoma evansi 
goat model. The efficacy of these compounds was examined at doses of 2.5 mg/kg and 1.25 
mg/kg. Diminazene was included as a positive control drug and was given as 5 mg/kg. After 
treatment of the infected goats, a five month follow up study was conducted to determine the 
curative potential of the compounds used. Curative efficacy was assessed using three types of 
detection tests; a parasitological test (Haematocrit Centrifugation Technique), a serological 
test (CATT / T. evansi) and a molecular based test (PCR / T. evansi). At the end of the follow 
up efficacy trial, it was seen that DB 75 was able to effectively cure infected goats at a quarter 
of the dose (1.25 mg/kg) used by the positive control drug (Diminazene) and that DB 867 
could cure infected goats at half the dose (2.5 mg/kg) used by that of diminazene. The third 
compound, DB 1192 was not able to treat goats at either the high or low doses tested and the 
infected goats relapsed, just two weeks post treatment.  
Moreover, pharmacokinetic data was gathered from the efficacy study and the plasma 
samples collected were analysed using HPLC/MS-MS techniques, to determine the drug 
concentrations present in the goats over several time points. This enabled distinct 
pharmacokinetic profiles to be produced, revealing a clearer comprehension as to why DB 
1192 failed to treat the experimentally infected goats. Drug concentrations obtained in plasma 
samples for DB 75 and DB 867 were found to be well within the therapeutic range. Several 
pharmacokinetic parameters were calculated to provide a better understanding of diamidines 
within goats. Furthermore, the long half lives of DB 75 and DB 867 may indicate drug 
accumulation within tissues, whilst the kinetoplast, nucleus and acidocalcisomes were 
identified as structures within trypanosomes where these diamidines accumulate, based on 
preliminary fluorescent experiments.  
In conclusion, two novel diamidine compounds (DB 75 and DB 867) have been 
identified as potential clinical candidates against Trypanosoma evansi infection. 
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Chapter 1: General Introduction 
General Introduction 
 
Trypanosomes 
 
Within the order Kinetoplastida (family Trypanosomatidae), belong trypanosomes, 
haemoflagellated protozoan parasites characterised by one nucleus and one flagellum, either 
free or attached to the parasites body by means of an undulating membrane. They also usually 
contain a small, compact kinetoplast, a disc-shaped, DNA-containing organelle, situated 
within a large mitochondrion (Brun et al., 1998). Kinetoplast DNA is arranged into a network 
of linked circles, grouped into minicircles and maxicircles. Within the kinetoplast network, 
there are around 20’000 minicircles and 20-50 maxicircles.  
A certain collection of salivarian trypanosomes can be further classified into the 
Trypanozoon group (Figure 1.1). Within this subgenus, there are three major trypanosome 
species; Trypanosoma brucei, T. equiperdum and T. evansi.  
 
Figure 1.1. Taxonomic classification of the Trypanozoon group of salivarian trypanosomes. 
 
Trypanozoon 
 
T. brucei 
 
T. equiperdum 
 
T. evansi 
 
T. b. rhodesiense 
 
T. b. gambiense 
 
T. b. brucei 
 
T. brucei can be additionally divided into three subspecies, of which T. brucei 
rhodesiense and T. b. gambiense are the causative agents of the respective, acute form (found 
in Eastern Africa) and the chronic form (found in Western and Central Africa) of the 
debilitating sleeping sickness disease, Human African Trypanosomiasis (HAT). T. b. brucei is 
not human pathogenic and together with T. congolense (belonging to the subgenus, 
Nannomonas) and T. vivax (belonging to the Duttonella subgenus, which is also found in 
South America), is associated with trypanosomiasis within domestic animals and livestock, 
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causing a disease called Nagana. T. equiperdum appears to infect only equids (horses, 
donkeys and mules), causing a veneral disease called Dourine. T. evansi on the other hand, 
has the widest distribution of all species of trypanosomes and the greatest range of 
mammalian hosts (Hoare, 1972), making it one of the most economically important protozoan 
diseases present in the veterinary world today.  
All these trypanosome species are morphologically indistinguishable from one another 
(except T. congolense and T. vivax), have a size range of 15-55 μm and typically live in the 
blood, lymph and tissues of their hosts. Bloodstream forms of trypanosomes are covered by a 
protective surface coat consisting of variant surface glycoproteins (VSG) linked in turn to the 
plasma membrane surface by means of glycosyl-phosphatidyl-inositol (GPI) anchors. This 
surface coat has the ability to undergo antigenic variation, whereby only one (out of a 
thousand) VSG gene is expressed at any one time (Vickerman, 1985). The trypanosomes can 
then spontaneously switch and express a different VSG gene, hence enabling an entirely 
different surface coat to be produced. Antibodies, previously mounted by an immune 
response, will not be able to recognise this newly expressed VSG gene and thus the 
trypanosome escapes detection. By the time the immune system has created new antibodies 
against this other VSG gene, the trypanosome has switched again, begun expressing an 
alternative VSG gene and as a consequence, can produce a persistent (chronic) infection. It is 
this special functioning coat, which helps trypanosomes evade the immune system and 
maintain their survival within hosts. 
With the exception of T. equiperdum and T. evansi, which possesses only minicircles 
and no maxicircles within its kinetoplast, the majority of trypanosome species also undergo a 
developmental phase in insect vectors, such as the tsetse fly (Vickerman, 1985). In the host, 
short stumpy forms are the so-called non-dividing state and must be taken up by a feeding 
vector to ensure their continued survival and transformation into procyclic forms, where the 
protective VSG coat is lost. It is within the insect vector that trypanosomes undergo a chain of 
events involving differentiation, multiplication and biochemical alterations, such as swapping 
their energy metabolism from glucose (in bloodstream forms) to proline (in procyclic forms), 
before migrating to the salivary glands, where they progress into infective metacyclic forms 
by re-gaining their VSG coat and are then ready to be inoculated into a new host during the 
next bloodmeal. Once they enter their new host, these metacyclic forms differentiate into 
rapidly-dividing, long slender bloodstream forms, allowing the life cycle to complete itself, 
before short stumpy forms are then proliferated and the next insect vector is awaited 
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(Vickerman, 1985). Although multiplication generally occurs via binary fission, genetic 
exchange has been shown to occur in insect forms (Jenni et al., 1986). 
 
Trypanosoma evansi 
 
Trypanosoma evansi, a haemoflagellated parasite (Figure 1.2), is the causative agent 
of a progressive (and ultimately fatal) wasting disease called Surra. Other terms for this 
condition include “Mal de Caderas” in South America, “El debab” in the Middle East and 
Africa and “Gufar” in Sudan (El Rayah et al., 1999; Giardina et al., 2003). Surra is 
extensively distributed geographically, has a wide range of mammalian hosts and results in 
great economical loss in areas of Africa, Asia and South America as thousands of animals die 
each year from this infection.  
 
Figure 1.2. Trypanosoma evansi isolated from the blood of an infected camel (Giemsa stain). 
 
 
 
Trypanosoma evansi is pathogenic in most domestic animals and some wild animals 
(Lun et al., 2004; Zhou et al., 2004). Horses, mules, donkeys, camels, llamas, deer, cattle, 
buffalo, cats and dogs are generally affected; yet asymptomatic, mild or chronic infection has 
also been seen in sheep, goats, elephants and pigs. However, the main host species varies 
according to geographical location: Camels are most often affected in the Middle East and 
Africa, horses in South America and horses, mules, buffalo and deer in China. Surra in 
Southeast Asia is mostly seen in horses, cattle and buffalo (Holland et al., 2004). In Central 
and South America, capybara and vampire bats act as reservoir hosts. Vampire bats even have 
the potential to operate as disease vectors (Davila and Silva, 2000). The endemic geographic 
distribution of this disease (Figure 1.3) ranges from China, the Philippines and parts of 
Indonesia, across Southeast Asia and parts of the former U.S.S.R, into the Indian 
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subcontinent, the Middle East and Africa, until it reaches Central and South America (OIE, 
2004). 
 
Figure 1.3. Geographical distribution of endemic areas of Trypanosoma evansi infection. 
 
 
T. evansi endemic areas 
 
The severity of the disease varies according to the strain of T. evansi in question and 
host factors like general health and stress of the animal (Kaminsky et al., 1997). Symptoms of 
the disease include anaemia, recurrent fever and oedema with muscular weakness. There is 
usually a loss of appetite and a reluctance to move, the coat condition of the animal worsens 
and pregnant females can abort their foetuses (Gutierrez et al., 2005). Without effective 
treatment, animals infected with T. evansi face a fatal outcome. 
Disease outbreaks tend to be associated with movement of infected animals into 
disease-free areas or susceptible animals into highly endemic regions. Morbidity can be 50 - 
70 % in some outbreaks with a similar value for mortality. In China, the average mortality 
rate is 41 % in horses and 28 % in cattle and water buffalo (Brun and Lun, 1994). In Sudan, 
disease prevalence in camels is said to be reported at 20 %, which unsurprisingly increases 
during severe outbreaks (Rae et al., 1989). Few studies have been done on disease prevalence 
in endemic regions and consequently little is known about exact figures, but they are often 
thought to be much higher than actually described. 
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Transmission 
 
Unlike other trypanosome species, T. evansi is not restricted to Africa alone, since 
transmission is mechanically performed by biting flies in the genera Tabanus, Stomoxys and 
Lyperosia, yet species of Tabanus (Figure 1.4) tend to be the most significant vectors, with 
only the females being haematophagous (Luckins, 1992).  
 
Figure 1.4. One of the vectors (Tabanus sp) responsible for the mechanical transmission of T. evansi. 
 
      
               (Source: Bruce Marlin, Cirrus Digital Imaging, 2005) 
 
Successful transmission depends on the time taken for an infected vector to find a new 
host, as the viable trypanosomes remain within the mouthparts of the flies only and are 
therefore susceptible to rapid dessication. No intermediate hosts are present and there is no 
insect developmental cycle available in T. evansi (Foil, 1989). Transmission in milk and 
during coitus has been reported and carnivores may pick up infection after feeding on infected 
meat (Herrera et al., 2004).  
T. evansi has never really been human pathogenic, as shown by E. Brumpt himself, 
when he infected himself in 1902 with blood from the jugular vein of a dromedary camel, rich 
in T. evansi. He experienced no symptoms as a result of this injection. In summer, 1999, a 
patient in Colombo, Sri Lanka, was considered to have a T. evansi infection after having been 
in direct contact with cattle. The parasite was later identified as belonging to the T. evansi 
group, yet the trypanosomes disappeared from the patient’s blood after a year. Recently, in the 
autumn of 2004, in the Indian state of Maharashtra, a male (also in close contact with cattle) 
contracted the first official human case of T. evansi infection (Joshi et al., 2005). Then in 
January, 2005, a female patient, from West Bengal state in India, actually died from a T. 
evansi infection, making her the second human case of this parasite. It was later identified that 
patients missing the typical trypanolytic factor (apolipoprotein L1) usually found in human 
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serum, resulted in their susceptibility to this infection (Vanhollebeke et al., 2006). It is still too 
early to consider T. evansi as a new zoonosis; however, should this be the case, major 
implications could occur for future chemotherapeutic research against this parasite (Touratier, 
personal communication, 2005). 
 
Diagnosis 
 
It is vital to be able to diagnose T. evansi infection properly for effective control 
purposes, as disease symptoms are generally too vague. Several techniques are available 
depending on the type of diagnostic approach followed. For parasitological tests, a thick or 
thin wet blood smear can be performed and examined under light microscopy. Positive results 
are achieved upon detection and observation of the parasite in the blood (OIE, 2004). For 
infections with a low parasitaemia, concentration techniques can be carried out, where the 
trypanosomes are concentrated into a specific region and then observed under light 
microscopy. The haematocrit centrifugation (HCT or Woo) technique (Figure 1.5) involves 
filling heparinised capillary tubes with the blood sample, centrifuging the capillaries and then 
searching for viable parasites in the so-called buffy coat layer, found between the red blood 
cells and the plasma (Woo, 1970).  
A second concentration method, the mini-
AECT (Anion Exchange Centrifugation Technique) 
involves the blood sample passing through a DEAE-
cellulose column, which separates trypanosomes from 
red blood cells, based on charge. The highly 
negatively-charged red blood cells stick to the column, 
whilst the trypanosomes pass through the column and 
are collected as eluate at the other end. This eluate can 
then be centrifuged and examined for the presence of 
trypanosomes (Lumsden et al., 1979). A further 
parasitological test includes animal inoculation, where 
the suspected blood sample is inoculated into small 
rodents (usually rats or mice) and in positive cases, a 
parasitaemia will establish itself. The small rodents are checked regularly for the presence of 
T. evansi parasites via tail blood examination.  
Capillary 
Red 
blood 
cells 
Buffy coat layer 
with trypanosome 
Figure 1.5. Diagrammatic representation 
of the HCT for parasitological diagnosis 
of T. evansi. 
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Another approach is to use serological tests, such as the indirect fluorescent antibody 
test (IFAT) or the enzyme-linked immunosorbent assay (ELISA), where specific antigens 
against the parasite are previously fixed to a slide (IFAT) or a microtitre plate (ELISA). The 
test serum is placed on the slide/plate and then washed off. If antibodies against the parasite 
are present in the test serum, they stick to the respective antigens and are left on the slide/plate 
after washing. An enzyme labelled conjugate is then applied to the slide/plate. A positive 
reaction binds the conjugate, causing it to fluoresce, which is then detected when examined 
under UV light in a microscope or fluorescent plate reader (OIE, 2005). Recently, a card 
agglutination test for trypanosomiasis (CATT) was designed to detect antibodies against 
Trypanosoma evansi (CATT/T. evansi) (Bajyana Songa and Hamers, 1988; Diall et al., 1994; 
Gutierrez et al., 2000); the first CATT test was produced for T. b. gambiense detection 
(Magnus et al, 1978). Here, test serum is diluted and placed onto the card within the circles. 
The reagent containing a specific antigen is placed on top, mixed carefully and the card is 
allowed to rotate on a motorised rotating machine (Figure 1.6). Samples which agglutinate are 
considered positive for infection. However, the presence of antibodies does not determine 
whether an infection is current or past and therefore serological tests are unable to detect new 
infections, where antibodies might not have developed yet. 
 
Figure 1.6. The CATT/T. evansi test used for the serological diagnosis of T. evansi infection. 
 
 
 
A final approach may be to use molecular techniques based on specifically designed 
sequences, where detection of parasite DNA indicates the active infection and presence of the 
parasite in the sample. It is believed that parasite DNA will not persist within the host for 
long, after all viable parasites have been eliminated. Molecular techniques, of which the most 
well known is the polymerase chain reaction (PCR), tend to be highly specific and sensitive 
and may constitute as the gold standard test for many infections. The PCR process allows a 
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small amount or a specific region of DNA to be amplified, using precise temperature 
conditions and ingredients like primers, which read the specific region, a DNA polymerase, 
which can synthesise a copy of the DNA region and deoxynucleotide triphosphates (dNTPs), 
which build up the new DNA copy (Holland et al., 2001). However, most molecular tests 
usually require well-equipped laboratories, expensive reagents and well-trained personnel. 
Due to such features, these techniques remain primarily as research tools and are not currently 
utilised as routine diagnostic tests.  
 
Control 
 
Vector control has demonstrated an effective measure for controlling the tsetse fly 
situation with HAT. Through constant maintenance of cleverly-designed tsetse fly traps and 
insecticidal spraying regimens, it is possible to significantly reduce the number of tsetse flies 
in a given region. The tsetse fly population was actually successfully eradicated on the island 
of Zanzibar in 1998, through the release of sterile male tsetse flies, which competed with the 
natural male population and resulted in infertile female flies unable to lay larvae (Vreysen et 
al, 2002). This method is known as the sterile insect technique (SIT). Whether this approach 
will be as successful in the expanded area of mainland Africa, in connection with the 
geographical tsetse fly habitat belt, is not yet evident.  
Unfortunately, vector control for the prevention of T. evansi infection is not considered 
a viable option, since transmission occurs mechanically and potentially any blood-sucking 
insect has the ability to transmit this infection. Based on its vast area of global endemicity, 
vector control against T. evansi infection would also result in an unnecessary economical 
drain on several countries involved.  
Control measures for protozoan diseases, such as Surra, therefore tend to rely on either 
treatment or prophylaxis. Treatment usually involves the use of anti-parasitic drugs, whereas 
prophylaxis can be accomplished by either drugs or vaccination. Whether “prevention is 
better than cure” depends on the parasite being dealt with, the type of drugs available, the 
occurrence and severity of the disease and the economics obtainable in such a situation 
(Ryley, 1982). 
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Treatment 
 
Chemotherapeutic treatment against T. evansi infection is currently dependent on four 
main drugs, namely Germaine® (seamen), Berenil® (diminazene aceturate), Trypacide® 
(quinapyramine sulphate) and MelCy® (cymelarsan) (Zhang et al., 1992). While the first three 
have been utilised for more than 50 years (Kaminsky and Zweygarth, 1989), cymelarsan, 
belonging to the family of melaminophenyl arsenicals, was pharmaceutically developed less 
than twenty years ago (Williamson, 1970; Raynaud et al., 1989; Tuntasuvan, 2003).  
 
Suramin (Germanin®, Bayer in Germany) was originally synthesised as a dye in 1916. 
This naphthalene compound (Figure 1.7) binds strongly to plasma proteins and low-density 
lipoproteins (LDL), followed by a subsequent slow release mechanism. Due to the molecule’s 
charge and large size, diffusion and/or endocytosis are believed to be the key methods of 
uptake into the parasite. Its mode of action is not fully understood, yet anionic interactions 
with enzymes, in particular those associated with glycolysis in trypanosomes, would enable 
inhibition of reverse transcriptase and receptor mediated uptake of low-density lipoproteins by 
trypanosomes to occur (Cheson et al., 1987; Vansterkenburg et al., 1993; Denise and Barrett, 
2001). Suramin is principally used for the early treatment of East African T. b. rhodesiense 
sleeping sickness in humans, as well as for T. evansi infections in animals. 
 
Figure 1.7. Chemical structure of suramin, a naphthalene compound. 
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Diminazene aceturate (Berenil®, Sigma in USA) is a triazene molecule, belonging to 
the aromatic diamidines, of which pentamidine is the best known example, due to its use 
against the early stages of the chronic T. b. gambiense form in humans, along with early stage 
visceral leishmaniasis and Pneumocystis carinii pneumonial infections in HIV-infected 
individuals. Diminazene (Figure 1.8) was originally discovered in 1944, having been 
developed based on compounds similar to amino-quinaldines, with good anti-trypanosomal 
properties (Peregrine and Mamman, 1993). It is actively taken up through a nucleoside P2 
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transporter, coded by the TbAT1 gene, in trypanosomes (Mäser et al, 1999). This transporter 
is vital in the uptake of adenosine and adenine within trypanosomes, allowing them to salvage 
purines and nucleoside bases. Its mode of action is believed to centre on nucleic acid binding, 
especially at AT-rich regions of the minor groove in DNA (Wilson et al., 2005). 
 
Figure 1.8. Chemical structure of diminazene aceturate, an aromatic diamidine. 
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Cymelarsan (MelCy®, Rhône Mérieux in France) is a member of the melaminophenyl 
arsenical family and thus related to melarsoprol, the first line drug for the second stage 
treatment of human African Trypanosomiasis. The first organic arsenical drug, Atoxyl®, 
appeared in 1905 for the treatment of syphilis. It included slight efficacy against 
trypanosomes, but its toxicity was unbearable (Williamson, 1970). Thereafter, thousands of 
similar compounds were then synthesised, whilst trying to reduce the toxic effects of this 
chemical family. Finally in the 1940s, melarsoprol was produced, demonstrating a 
breakthrough in the treatment of the late stage of human African sleeping sickness 
(Friedheim, 1949). Following this success, cymelarsan (Figure 1.9) arrived on the scene, as a 
prodrug called melarsenoxide cysteamine, requiring two cysteamine molecules to be released 
to produce its activity. 
 
Figure 1.9. Chemical structure of cymelarsan, a melaminophenyl arsenical. 
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Cymelarsan is a highly active drug against T. evansi infection, yet its downfalls 
revolve around its toxicity, expensive market price and global unavailability. It is taken up 
into trypanosomes with the same nucleoside P2 transporter as that seen for diminazene 
(Carter and Fairlamb, 1993), whilst its mode of action involves a high affinity for 
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intracellular thiols, in particular trypanothione, which is necessary for the redox balance of 
trypanosomes. 
 
Quinapyramine sulphate (Trypacide®, May & Baker in Nigeria) is a quinoline 
pyramidine, used to treat trypanosomiasis in cattle from the 1950s until the 1970s. Resistance 
to this compound built up rapidly and coupled with severe toxicity, production ceased in 1976 
and quinapyramine was removed from the market. Nevertheless, in 1984 it was reintroduced 
to the market for use solely in camels (Ndoutamia et al., 1993). Even so, several African 
countries are still using quinapyramine for the treatment of livestock (including cattle) despite 
the problems experienced 30 years ago. Quinapyramine (Figure 1.10) is thought to act 
indirectly by inhibiting protein synthesis through the displacement of magnesium ions and 
polyamines from ribosomes. Uptake is probably through the P2 transporter, similar to 
diminazene and cymelarsan. 
 
Figure 1.10. Chemical structure of quinapyramine, a quinoline pyramidine. 
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Standard drugs 
 
Several problems are associated with the current standard drugs available for the 
treatment of T. evansi infection. Resistance to drugs tends to occur in situations, where the 
drugs available are old and few and hence are repeatedly used over a long period of time. 
Together with possible under-dosing, where inadequate or erroneous applications of 
subcurative doses of the drugs are given (especially under field conditions) (Bacchi, 1993), 
natural selection pressures instantly favour less drug-sensitive trypanosomes. Drug resistance 
in trypanosomes arises through either the loss or alteration of certain transporter proteins, 
implying a decrease in the amount of drug entering the parasite, or through increased 
expression of efflux pumps, which then expels the drug at a faster rate from the parasite, than 
it can actually enter the cell (Mäser and Kaminsky, 1997). 
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With the rising appearance of resistance to these drugs, their effective use is severely 
threatened. For example, Zhang et al. (1993) induced resistance in laboratory mice resulting 
in T. evansi resistance to suramin, diminazene and cymelarsan, indicating that inappropriate 
use of these drugs can easily lead to resistance in the field. Zhou et al. (2004) tested various T. 
evansi isolates and found differences in their levels of sensitivity to suramin and 
quinapyramine, with some being highly sensitive and others showing complete drug 
resistance. No cross-resistance was observed between these two drugs. Similarly, El Rayah et 
al. (1999) demonstrated suramin and quinapyramine resistance in sixteen T. evansi isolates 
from Sudan. In addition, several studies have already shown the possible cross resistance 
between diamidine drugs, such as diminazene, and melaminophenyl arsenical compounds, 
such as cymelarsan (Zhang et al., 1993; Ross and Barns, 1996). Since the P2 transporter is 
involved in the active drug uptake of diamidine compounds and melaminophenyl arsenicals, 
loss of this P2 transporter would render that organism resistant to such compounds (Carter 
and Fairlamb, 1993; Carter et al., 1995; Barrett et al., 1995).  
Many of these drugs have already lost their ability to cure infected animals efficiently; 
some have toxicity associated with their use in certain species or are just too costly for the 
poorer communities within the world to afford. If there were even an alternative, the 
circumstances might not look so dire, yet alternatives are not currently accessible, due to a 
sparse drug repertoire. Furthermore, for those communities that can afford the more costly 
standard drugs, treatment of their infected animals is not made easier, thanks to the fact that 
some drugs are simply not obtainable within that country’s market. With such limited 
availability, soaring expenses and emerging drug resistance, many T. evansi infections are 
reaching epidemic proportions in regions, where the loss of livestock and expensive, 
prestigious animals can have staggering repercussions and consequences, both for the 
individuals and the communities involved (Touratier, personal communication, 2006).  
In the case of Surra, drugs containing antiparasitic properties were usually 
administered once an infection had already established itself, in the hope that such activity 
would render the parasite non-viable and the infection would disperse (Davila and Silva, 
2000; Seidl et al., 2001). However, this tactic is now failing miserably and the pressing need 
for new, alternative chemotherapeutic agents is becoming critical (Touratier, 2000; Reid, 
2002). Moreover, the prospect of a vaccination against T. evansi infection appears non-
existent, for which a large proportion of blame can be placed upon the mystifying antigenic 
variability of trypanosomes in general. 
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Drug discovery 
 
Drug research and development for animal diseases is a similar process to that 
involved for human diseases. There are some key differences however between the two, 
which should be taken into account when regarding the clinical trials and costs of drug 
discovery for animal diseases. Nevertheless, drug discovery for human diseases will be 
discussed initially to enable these differences to be adequately highlighted. To discover a new 
drug is a timely, expensive and immense process, which involves several different stages of 
research, together with numerous developmental phases, followed by the final regulatory 
affairs section deciding the overall outcome of the new drug (Figure 1.11). The overall 
estimated time involved in discovering, developing and registering a new drug is between 
eight to twelve years. Often the disadvantages of a new drug outweigh the beneficial risks, so 
that many potential drug candidates are “dropped” during the discovery process as the 
investment costs associated with them are clearly too high. Figures currently demonstrate that 
on average, US$ 800 million need to be invested, from start to finish, for the complete 
development of merely one new drug. This figure incorporates all the drug failures too. In 
addition to this, production success rates are poor, as only 1 - 2 drugs actually reach 
registration out of every 15’000 compounds originally synthesised (Nwaka and Hudson, 
2006). 
 
Figure 1.11. Drug pipeline showing the various stages, time and costs involved in producing a new drug against 
human diseases. 
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Naturally, large pharmaceutical companies tend to be in possession of such financial 
sums and therefore are the industrial leaders in manufacturing new drugs. However, no 
business is prepared to invest millions to produce a drug, which provides no safe assurance, 
that a financial return will be made. Such attitudes would only result in the demise of these 
businesses. To add to this conundrum, the rules and regulations required to be met by new 
drug candidate molecules have been tightened and strict health and safety guidelines must 
now be met in order to produce new drugs for our markets. Developing and producing drugs 
was easier 20 - 30 years ago, when these guidelines were not as strict, hence many of the 
drugs found on our market today would never have been passed and registered according to 
the present day guidelines.  
Good examples can be seen in tropical and infectious diseases, where the majority of 
drugs available for treating parasitic, viral or bacterial infections, generally found in tropical 
climates, are so toxic that the drugs themselves cause fatalities. Melarsoprol, mentioned 
earlier as the drug of choice for late stage African trypanosomiasis, is associated with an 
adverse post treatment reactive encephalopathy, occurring in 5 - 10 % of all patients treated. 
Of this 5 - 10 %, a staggering 50 - 70 % of them die as a result of this adverse effect (Pepin 
and Milord, 1991). Nonetheless, patients suffering from this disease have nothing to lose, 
especially when faced with a 100 % mortality rate if the infection goes untreated.  
Although the choices are bleak for those suffering from or at risk of contracting 
tropical and infectious diseases, the conditions appear more desperate when faced with the 
possibility that the only remaining (albeit toxic) drugs no longer work against infection, 
coupled with the fact that such powerful and effective drugs are no longer coming out of the 
drug discovery process, as a direct result of the new rules and regulations. The harsh reality 
continues whereby those most in need of such drugs include some of the poorest regions in 
the world, hence no pharmaceutical company is interested in investing millions to produce 
drugs that cannot provide a decent financial return.  
Therefore to summarise, the situation appears hopeless for all involved – the 
pharmaceutical industry cannot produce drugs with no financial return, otherwise their 
businesses will suffer and the success rate of new drug candidates decreases further, as less 
candidates will pass the new health and safety regulations, providing larger financial losses 
for pharmaceutical companies and consequently resulting in fewer new drugs being 
introduced onto our markets. This in turn condemns those requiring the drugs, be it humans or 
animals, many of whom will not be able to pay for the new drugs anyway. With this sorry 
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sight, pharmaceutical companies retracted from investigating new drugs for tropical medicine 
and for a long time, nothing was done to improve the situation.  
At the beginning of the 21st century, this gap was bridged with the manifestation of 
public-private partnerships (PPPs), consortia made up of various governmental research 
departments and institutes (the public half), along with several small pharmaceutical entities 
(the private half), all with the general goal to improve the drug situation against parasitic 
diseases occurring in developing countries. New drugs were to be discovered through in vitro 
and in vivo screening techniques, using the facilities available in research institutes, followed 
by the private sectors undertaking the more costly, preclinical (ADME and toxicity) and 
clinical trials. Overall, new, safer and cheaper compounds, featuring high anti-parasitic 
activity, were aimed to be discovered. 
In the case of animal health, several studies need to be presented in order to pass a new 
drug onto the veterinary market as a safe and reliable product. Such tests include in vitro and 
in vivo experiments with laboratory animals. Studies performed in a target species 
investigating tolerance, reproductive features, as well as the class of animal and specific 
breeds targeted, along with various field investigations and environmental safety assessments 
must be carried out. A range of toxicity trials including aspects of mutagenicity, reproduction, 
resistance studies and user safety must be dealt with. A large proportion of the regulations 
focus on the clinical phases, in particular on drug residue, whereby the total metabolism 
within the target animal must be demonstrated and understood, in addition to the comparative 
metabolism within rodents, tissue residue depletion analysis and method validation. This is 
critical for any drugs wishing to target livestock or agricultural animals, since meat, milk and 
other dairy products will be consumed by humans and any acute or chronic toxic responses 
need to be fully examined before a new drug can be approved. New veterinary drugs must be 
approved by the Centre for Veterinary Medicine (CVM), which is a division of the United 
States of America, food and drug administration (FDA), before they can enter the global 
market. 
 
Diamidines 
 
With the introduction of novel aromatic diamidines (dicationic molecules), a new class 
of anti-trypanosomal drugs was revealed (Francesconi et al., 1999; Wilson et al., 2005). Their 
principle activity is based on the two functional amidine groups separated by a spacer region, 
the distance of which is important for optimal compound activity (Figure 1.12). These 
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chemicals bind to the minor-groove of DNA at AT-rich sites. Their interaction with the DNA 
minor groove has been examined at a molecular level, using biophysical techniques and X-ray 
crystallography, concluding that these compounds apply their biological activity by primarily 
binding to DNA and then inhibiting one or more of the DNA dependent enzymes (such as 
topoisomerases or nucleases) or by directly impeding the transcription process (Wilson et al., 
2005). The selective binding to kinetoplastic DNA has also been shown to play a vital role in 
the action of aromatic diamidines against pathogens (Francesconi et al., 1999).  
 
Figure 1.12. Aromatic diamidines based on the two cationic moieties separated by the spacer region. 
 
 
The first antiprotozoan diamidine was called synthalin, a diguanidine originally 
produced as a synthetic analogue of insulin. It was tested on trypanosome infections with the 
theory that induced hypoglycaemia could control these infections in mammals (Von Jansćo 
and Von Jansćo, 1935). In 1937, synthalin was discovered to have similar activity against 
trypanosomes in vitro as trivalent arsenicals (King, 1937). From this, further development and 
testing lead to a large number of related compounds being produced. It was then that aromatic 
diamidines, such as pentamidine, were noticed as highly effective in treating first stage (and 
early second stage) trypanosomiasis (Lourie and Yorke, 1939), as well as other infections, 
such as leishmaniasis and Pneumocystis carinii pneumonia. 
With regard to human African Trypanosomiasis, several diamidine compounds have 
shown outstanding success. The compound DB 289, a prodrug of DB 75, is currently in phase 
III clinical trials. Although only sub-curative levels cross the blood brain barrier, it looks 
promising as a safe and effective oral drug against the early stage of the disease, not to 
mention more cost-efficient (Legros, 2002). Another excellent candidate is DB 844, a prodrug 
of DB 820, which does possess the ability to cross the blood brain barrier and could therefore 
be an alternative to melarsoprol for treating the second stage of sleeping sickness.  
Based on such hopeful results observed with diamidines against the T. brucei species, 
considerations were made whether a similar level of success could be achieved with T. evansi. 
An alternative drug for T. evansi would produce a major benefit to the present market, which 
is currently hindered by the emergence of drug-resistant strains, old and ineffective drugs, 
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severe drug toxicity and expensive alternatives, leading to great economic loss for those who 
depend entirely on their domestic animals for income. A cheap, safe and efficient drug, which 
can easily be synthesised, is available for large-scale production and has a reduced potential 
for future drug resistance is desperately sought after. All these aspects are vital to ensure the 
successful control of T. evansi infection, where the most reliable method of disease control 
still remains the administration of anti-trypanocidal drugs. 
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Aims and objectives 
 
The main aim of this thesis is to discover and develop a potential clinical candidate 
compound (or compounds), for the future drug development against Trypanosoma evansi 
infection. By means of in vitro and in vivo drug screening, the most active compounds can be 
selected for and tested in a higher animal model before further clinical trials are undertaken. 
Through preliminary toxicity tests and a “proof of concept” pilot study, additional data on 
diamidines can be attained and all-important drug levels can be determined and 
pharmacokinetic parameters can be calculated. A better understanding of drug metabolism 
within higher animals is expected to be gained. Together with a clearer insight into the exact 
mode of action and uptake processes involved in diamidines, it will be possible to establish 
how these compounds are taken up by trypanosomes and where they exert their activity.  
 
 
Precise objectives include: 
 
• To establish the drug profile of a global panel of Trypanosoma evansi and Trypanosoma  
equiperdum strains to be used for future drug screening studies 
 
• To test various diamidine compounds and determine in vitro activity against Trypanosoma  
evansi strains to identify molecules for animal model experiments 
 
• To analyse the most active diamidine compounds and investigate their in vivo toxicity and  
efficacy within a mouse model 
 
• To perform a pharmacokinetic study and gain vital information over such parameters for  
active diamidine compounds using an experimentally infected Trypanosoma evansi goat model 
 
• To undertake a “proof of concept” pilot trial to verify the treatment efficiency of active 
diamidine compounds within an experimentally infected Trypanosoma evansi goat model 
 
• To explore the mode of action and mechanism of uptake used by these active diamidine  
compounds using fluorescent techniques  
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Abstract 
 
The animal pathogenic protozoan, Trypanosoma evansi, leads to a wasting disease in 
equines, cattle and camels, commonly known as Surra. It is extensively distributed 
geographically with a wide range of mammalian hosts and causes great economical loss. 
Trypanosoma equiperdum causes a venereal disease called Dourine in horses and donkeys. 
Chemotherapy appears to be the most effective form of control for T. evansi, whereas 
infections caused by T. equiperdum are considered incurable. Due to emerging drug 
resistance, efficient control of T. evansi is severely threatened, emphasising the urgent need to 
find new alternative drugs. 
A drug profile for a panel of T. evansi and T. equiperdum strains has been established 
for the four standard drugs currently used in treatment. The 3H-hypoxanthine incorporation 
assay was used to obtain 50 % inhibitory concentration (IC50) values for each standard drug 
against the various strains. The results indicate the presence (and in some cases, the 
emergence) of drug resistance in several strains. This panel of characterised strains with 
known drug sensitivities and resistances will be of great value for the screening of new active 
compounds, in comparison with the four standard drugs currently available. 
 
Keywords: Trypanosoma evansi; Trypanosoma equiperdum; chemotherapy; drug resistance; 
drug screening. 
 
 
 
Introduction 
 
Trypanosoma evansi is a flagellated animal pathogenic protozoan parasite, where 
infection leads to a wasting disease called Surra. This disease has a wide geographical 
distribution and range of mammalian hosts, causing great economical loss in areas of Africa, 
Asia and South America as thousands of animals die each year resulting from infection 
(Giardina et al., 2003). T. evansi is pathogenic in most domestic animals and some wild 
animals (Lun et al., 2004; Zhou et al., 2004). However, the main host species varies according 
to geographical location: Camels are most often affected in the Middle East and Africa, horses 
in South America and horses, mules, buffalo and deer in China. The severity of the disease 
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varies according to the strain of T. evansi in question and host factors like general health and 
stress of the animal (Brun et al., 1998).  
Unlike other trypanosome species (such as Trypanosoma brucei brucei and 
Trypanosoma congolense), T. evansi is not restricted to Africa alone, since transmission is 
mechanically performed by biting flies of the genera Tabanus, Stomoxys and Lyperosia. 
Successful transmission depends on the time taken for a contaminated vector to find a new 
host, as the viable trypanosomes remain within the mouthparts of the flies only and are 
therefore susceptible to rapid dessication. No intermediate hosts are present and there is no 
insect developmental cycle available in T. evansi (Foil, 1989).  
Although T. evansi and T. equiperdum are closely related, they remain classified as 
two distinct species (Hoare, 1972; Claes et al., 2003; Claes et al., 2006). T. equiperdum 
causes a venereal disease called Dourine in horses and donkeys and is morphologically 
indistinguishable to other Trypanozoon species (Verducci et al., 1989; Brun et al., 1998). 
Disease transmission is thought to occur during coitus as no arthropod vector has been 
discovered for this species. Dourine is found in Africa, Asia, Southern and Eastern Europe, 
Russia and Mexico (Davila and Silva, 2000).  
Both T. evansi and T. equiperdum infections are fatal if left untreated. T. equiperdum 
infections are considered incurable in terms of chemotherapy, where administered drugs can 
reach parasites within the blood, yet cannot necessarily access parasites hidden in certain 
tissues (OIE, Surra fact-sheet, 2004 (www.oie.int/eng.htm); OIE homepage, 2005 
(www.oie/int/eng/en_index.htm); Claes et al., 2005), while treatment for T. evansi infection is 
dependent on four drugs, namely suramin, diminazene aceturate, quinapyramine and 
cymelarsan (Zhang et al., 1992; Brun and Lun, 1994). While the first three have been utilised 
for more than 50 years, cymelarsan, belonging to the family of melaminophenyl arsenicals, 
was pharmaceutically developed less than twenty years ago (Williamson, 1970; Zelleke et al., 
1989; Raynaud et al., 1989; Tuntasuvan, 2003). As drug resistance is emerging, severe 
drawbacks in controlling T. evansi are occurring, hence emphasising the urgency and 
necessity for finding new alternative drugs (Kaminsky et al., 1989; De Koning, 2001; Suswam 
et al., 2001). Inappropriate use of these drugs can easily lead to resistance in the field, as 
shown by Zhang et al. (1993), who induced resistance in laboratory mice resulting in T. 
evansi resistance to suramin, diminazene and cymelarsan. Zhou et al. (2004) tested various T. 
evansi isolates and found differences in their levels of sensitivity to suramin and 
quinapyramine, with some being highly sensitive and others showing complete drug 
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resistance. Similarly, El Rayah et al. (1999) demonstrated suramin and quinapyramine 
resistance in 16 T. evansi isolates from Sudan.  
Since many of the hosts affected in these disease endemic countries represent 
expensive and prestigious animals, a new drug against these trypanosome infections would 
have a potentially high market value amongst the other antitrypanosomal agents. In order to 
aid drug discovery within this field, a panel of reference T. evansi and T. equiperdum strains 
was established and their sensitivity profiles in relation to existing drugs were determined. 
 
 
 
Materials and Methods 
 
Parasite strains 
 
In total, eleven Trypanosoma evansi strains were included in this study (Table 2.1). 
The STIB 806K (kinetoplastic) strain was isolated by ZR Lun, from a water buffalo in China 
and was used as a reference strain in all experiments performed. Two African strains, STIB 
780 and STIB 781, were received from the International Livestock Research Institute (ILRI) 
in Nairobi, Kenya. The remaining eight T. evansi strains were obtained from the cryobank of 
the Institute of Tropical Medicine (ITM) in Antwerp, Belgium. 
Likewise, eleven Trypanosoma equiperdum strains were also used for this study 
(Table 2.1). All T. equiperdum strains were obtained from the ITM cryobank in Antwerp, 
Belgium, with the exception of STIB 818, which was collected by ZR Lun from China. The 
BoTat 1 (Bordeaux Trypanosoma antigen type 1) clone was derived from a T. equiperdum 
strain from the Institut Pasteur in Paris, France. The strain, originally isolated in 1924 from a 
horse in Morocco, was transferred to Bordeaux in 1961 and maintained in serial passages in 
mice until 1971, whereupon it was cloned and stored in liquid nitrogen. The BoTat 1.1 strain 
was designated as a reference strain in all experiments performed.  
Unfortunately, the precise history for some of the strains is unknown, especially in the 
case of the AnTat 4.1 (Antwerp Trypanosoma antigen type 4) strain, the Hamburg strain and 
the SVP (Staatliches Veterinärmedizinisches Prüfungsinstitut) strain. Nevertheless, the 
Hamburg, SVP and Alfort strains are currently used as reference T. equiperdum strains for the 
diagnosis of dourine in Germany. Even though the majority of data for these strains are 
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unknown, this remains the most globally updated list of T. equiperdum strains (Claes et al., 
2005). 
 
Mice 
 
All mice used were female NMRI, aged between 3 and 4 weeks and were maintained 
under standard animal housing facilities in air conditioned rooms (22 - 23 °C), with a relative 
humidity of 60 - 70 %. The mice were specific pathogen free (SPF) and were kept in standard 
Macrolon type II cages, with pelleted food and water ad libitum. 
 
Standard trypanocidal drugs 
 
Suramin (Germanin® from Bayer, Leverkusen, Germany), diminazene aceturate (D-
7770, Sigma, St Louis, MO, USA), cymelarsan (MelCy®, Rhône Mérieux, Toulouse, France) 
and quinapyramine sulphate (Trypacide®, May & Baker, Lagos, Nigeria) were used as the 
standard drugs in this study. 
 
Stock solutions and dilutions 
 
A 10 mg amount of each drug was weighed out in powder form and dissolved in 1 ml 
of sterile distilled water, to provide a 10 mg/ml stock solution. These stock solutions were 
then stored frozen at -20 °C. From these stock solutions, further drug dilutions were made for 
use in the in vitro drug sensitivity assays, using culture medium as a solvent. Drug dilutions 
were made fresh on the day of each experimental assay procedure. 
 
Culture medium 
 
Bloodstream form trypanosomes were cultivated in Minimum Essential Medium 
(MEM) (powder, GIBCO/BRL, No: 11400-033) with Earle’s salts, supplemented with 25 mM 
HEPES, 1 g/l additional glucose, 2.2 g/l NaHCO3 and 10 ml/l MEM non-essential amino 
acids (50x concentration). The medium was then further supplemented by adding 1 % of a 2-
mercaptoethanol stock (14 μl of 12 mM 2-mercaptoethanol was diluted in 10 ml of distilled 
water), 1 % of a stock consisting of 100 mM sodium pyruvate and 50 mM hypoxanthine and 
15 % heat inactivated horse serum, according to Baltz et al. (1985). The complete medium is 
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called Baltz MEM (BMEM). For the in vitro drug sensitivity assays, the 50 mM hypoxanthine 
was not present in the complete BMEM medium used. 
 
Radioactive hypoxanthine 
 
Radioactively labelled (8-3H) hypoxanthine (TRK74, Amersham Biosciences UK 
Limited, Buckinghamshire, UK) was used for the drug sensitivity assays. 
 
Average survival in mice 
 
Female NMRI mice (two mice per strain) were infected with the different T. evansi 
and T. equiperdum strains. As a control, the average survival day for each strain was 
calculated after infecting the mice with 104 parasites and then allowing the parasitaemia to 
establish itself. The development of parasitaemia was observed daily by using a tail blood 
examination technique. Once these average survival days were known, experimental 
trypanosome populations could be propagated successfully, through infecting two new NMRI 
mice (per strain) with a 104 parasite concentration and then collecting the trypanosomes at 
peak parasitaemia. 
 
In vivo trypanosome propagation 
 
Trypanosomes were collected from donor mice using a 1 ml syringe with a 25 gauge 
sterile needle containing 20 μl of heparin. Once the blood had been collected, it was placed 
into a 5 ml Bijou bottle and immediately placed on ice. Thereafter, the mouse blood was 
passed through a DEAE (diethylaminoethyl)-cellulose column, in order to separate the 
trypanosomes from the blood. The filtrate was collected in a 15 ml Falcon tube and left on ice. 
 
In vitro drug sensitivity assay 
 
Once the trypanosomes had been passed through the DEAE-cellulose column, the 
resulting suspension could be concentrated by centrifugation, resuspended in fresh culture 
medium and counted using a cell analyser system (CASY, Schaerfe System, Reutlingen, 
Germany). The 3H-hypoxanthine incorporation assay was used to determine the drug 
sensitivity for all four standard drugs for each of the trypanosome strains tested. The exact 
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assay procedure is detailed in Brun and Kunz (1989) and has been modified slightly for use in 
this study. 
Briefly, 50 μl of BMEM containing no hypoxanthine, were added to each well of a 96-
well microtitre plate, except for the last four wells on the top row (where 100 μl were added 
instead to act as a negative control) and all the wells on the second row. The test compounds 
were applied at 75 μl volumes into the empty wells of this second row, according to the 
required starting concentration of each compound being tested. Thereafter, 25 μl were 
removed from this second row using a multi-channel pipette and mixed with the wells in the 
row beneath. Again 25 μl were removed from this third row, placed into the next row down 
and mixed several times. This step was repeated until the last row had been reached. The final 
25 μl from the last row were discarded. This process created a 3-fold serial compound dilution 
down the microtitre plate, which enabled a compound range of 1000 - 1.37 ng/ml to be tested 
for suramin, diminazene and quinapyramine. The compound range tested for cymelarsan 
included 30 - 0.04 ng/ml. In the case of suramin, an additional compound range, starting at 30 
μg/ml was applied. The trypanosome density was then adjusted to provide a 2x106 / ml 
starting concentration. A volume of 50 μl of this trypanosome suspension was then added to 
all 96 wells, with the exception of the four negative controls in the top row, and the plates 
were then incubated in a humidified atmosphere at 37 °C and 5 % CO2. After 24 hours 
incubation, the plates were removed and 20 μl of a 1 μCi solution of radioactive hypoxanthine 
mixed with BMEM (containing no hypoxanthine) were placed into each well. The plates were 
then returned to the incubator for a further 16 hours incubation under the same conditions. 
After a complete incubation time of 40 hours, the plates were removed from the incubator and 
the wells harvested using a 96-well harvester (1290-004 Betaplate™, Berthold Technologies 
(Schweiz) GmbH, Regensdorf, Switzerland), followed by a liquid scintillation counter (1205 
Betaplate™, Berthold Technologies (Schweiz) GmbH, Regensdorf, Switzerland) to measure 
the radioactivity. All experiments were performed three to four times and in duplicate. The 
data obtained were further analysed by transferring them into a standard operating procedure 
template in a graphics programme (Microsoft Excel) for determination of IC50 values. 
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Results 
 
In this study, a total of eleven T. evansi and eleven T. equiperdum strains were 
available for drug profiling. Out of these twenty-two strains, twenty were successfully 
propagated in mice and then tested with the 3H-hypoxanthine incorporation assay to give IC50 
values against the four standard drugs currently used for treatment. The average survival days 
for NMRI mice, when infected separately with either the T. evansi or T. equiperdum study 
strains is shown in Table 2.1. 
 
Table 2.1. Trypanosoma evansi and Trypanosoma equiperdum strain information detailing the originating 
country, host and year isolated including the average survival days for NMRI mice infected separately with these 
study strains.  
 
Strain     Country        Host Year  isolated 
Average survival 
(days) 
T. evansi strains  
CAN 86/Brazil       Brazil       Dog 1986 8 
Colombia       Colombia       Horse 1973 8 
Kazakhstan       Kazakhstan       Bactrian camel 1995 8 
Merzouga 56       Morocco Dromedary camel 1998 -- 
MHRYD/Brazil       Brazil       Capybara 1986 -- 
Philippines       Philippines       Water buffalo 1996 6 
RoTat 1.2       Indonesia       Water buffalo 1982 7 
STIB 780       Kenya       Camel 1982 5 
STIB 781       Kenya       Camel 1984 5 
STIB 806K       China       Water buffalo 1983 7.5 
Vietnam       Vietnam       Water buffalo 1998 7 
T. equiperdum strains     
Alfort       Unknown       Horse 1949 7 
American       America       Horse Unknown 6.5 
AnTat 4.1       Unknown       Unknown Unknown 5.5 
ATCC30019       France       Horse 1903 5 
ATCC30023       France       Horse 1903 5 
BoTat 1.1       Morocco       Horse 1924 4 
Canadian       Canada       Horse Unknown 9 
Hamburg       Unknown       Unknown Unknown 7.5 
OVI       South Africa       Horse 1977 5 
STIB 818       China       Horse 1979 2 
SVP       Unknown       Unknown Unknown 5 
   -- denotes unsuccessful in vivo propagation 
 
The drug sensitivities established for the nine T. evansi strains against the four current 
standard drugs are shown in Table 2.2. The STIB 806K T. evansi reference strain typified IC50 
values considered to be sensitive to the drugs suramin (70.4), diminazene (4.5) and 
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cymelarsan (1.4). All other strains, except the two Kenyan strains and the Colombian strain, 
showed similar sensitivity to suramin. These two Kenyan strains isolated from camels (STIB 
780 and STIB 781), produced IC50 values of 14’500 and 11’000 ng/ml respectively (around 
200 times higher than the reference strain), demonstrating resistance to suramin, whilst a 
reduced sensitivity (four times greater than the reference strain) was observed in the 
Colombian strain with an IC50 value of 278.9 ng/ml. 
Diminazene sensitivity is demonstrated in the reference strain, in the Kenyan strains 
(STIB 780 and STIB 781), the Kazakhstan strain and the South American strains 
(CAN86/Brazil and Colombia). A reduced sensitivity was seen in strains originating from the 
South East of Asia, in the Indonesian RoTat 1.2 and the Philippines strain, being 
approximately four times and five times, respectively, less sensitive than the reference strain. 
All T. evansi strains tested against cymelarsan produced IC50 values within the range of > 0.1 
to 2.8 ng/ml. The Colombian strain showed the least sensitivity to quinapyramine (greater 
than six times that of the reference strain), followed by the CAN86/Brazil strain, the RoTat 
1.2 strain, the Kazakhstan strain and the Philippines strain. The more sensitive T. evansi 
strains were STIB 780, STIB 781 and the Vietnam strain. 
Also displayed in Table 2.2 are the IC50 values for the eleven T. equiperdum strains 
tested. All strains demonstrated similar sensitivities for suramin as that of the reference strain, 
BoTat 1.1 (87.5 ng/ml), with the increasing exceptions of the strains, Hamburg, AnTat 4.1, 
ATCC30023 and American, which demonstrated approximately 1.5, 2, 3 and 4 -fold 
differences, respectively. The AnTat 4.1 strain revealed the highest sensitivity against 
diminazene, with five T. equiperdum strains showing similar diminazene sensitivity as those 
displayed by the majority of the T. evansi strains (Alfort, ATCC30023, BoTat 1.1 (reference 
strain), Hamburg and SVP strains). Both the American and the ATCC30019 strains revealed 
decreased sensitivity to diminazene, compared to the reference strain, by a factor of three, 
whilst the Canadian and STIB 818 strains revealed decreased sensitivities through a factor of 
four. The South African OVI strain was 70 times less sensitive to diminazene as the BoTat 1.1 
reference strain, signifying resistance to this drug. 
Similar to the T. evansi strains, all the T. equiperdum strains tested showed drug 
sensitivities of > 0.1 to 2.0 ng/ml against cymelarsan, apart from the OVI strain, which was 
twenty-five times higher than the reference value. The majority of T. equiperdum strains 
demonstrated quinapyramine sensitivities within the range of > 0.1 to 2.2 ng/ml. The 
reference strain (3.3 ng/ml) was thirteen times more sensitive than the Hamburg strain (43.8 
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ng/ml), fourteen times more sensitive than the Canadian strain (47.6 ng/ml) and twenty-three 
times more sensitive than the OVI strain (76.4 ng/ml) to quinapyramine. 
 
Table 2.2. Mean drug sensitivities (given as IC50 in ng/ml) obtained for the four standard drugs tested against 
Trypanosoma evansi and Trypanosoma equiperdum study strains. 
 
Standard drugs ( inhibitory concentration (IC50) values in ng/ml) Strain 
  Suramin       Diminazene    Cymelarsan Quinapyramine 
T. evansi strains         
CAN86/Brazil 76.5 (±4.21) 2.7 (±0.28) 0.8 (±0.00) 15.8 (±0.35) 
Colombia 278.9 (±5.84) 2.2 (±0.14) 0.5 (±0.07) 84.5 (±0.00) 
Kazakhstan 97.8 (±1.48) 4.1 (±0.07) 1.1 (±0.14) 12.8 (±0.00) 
Philippines 81.5 (±3.42) 20.2 (±0.35) 2.8 (±0.28) 7.4 (±4.24) 
RoTat 1.2 69.5 (±6.99) 15.9 (±0.07) 2.2 (±0.00) 14.4 (±1.70) 
STIB 780 14’500.0 (±0.00) 1.9 (±0.22) 0.2 (±0.07) <0.1 (±0.00) 
STIB 781 11’000.0 (±0.00) 5.4 (±0.42) <0.1 (±0.00) 3.4 (±0.28) 
STIB 806K 70.4 (±4.05) 4.5 (±0.07) 1.4 (±0.07) 13.3 (±0.57) 
Vietnam 91.1 (±5.58) 8.2 (±0.71) 2.1 (±0.07) 3.0 (±0.28) 
T. equiperdum strains         
Alfort 76.9 (±5.91) 6.1 (±0.35) 1.3 (±0.09) <0.1 (±0.00) 
American 22.1 (±6.92) 13.5 (±0.07) 1.4 (±0.21) <0.1 (±0.00) 
AnTat 4.1 46.7 (±7.91) <0.1 (±0.00) <0.1 (±0.00) 2.2 (±2.83) 
ATCC30019 31.4 (±2.84) 14.3 (±0.92) 0.9 (±0.07) <0.1 (±0.00) 
ATCC30023 75.6 (±4.17) 3.6 (±0.57) 1.8 (±0.28) <0.1 (±0.00) 
BoTat 1.1 87.5 (±3.30) 4.3 (±0.21) 0.7 (±0.00) 3.3 (±1.34) 
Canadian 68.8 (±6.50) 19.0 (±0.57) 1.6 (±0.14) 47.6 (±0.57) 
Hamburg 61.2 (±4.04) 5.5 (±0.42) 0.6 (±0.00) 43.8 (±1.49) 
OVI 92.7 (±6.84) 302.5 (±12.1) 17.6 (±0.78) 76.4 (±2.47) 
STIB 818 86.6 (±4.60) 19.2 (±0.00) <0.1 (±0.00) 1.6 (±0.23) 
SVP 71.1 (±10.6) 6.5 (±0.42) 2.0 (±0.00) <0.1 (±0.00) 
    (±) denotes standard deviations of at least three to four experiments, each performed in duplicate. 
 
 
 
Discussion 
 
The aim of this study was to produce a drug profile for a panel of Trypanosoma evansi 
and Trypanosoma equiperdum strains, against the four standard drugs currently used for 
treatment of Surra (suramin, diminazene, cymelarsan and quinapyramine). With this 
collection, it was possible to demonstrate the presence of resistance and reduced drug 
sensitivity occurring in various locations around the world. 
A major advantage of using the 3H-hypoxanthine assay is that it allows original 
isolates, which have not yet been adapted to in vitro cultivation, to be tested under laboratory 
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conditions to determine sensitivities against certain drugs. The IC50 values produced in this 
way tend to reflect a more accurate sensitivity of a specific field isolate to a certain drug, than 
if the isolate had been culture adapted and kept under in vitro conditions for a long period of 
time, before it is then tested. However, in order to produce such drug sensitivity values, a high 
parasite starting concentration is required (in this study, 2x106 / ml parasites were required for 
each isolate). Whilst many of the field isolates do not contain such high numbers of parasites, 
it is possible to pass them once through mice and hence establish higher parasitaemias, which 
in turn can be harvested and utilised in the 3H-hypoxanthine assay. By means of an in vivo 
trypanosome propagation technique in mice, the majority of T. evansi and T. equiperdum 
study isolates were primarily propagated (parasitaemias were established within a week), then 
harvested, by passing the mouse blood through a DEAE-cellulose column, to finally achieve 
the high parasite concentrations needed to perform the drug sensitivity assays. Two T. evansi 
strains could not be successfully propagated in NMRI mice (Merzouga 56 and 
MHRYD/Brazil). Although parasites were detected after infection with these strains, no 
suitable trypanosome propagation could be carried out even after several mouse subpassages. 
These two strains were thus removed from the study and no further tests were performed with 
them. 
The results produced by the T. evansi study strains (seen in Table 2.2) demonstrate 
that variations in drug sensitivities for the four standard drugs can occur between the 
geographically different strains. This is best seen in the two Kenyan strains isolated from 
camels (STIB 780 and STIB 781), both of which clearly display resistance to suramin with 
IC50 values of 14’500 and 11’000 ng/ml respectively. In terms of field application, ineffective 
treatment of these isolates with suramin suggests that either cymelarsan or quinapyramine 
could be used as an alternative. To add to this dilemma, not only are cymelarsan and 
quinapyramine not readily available in locations such as Africa, but they are also rather 
expensive. In addition, reduced suramin sensitivity was also shown in the Colombian strain 
(278.9 ng/ml), originally isolated from a horse in 1973. 
The Indonesian RoTat 1.2 and the Philippines strains demonstrated the least 
diminazene sensitivity of all the T. evansi study strains. Since diminazene is used in these two 
Southeast Asian countries as the standard drug for treating T. evansi infections in cattle and 
buffalo and as resistance in the field tends to occur primarily through inadequate or erroneous 
application of subcurative doses of a drug over a period of time (Bacchi, 1993), the reduced 
sensitivities found in the RoTat 1.2 and the Philippines strains could be due to an 
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overexposure of diminazene treatment in water buffaloes and thus less sensitive strains 
against this drug. 
A substantial reduction in diminazene sensitivity can be seen in the South African T. 
equiperdum OVI strain (302.5 ng/ml). Since T. equiperdum infections are not considered 
curable on a clinical basis and there are currently no officially approved drugs, it is uncertain 
as to whether the OVI strain has developed diminazene resistance through the misuse of 
chemotherapeutic regimens in the field. However, this high IC50 value seen with diminazene 
helps to explain the equally high IC50 value seen for cymelarsan (17.6 ng/ml). Previous 
reports have described a TbAT1 gene found in trypanosomes, responsible for encoding a 
nucleoside P2 transporter (Mäser et al, 1999). This transporter is vital in the uptake of 
adenosine and adenine within trypanosomes, allowing them to salvage purines and nucleoside 
bases. Moreover, the P2 transporter is involved in the active drug uptake of diamidine 
compounds and melaminophenyl arsenicals. Furthermore, loss of this P2 transporter renders 
that organism resistant to such compounds (Carter and Fairlamb, 1993; Carter et al., 1995; 
Barrett et al., 1995). Therefore, if the OVI strain is missing a functional P2 transporter, it 
would be prevented from adequately taking up the drugs, diminazene and cymelarsan. Several 
studies have already shown the possible cross resistance between diamidine drugs, such as 
diminazene, and melaminophenyl arsenical compounds, such as cymelarsan (Zhang et al., 
1993; Ross and Barns, 1996). Although cymelarsan is officially registered for 
chemotherapeutic use in horses, as well as in other animals, such as camels and goats, 
whether this drug is readily available on the veterinary market in South Africa is another 
issue. Due to the limited availability and high costs of cymelarsan, it is doubtful as to whether 
the OVI strain has lost part of its cymelarsan sensitivity through drug overexposure in the 
field, whereas cross resistance to another drug provides a more probable explanation. 
The high IC50 value seen with quinapyramine for the South African OVI strain (76.4 
ng/ml) could indicate additional cross resistance between quinapyramine, cymelarsan and 
diminazene. Ndoutamia et al. (1993) were able to induce quinapyramine resistance in 
Trypanosoma congolense in vivo, which was associated with cross resistance to 
isometamidium, homidium and diminazene. As cross resistance is frequently seen in drugs 
belonging to similar chemical families, this could be an explanation why the OVI strain 
demonstrates such reduced sensitivity against all three standard drugs (diminazene, 
cymelarsan and quinapyramine). 
The use of quinapyramine as the drug of choice in Colombia to treat T. evansi 
infections in horses, could explain the reduced sensitivity to this drug. As the Colombian 
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strain was itself isolated from an equine host, the overuse and mismanagement of 
quinapyramine therapy in the field could be causing the emergence of potential resistance, 
which consequentially would lead to less sensitive T. evansi strains in South America. This 
could also be the case for the standard drug suramin, which was previously used to treat 
infected horses and cattle throughout South America, hence leading to the reduced sensitivity 
shown by the Colombian strain against suramin. 
With this range of T. evansi and T. equiperdum isolates from around the world, a 
reference panel of isolates with known drug sensitivity could be established. The study has 
demonstrated drug resistance and reduced drug sensitivity in certain strains, a development 
which needs to be further monitored. Moreover, this leads to the suggestion that this drug 
profile could also be used as a reference when screening and testing new compounds against 
these two infectious agents. Since chemotherapy remains the most efficient and effective way 
to control Surra, it is vital that new, effective and preferably cheaper drugs are discovered to 
combat infection as soon as possible. 
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Abstract 
 
Trypanosoma evansi is an animal pathogenic protozoan, causing a wasting disease 
called Surra. Transmitted mechanically by biting flies of the Genera, Tabanus, Stomoxys and 
Lyperosia, Surra is broadly distributed with a wide range of mammalian hosts. Chemotherapy 
is the most efficient control method with treatment for Surra currently dependent on four main 
drugs. Unfortunately, with the appearance of resistance to these drugs, their effective use is 
threatened, emphasising a need to find new drugs. 
Diamidines (dicationic molecules) bind to the minor groove of DNA at AT-rich sites. 
They apply their biological activity by primarily binding to DNA and then inhibiting one or 
more DNA dependent enzymes or by directly impeding the transcription process. In total, 181 
novel diamidine compounds were tested in vitro to determine activity against an animal 
pathogenic Chinese kinetoplastic Trypanosoma evansi strain. In comparison, a human 
pathogenic Trypanosoma brucei rhodesiense strain and a P2 transporter knock out of a 
Trypanosoma brucei brucei strain were also tested. 
All diamidine compounds tested in this study against T. evansi produced inhibitory 
concentration (IC50) values below 30 ng/ml; whereas 70 % of these compounds had IC50 
values below 10 ng/ml. The results demonstrate that these compounds are highly active 
against T. evansi in vitro. In addition, preliminary in vivo toxicity tests were performed on all 
181 novel diamidines with 55 % of the compounds showing no acute toxicity. In contrast, 8 % 
were toxic and 37 % were lethal within a mouse model. 
 
Keywords: Trypanosoma evansi, Surra, diamidines, chemotherapy. 
 
 
 
Introduction 
 
Trypanosoma evansi is an animal pathogenic protozoan, which causes a wasting 
disease called Surra. Surra is widely distributed geographically and has a broad range of 
mammalian hosts, thus causing great economical loss in areas of Africa, Asia and South 
America (Giardina et al., 2003). Transmitted mechanically by biting flies (Tabanus, 
Stomoxys and Lyperosia species) (Luckins, 1992), T. evansi is pathogenic in most domestic 
animals and some wild animals, depending on the virulence of the strain and various host 
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factors (Kaminsky et al., 1997). The main host species varies according to geographical 
location (Davila and Silva, 2000; Holland et al., 2004; Lun et al., 2004; Zhou et al., 2004). 
The endemic geographic distribution of this disease ranges from China, the Philippines and 
parts of Indonesia, across Southeast Asia and parts of the former U.S.S.R, into the Indian 
subcontinent, the Middle East and Africa, until it reaches Central and South America (OIE, 
2004). 
Treatment for Surra is currently dependent on four drugs, namely suramin, diminazene 
aceturate, quinapyramine and cymelarsan (Zhang et al., 1992). While the first three have been 
utilised for more than 50 years (Lourie and York, 1939; Kaminsky and Zweygarth, 1989), 
cymelarsan, belonging to the family of melaminophenyl arsenicals, was pharmaceutically 
developed less than twenty years ago (Zelleke et al., 1989; Raynaud et al., 1989). With the 
rising appearance of resistance to these drugs, their effective use is threatened, emphasising 
the necessity for finding new alternative drugs (Kaminsky et al., 1989; De Koning, 2001; 
Suswam et al., 2001). Since many of the hosts affected in these endemic countries represent 
expensive and prestigious animals, a new drug against T. evansi infection would have a 
potentially high market value amongst other agents currently available for trypanosomal 
diseases. 
An important step to consider in discovering any anti-parasitic drug is to determine the 
efficiency with which it can be taken up by the parasite. This can occur via one (or more) of 
four main processes; passive diffusion, endocytosis, receptor-mediated uptake or transporter-
mediated uptake. Certain consequences, such as the mode of action, selectivity and potential 
development of resistance of a drug are derived and will in turn depend on the method of 
uptake used (Carter et al., 1995; De Koning, 2001). The selectivity of diamidines for 
example, is primarily due to the selective accumulation by the pathogen rather than by host 
cells (Denise and Barrett, 2001). 
Diamidines are dicationic molecules, which bind to the minor groove of DNA at AT-
rich sites. Their interaction with the DNA minor groove has been examined at a molecular 
level, concluding that these compounds apply their biological activity by primarily binding to 
DNA and then inhibiting one or more of the DNA dependent enzymes (such as 
topoisomerases or nucleases) or by directly impeding the transcription process (Wilson et al., 
2005). The selective binding to kinetoplastic DNA has also been suggested to play a vital role 
in the action of aromatic diamidines against pathogens (Francesconi et al., 1999). 
The aim of this study was to test 181 diamidine compounds, found to be active against 
T. b. rhodesiense in vitro, and determine their activity against T. evansi strains. Since T. 
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evansi is phylogenetically very close to Trypanosoma brucei, its drug sensitivity is very 
similar to that of the T. brucei trypanosomes. It was therefore hypothesised that diamidine 
compounds, found active against T. brucei subgroups, could also be effective against T. 
evansi. Selection of the 181 active diamidine compounds was hence based on the inhibitory 
concentration (IC50) values and relative activity shown by a T. b. rhodesiense strain used in 
previous experimental procedures. 
 
 
 
Materials and methods 
 
Trypanosome stocks  
 
Three different trypanosome strains were used in this study. The reference strain, 
Trypanosoma evansi (STIB 806K) is kinetoplastic and was isolated from a water buffalo in 
China in 1983. A human pathogenic Trypanosoma brucei rhodesiense (STIB 900) strain, 
isolated in 1982 from a male patient in Ifakara, Tanzania, was used as a comparison. The third 
strain used was a genetic knock out of a T. b. brucei strain (STIB 777S), which is missing the 
TbAT1 gene encoding the nucleoside P2 transporter. All three strains were cloned and adapted 
to axenic culture conditions as described in Baltz et al. (1985). 
In addition to these strains, six further T. evansi strains, isolated from various 
geographical regions, were tested against a selection of diamidines to determine strain 
sensitivity. These six strains (CAN86/Brazil, Colombia, Kazakhstan, Philippines, RoTat 1.2 
(Indonesia) and Vietnam) were originally obtained from the cryobank of the Institute of 
Tropical Medicine (ITM) in Antwerp, Belgium, and then adapted to axenic culture conditions 
as described in Baltz et al. (1985). 
 
Mammalian cell lines  
 
Rat skeletal myoblast cells, designated L6 cells, were used for the in vitro cytotoxicity 
assay to evaluate the toxicity of the diamidine compounds tested. The L6 cell line cultures 
were kept in 25 ml tissue culture flasks (Becton Dickinson, USA) and were incubated at 37 
°C and 5 % CO2. 
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Mice  
 
Female NMRI mice, weighing 22 - 25 g, were used for the in vivo preliminary toxicity 
tests. Mice were specific pathogen free (SPF) and were housed in standard Macrolon type II 
cages, at 22 °C and with a relative humidity of 60 - 70 %. The mice received pelleted food 
and water ad libitum. 
 
Standard trypanocidal drugs  
 
Suramin (Germanin® from Bayer, Leverkusen, Germany), diminazene aceturate (D-
7770, Sigma, St Louis, MO, USA), cymelarsan (MelCy®, Rhône Mérieux, Toulouse, France) 
and quinapyramine sulphate (Trypacide®, May & Baker, Lagos, Nigeria) were used as the 
standard drugs in this study. 
 
Diamidine compounds  
 
The diamidine compounds were previously designed, synthesised and chosen by the 
chemists, David Boykin and Richard Tidwell, based on the compounds’ chemical and 
physical properties, general biological stability and the overall costs involved in their 
manufacture. Previous knowledge on some structure-function relationships was also applied, 
to ensure the most active chemical groups and compositions were included within these newly 
designed compounds. 
 
Culture medium  
 
Bloodstream form trypanosomes were cultivated in Minimum Essential Medium 
(MEM) (powder, GIBCO/BRL, No: 11400-033) with Earle’s salts, supplemented with 25 mM 
HEPES, 1 g/l additional glucose, 2.2 g/l NaHCO3 and 10 ml/l MEM non-essential amino 
acids (50x concentration). The medium was then further supplemented by adding 1 % of a 2-
mercaptoethanol stock (14 μl of 12 mM 2-mercaptoethanol was diluted in 10 ml of distilled 
water), 1 % of a stock consisting of 100 mM sodium pyruvate and 50 mM hypoxanthine and 
15 % heat inactivated horse serum, according to Baltz et al. (1985). The complete medium is 
called Baltz MEM (BMEM). 
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The L6 (rat myoblast) cells were cultivated using RPMI 1640 medium (powder, Life 
Technologies) and supplemented with 25 mM HEPES and 2 g/l NaHCO3. The medium was 
then further supplemented with 1.7 μM L-glutamine and 10 % heat inactivated foetal calf 
serum. 
 
Stock solutions and dilutions  
 
Stock solutions of 10 mg/ml of each compound were prepared and then stored frozen 
at -20 °C. From these stock solutions, further compound dilutions were made for use in the 
various in vitro cell viability assays, using the appropriate culture medium as a solvent. 
Compound dilutions were made fresh on the day of each experimental procedure. 
 
In vitro cell viability assay  
 
To determine the IC50 values for the compounds tested, the Alamar Blue® assay 
detailed in Räz et al. (1997) was used. In brief, 50 μl of BMEM were added to each well of a 
96-well flat bottomed microtitre plate (CostarTM, Corning, NY, USA), except for the final 
row. Instead, 75 μl of BMEM, containing two times the highest compound concentration, 
were placed into each well on the last row. Thereafter, serial compound dilutions were 
performed, whereby 25 μl from the final row were removed and mixed thoroughly with the 
contents of the row above. Again, 25 μl from this second-to-last row were then removed and 
mixed with the next row above and so on until all rows had achieved this series of 1:3 
compound dilutions. The final 25 μl were discarded. However, no compound dilutions were 
made within the first row, since this row acted as a control. A further 50 μl of BMEM were 
then added to every third column along the 96-well plate, to provide background control wells 
containing no trypanosomes. Finally into all the remaining wells, 50 μl of a trypanosome 
suspension were added. The trypanosome density was calculated using a cell counter and 
analyser system (CASY, Schaerfe System, Reutlingen, Germany) to enable a trypanosome 
seeding density of 4x104/ml of culture medium to be added to the assay. The assay plates 
were then incubated at 37 °C with 5 % CO2 for 69 hours, whereupon the plates were removed 
from the incubator and 10 μl of Resazurin dye (12.5 mg in 100 ml phosphate buffered saline) 
(Aldrich/Fluka, #33934, Buchs, Switzerland) were placed into each well. The assay plates 
were returned once again to the incubator for a further 3 hours under the same incubation 
conditions. Once the assay plates were ready, they were removed and read using a fluorescent 
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reader (SpectraMax, Gemini XS, Bucher Biotec, Basel, Switzerland) at an excitation 
wavelength of 536 nm and an emission wavelength of 588 nm. The IC50 values were 
determined using appropriate computer software (SOFTmax Pro 3.1.2). All experiments were 
performed on all trypanosome strains in two separate experimental procedures. 
 
In vitro cell cytotoxicity assay  
 
To determine the cytotoxicity of each of the compounds tested, a standard operating 
procedure (SOP) using the L6 (rat skeletal myoblast) cell line was followed. It is similar to 
that of the Alamar Blue® assay, except for a few modifications. First, 100 μl of a 
4x104cells/ml cell suspension were added to each well of a 96-well flat bottomed microtitre 
plate (CostarTM, Corning, NY, USA), except for the wells in every third column. The cell 
suspension was calculated using a Neubauer counting chamber and then diluted with culture 
medium to obtain the correct concentration. Into all other remaining wells, 100 μl of culture 
medium were placed without cells, acting as control wells. The plates were then incubated at 
37 °C and 5 % CO2 overnight, to enable the L6 cells to attach to the microtitre plates. The 
following day, the medium was removed from all the wells and all rows (except the last row) 
replaced with 100 μl of fresh culture medium. Thereafter, 150 μl of culture medium 
containing two times the highest compound concentration were added to the wells in the last 
row. Serial compound dilutions were performed by removing 50 μl from the last row and 
mixing them thoroughly with the contents of the wells in the second-to-last row. Then a 
further 50 μl from this row were removed and mixed thoroughly with the row above it and so 
on until all rows had achieved this compound dilution factor of 1:3. The final 50 μl were 
discarded. Again the top row of the microtitre plate was not included in the serial compound 
dilutions, since this row represented a control. The assay plates were then placed into the 
incubator at 37 °C with 5 % CO2 for 69 hours. After this time had elapsed, the plates were 
removed from the incubator and 10 μl of Resazurin dye (Aldrich/Fluka, #33934, Buchs, 
Switzerland) were placed into each well. The assay plates were returned once again to the 
incubator for a further 3 hours under the same incubation conditions. Once the assay plates 
were ready, they were removed and read using a fluorescent reader (SpectraMax, Gemini XS, 
Bucher Biotec, Basel, Switzerland) at an excitation wavelength of 536 nm and an emission 
wavelength of 588 nm. The IC50 values were determined using appropriate computer software 
(SOFTmax Pro 3.1.2). All experiments were performed in three separate experimental 
procedures. 
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In vivo preliminary toxicity tests  
 
For the in vivo preliminary toxicity tests, an SOP was followed. The compounds were 
diluted freshly on the day of testing and injected into the mice using an intra-peritoneal (i.p.) 
route. A female NMRI mouse was taken and given an i.p. injection at 5 mg/kg. The mouse 
was then injected every 2 hours with an increasing dose, starting with the 5 mg/kg dose, then 
rising to 15 mg/kg, 30 mg/kg and 50 mg/kg. The cumulative dose corresponds to the injection 
dose, so that 15 mg/kg has an accumulation of 20, 30 mg/kg of 50 and 50 mg/kg of 100, 
respectively. During each 2 hour interval, the mouse was observed carefully for any signs of 
toxicity or sub-toxicity. After the final dose (50 mg/kg) had been administered, the mouse was 
observed for a further 2 hours and then again after 24 hours. The results of the in vivo 
preliminary toxicity tests were based on each compound being lethal (hence the mouse died), 
toxic (where the mouse showed signs of toxicity, but did not die) or not toxic (where the 
mouse appeared normal and could tolerate the highest accumulated dose of 100 mg/kg). 
 
 
 
Results 
 
In total, the four standard drugs against Trypanosoma evansi and 181 novel diamidine 
compounds were tested in vitro using a cell viability assay. For each compound, inhibitory 
concentration (IC50) values in ng/ml were obtained, against three different trypanosome 
strains; an animal pathogenic Chinese kinetoplastic T. evansi (STIB 806K), a human 
pathogenic T. b. rhodesiense (STIB 900) and a P2 transporter knock out of a T. b. brucei 
(TbAT1, originally STIB 777S). The IC50 values for the four standard drugs are shown in 
parallel in Table 3.1 for each of the three trypanosome strains, respectively. 
The greater IC50 values seen for suramin (a naphthalene compound) clearly 
demonstrate that this current standard drug has reduced activity in vitro against both STIB 
806K and STIB 900. Its value for the TbAT1 knock out strain resembles a drug that still has 
inadequate trypanocidal activity, even though it relies mainly on diffusion and/or endocytosis 
for its uptake. Diminazene (a dicationic diamidine) has a low IC50 value against STIB 900, yet 
gives a slightly elevated value for STIB 806K. Although it seems to be reasonably active 
against T. evansi, its value for the TbAT1 strain shows that it relies heavily on P2 transport, 
which in turn could cause problems with resistant strains. In vitro IC50 values for cymelarsan 
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(a member of the melaminophenyl arsenicals) are much lower than the two previous standard 
drugs against STIB 806K and STIB 900. The fourth standard drug, quinapyramine (belonging 
to the quinoline pyrimidines), reveals even lower IC50 values for STIB 806K and STIB 900 
than the other standard drugs. However, an elevated IC50 value for the TbAT1 strain 
demonstrates an involvement with P2 transport. 
 
Table 3.1. The four standard drugs currently used against T. evansi infection, with their chemical families and 
structures depicted alongside the IC50 values obtained with a kinetoplastic T. evansi strain (STIB 806K), a T. b. 
rhodesiense strain (STIB 900) and a T. b. brucei P2 transporter knock out strain (TbAT1). Cytotoxicity IC50 
values (using L6 cells) and preliminary in vivo toxicity values (using NMRI mice) are also shown. 
 
Inhibitory concentration (IC50) in ng/ml Drug 
identity 
Chemical 
family STIB 
806K 
STIB 
900 
TbAT1 
(K.O.) 
Cytotoxicity 
(L6 cells) 
Preliminary 
toxicity 
(mg/kg) 
Chemical 
structure 
        
Suramin Naphtha- 
lene 
87.6 75.8 >100 >90’000 Toxic at 
50 i.p. 
 
Diminazene Triazene 12.5 2.8 >100 4’091 Lethal at 
20 i.p. 
 
Cymelarsan Melamino- 
phenyl 
arsenical 
1.1 1.9 3.3 >90’000 Lethal at 
20 i.p. 
NaO3S
NaO3S
NH
O
CH3
N
H
O
N
H
N
H
O
SO3Na
O
N
H
CH3
NH
O
SO3Na
NaO3S
NaO3S
N
NH2
NH2
NN
H
NH2
NH2
N
N
N
NH2
NH2
N
H
As
S
S C
H2
C
H2
C
H2
C
H2
NH2
NH2
 
Quina-
pyramine 
Quinoline 
pyrimidine 
0.1 0.3 >87.4 83’623 Lethal at 
5 i.p. N
NH2
CH3
CH3
N
H
N N
CH3
CH3
CH3
  i.p. denotes an intra-peritoneal route was used 
 
The IC50 values for the Boykin compounds against all three trypanosome strains can 
be seen in Table 3.2. All compounds produced an IC50 value below 20 ng/ml for both the 
STIB 806K and STIB 900 strains. In addition, eighty-eight of these compounds produced an 
IC50 value below 10 ng/ml, again for both STIB 806K and STIB 900 strains. These 
compounds demonstrate higher in vitro activity against the T. evansi strain than the standard 
drugs provide. Therefore, compounds showing IC50 values of less than 10 ng/ml can be 
selected for further investigation. The IC50 values for the TbAT1 knock out strain for the 
Boykin compounds ranges from 0.1 ng/ml to greater than 93.7 ng/ml. The compounds 
showing higher IC50 results against this knock out strain can be selected against, since these 
compounds indicate probable P2 transport and hence have less potential activity against drug 
resistant T. evansi strains. In summary, only those compounds demonstrating high activity 
against the STIB 806K and the TbAT1 strains will be selected for based on the current 
selective criteria. This implies all compounds with low IC50 values against both STIB 806K 
and TbAT1 strains will continue on into in vivo investigations. 
 49
Chapter 3: In vitro activity of diamidines against T. evansi 
 
Table 3.2. Ninety-eight new diamidine compounds, designed by David Boykin, with their chemical families and 
structures depicted alongside the IC50 values obtained with a kinetoplastic T. evansi strain (STIB 806K), a T. b. 
rhodesiense strain (STIB 900) and a T. b. brucei P2 transporter knock out strain (TbAT1). Cytotoxicity IC50 
values (using L6 cells) and preliminary in vivo toxicity values (using NMRI mice) are also shown. 
 
Inhibitory concentration (IC50) in ng/ml Compound 
identity 
Chemical 
family STIB 806K 
STIB 
900 
TbAT1 
(K.O.) 
Cytotoxicity  
(L6 cells) 
Preliminary 
toxicity 
(mg/kg) 
Chemical 
structure 
        
DB 75 Diphenyl 
furan 
2.3 0.8 15.4 >90’000 Toxic at 
50 i.p. 
 
 
ONH
NH2 NH2
NH
 
DB 103 Diphenyl 
furan 
6.0 9.1 18.5 >90’000 Lethal at 
50 i.p. 
 
DB 201 Benz-
imidazole 
4.5 8.9 20.9 >90’000 Toxic at 
20 i.p. 
N
H
N N
N
H
O
N N
NN N NN
N N
 
DB 210 Benz- 
imidazole 
1.2 9.6 18.3 >90’000 Lethal at 
100 i.p. 
DB 211 Pyrimidine 10.4 3.9 4.7 >90’000 Not toxic  
at 100 i.p. 
N
N
NH
NH2
O
CH3
NH2
NH
 
DB 217 Benz-
imidazole 
2.2 3.2 3.9 >90’000 Lethal at 
50 i.p. 
 
DB 242 Diphenyl 
furan 
9.8 8.6 7.9 >90’000 Lethal at 
100 i.p. 
DB 262 Diphenyl 
pyrrole 
8.2 4.6 4.4 85’280 Not toxic 
at 100 i.p. 
 
DB 320 Diphenyl 
pyrrole 
5.0 2.1 2.8 >90’000 Not toxic 
at 100 i.p. 
N
N
N
NNH
NH2
O
CH3
N
N N
N N NN
N N
CH3 H
H H
H
O
NH
NH
CH2
NH
NH
CH2
N
H
NH
NH2 NH2
NH
NNH NH
NH2 NH2
CH3
 
DB 325 Benz- 
imidazole 
2.8 4.2 3.1 >90’000 Not toxic 
at 100 i.p. 
 
DB 346 Biphenyl 5.8 2.4 1.2 6’500 Not toxic 
at 100 i.p. 
 
DB 351 Diphenyl 
thiophene 
3.3 0.7 0.8 88’410 Not toxic 
at 100 i.p. SNH
NH2
NH2
NH
 
DB 417 Diphenyl 
furan 
3.6 2.9 3.6 >90’000 Lethal at 
100 i.p. ONH
NH
N
H
NH
CH3
CH3  
DB 427 Diphenyl 
furan 
7.2 4.1 5.7 89’530 Toxic at 
50 i.p. 
 
 
O
NH
NH
N
H
NH
CH2CH3
CH2CH3  
DB 484 Diphenyl 
oxazole 
6.5 1.5 3.2 >90’000 Lethal at 
100 i.p. 
 
DB 497 Benz- 
imidazole 
8.5 12.2 6.0 85’220 Toxic at 
20 i.p. 
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H
N
N
N
H
N
N
H
N
H
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C
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DB 508 Benz- 
imidazole 
9.6 2.4 5.1 >90’000 Toxic at 
20 i.p. 
 
DB 544 Diphenyl 
furan 
3.7 3.4 6.0 >90’000 Toxic at  
100 i.p. 
DB 545 Diphenyl 
Furan 
8.6 3.8 12.5 6’860 Toxic at 
20 i.p. 
 
DB 560 Diphenyl 
thiophene 
3.7 1.8 2.6 >90’000 Toxic at 
20 i.p. 
DB 609 Diaryl 
furan 
8.3 6.2 18.5 >90’000 Toxic at 
20 i.p. 
N
N
H
N
H
N
NH
NH
NH
NH
CH3CH3
CH3 CH3
NH
NH2
O
NH2
NH
CH3
CH3
N
H
N N
N
H
O
CH3CH3
NH
NH2
S
NH2
NH
O
NH
NH2
O
NH2
NH
 
 
DB 690 Diphenyl 
furan 
7.3 1.8 2.0 >90’000 Not toxic 
at 100 i.p. 
DB 746 Diphenyl 
furan 
10.6 9.0 13.5 53’490 Toxic at 
20 i.p. 
 
N
N
O
N
H
N
H
O
CH3
O
CH3
NH
NH
 
DB 763 Diphenyl 
furan 
2.7 6.6 5.7 >90’000 Toxic at 
50 i.p. 
 
NH2
NH2
O
N
H
N
H
O
CH3
O
CH3
NH
NH
 
DB 773 Thiophene 3.7 4.5 71.9 >90’000 Lethal at 
100 i.p. 
 
DB 820 Aza-furan 5.4 1.3 3.0 >90’000 Not toxic 
at 100 i.p. 
DB 828 Diaryl 
furan 
5.3 5.7 75.6 >90’000 Not toxic 
at 100 i.p. 
 
DB 832 Bifuran 8.7 3.6 6.1 >90’000 Not toxic 
at 100 i.p. 
DB 841 Indene 7.2 8.7 82.0 >90’000 Lethal at 
100 i.p. 
DB 846 Benz- 
imidazole 
10.0 10.7 5.0 >90’000 Lethal at 
50 i.p. 
DB 849 Indenone 1.8 3.7 6.4 >90’000 Toxic at 
50 i.p. 
 
N
H
N
H
NH2
NH
NH2
NH
O  
DB 850 Benz-
imidazole 
4.5 5.3 9.2 >90’000 Not toxic 
at 100 i.p. 
O
NH
NH2
NH2
NH
S
NH
NH2 NH2
NH
CH3 CH3
NNH
NH2
O
NH2
NH
O
N
ONH
NH2
NH2
NH
O
O
NH
NH
NH2
NH2
N N
NH2
NHH
NH
NH2
H
H
N
H
N
NH2
NH
O CH3
NH
NH2
N
NO
NH
NH
NH2 NH2
CH3
 
 
DB 851 Benz- 
imidazole 
7.4 12.9 15.5 >90’000 Not toxic 
at 100 i.p. 
DB 853 Benz- 
imidazole 
7.2 13.7 24.4 >90’000 Not toxic 
at 100 i.p. 
DB 866 Thiophene 3.4 2.4 25.6 >90’000 Lethal at 
100 i.p. 
 
N
H
N
H
S
N
H
N
H
O
CH3
O
CH3
NH
NH
CH3
CH3
 
DB 867 Aza-furan 1.7 0.8 1.1 >90’000 Not toxic 
at 100 i.p. 
Table 3.2. continued… 
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O
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N
 51
Chapter 3: In vitro activity of diamidines against T. evansi 
 
DB 877 Biphenyl 3.4 0.2 0.2 >90’000 Lethal at 
100 i.p. 
 
DB 902 Diphenyl 
furan 
3.5 7.4 28.9 >90’000 Lethal at 
100 i.p. 
 
NH2
NH2
O
N
H
N
H
NH
NH
CH3 CH3
 
DB 911 Benz- 
imidazole 
3.7 2.4 2.4 >90’000 Lethal at 
100 i.p. 
N
N
NH
NH
NH2
NH2
N
N
H
NH
NH2
NH2
NH
 
DB 930 Diphenyl 
furan 
4.3 1.8 19.5 >90’000 Not toxic 
at 100 i.p. 
 
O
OH
NH
NH2
NH2
NH
DB 935 Aza-furan 4.6 7.3 84.0 >90’000 Lethal at 
100 i.p. 
 
DB 943 Biphenyl 2.8 4.5 3.9 88’070 Not toxic 
at 100 i.p. 
 
DB 945 Diphenyl 
furan 
3.2 2.9 3.8 >90’000 Not toxic 
at 100 i.p. 
 
O
NH
NH2
NH2
NHCH3
DB 988 Benz- 
imidazole 
5.6 3.5 54.5 >90’000 Not toxic 
at 100 i.p. 
DB 989 Benz-
imidazole 
7.1 4.5 3.6 >90’000 Not toxic 
at 100 i.p. 
DB 994 Aza-furan 6.6 1.1 1.2 37’850 Not toxic 
at 100 i.p. 
 
N
N
O
NH
NH2
NH2
NH
DB 1012 Diaryl 
furan 
7.2 3.3 2.7 >90’000 Not toxic 
at 100 i.p. 
DB 1016 Triphenyl 
furan 
10.5 6.9 9.2 >90’000 Lethal at 
100 i.p. 
DB 1017 Diphenyl 
furan 
8.0 2.9 4.9 >90’000 Not toxic 
at 100 i.p. 
N
NH
NH2
O
CH3
NH2
NH
O
NH
NH2 NH2
NH
NH
NH2 NH
N
NH2
NH
H CH3
N
N
O
NH
NH
NH2
NH2F
NNH
NH2
O
N
CH3
NH2
NH
O
H
NH
NH2
NH2
NH
O
HH
NH2
NHNH
NH2
FF
 
DB 1019 Biphenyl 2.8 0.4 0.5 >90’000 Not toxic 
at 100 i.p. 
 
N
NH
NH2 O
NH2
NH
 
DB 1023 Diphenyl 
thiophene 
6.5 4.3 6.6 >90’000 Lethal at 
100 i.p. S
NH
NH2 NH2
NH
CH3
 
DB 1044 Diaryl 
pyridine 
11.6 6.7 5.3 >90’000 Not toxic 
at 100 i.p. 
DB 1046 Benz- 
imidazole 
3.2 4.2 >93.7 >90’000 Not toxic 
at 100 i.p. 
 
DB 1049 Aza-triaryl 7.0 9.2 15.7 >90’000 Lethal at 
100 i.p. 
DB 1050 Aza-triaryl 6.3 1.8 8.1 >90’000 Not toxic 
at 100 i.p. 
DB 1052 Thiazole 10.2 7.2 7.1 41’570 Not toxic 
at 100 i.p. 
 
Table 3.2. continued… 
N
NH
NH2 NH2
NH
NH
N
NN
N
C
H2
C
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CH3 CH3
NH2
NH2
NH
N
N
NH2
NH
NH
NH2
N
NNH
NH
NH2
NH2
N
SNH2
NH NH
NH2
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DB 1055 Benz- 
imidazole 
11.4 11.8 3.4 >90’000 Not toxic 
at 100 i.p. 
DB 1065 Pyrrole 2.4 0.8 0.1 >90’000 Lethal at 
100 i.p. 
DB 1077 Thiophene 8.2 3.4 61.2 >90’000 Not toxic 
at 100 i.p. 
DB 1114 Biphenyl 1.7 4.1 5.7 >90’000 Lethal at 
100 i.p. 
DB 1149 Diaryl 
thiophene 
6.1 4.3 4.3 >90’000 Not toxic 
at 100 i.p. 
DB 1152 Cinnamide 3.7 0.5 0.7 33’490 Lethal at 
100 i.p. 
Structure not shown 
due to patent reasons 
DB 1157 Terphenyl 3.5 12.6 11.8 88’840 Not toxic 
at 100 i.p. 
 
DB 1159 Benz-
oxazole 
3.8 10.2 5.9 >90’000 Lethal at 
100 i.p. 
 
DB 1164 Aza-
terphenyl 
8.9 0.3 0.2 >90’000 Lethal at 
100 i.p. 
 
DB 1165 Terphenyl 2.4 1.3 1.2 >90’000 Lethal at 
100 i.p. 
 
DB 1171 Indole 1.3 0.8 0.7 62’830 Not toxic 
at 100 i.p. 
DB 1172 Indole 3.3 4.6 2.9 >90’000 Not toxic 
at 100 i.p. 
DB 1173 Diaryl 
furan 
6.2 11.4 11.3 >90’000 Not toxic 
at 100 i.p. 
 
DB 1177 Biphenyl 5.0 2.7 3.7 >90’000 Not toxic 
at 100 i.p. 
DB 1191 Indole 3.8 8.3 9.5 >90’000 Not toxic 
at 100 i.p. 
 
N
H
N
N
H
CH3
N
H
N
 
DB 1192 Indole 10.5 0.4 0.5 >90’000 Not toxic 
at 100 i.p. 
DB 1194 Diaryl 
thiophene 
1.4 2.1 1.6 >90’000 Not toxic 
at 100 i.p. 
Structure not shown 
due to patent reasons 
DB 1197 Benz- 
imidazole 
2.9 9.9 15.0 >90’000 Lethal at 
100 i.p. 
H
H
N
H
N
NH2
NH
NH
NH2
ON
NH
NH2
CH3
NH2
NH
S
NH
NH2
NH2
NH
N
O
NH2
NH
NH
NH2
N
H
N S N
NH
N
H
N
H
N
H
NH2
NH
NH2
NH
N
O
N
N
NH
NH
NH2
NH2
N
NHNH
NH2
NH2
NHNH
NH2NH2
N
H
NH
NH2
NH2
NH
N
N
H
N
H
N
N
H
NH
NH2 O
NH
NH2
NH2
NH
NH
NH2
N
H
NH
NH2
CH3
NH
NH2
NH
N
N
H
N
SN
NH
 
 
DB 1206 Terphenyl 8.7 0.9 0.2 >90’000 Not toxic 
at 100 i.p. 
DB 1210 Pyrazine 1.3 1.6 3.2 >90’000 Lethal at 
100 i.p. 
Structure not shown 
due to patent reasons 
Table 3.2. continued… 
NHNH
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DB 1213 Diaryl 
seleno-
phene 
10.0 0.9 0.6 >90’000 Not toxic 
at 100 i.p. 
Structure not shown 
due to patent reasons 
DB 1214 Diaryl 
thiophene 
1.3 5.9 4.4 >90’000 Lethal at 
100 i.p. 
S
N
NH
NH2
NH
NH2
 
 
DB 1220 Terphenyl 5.9 12.2 16.9 >90’000 Not toxic  
at 100 i.p. 
DB 1228 Aza-
terphenyl 
11.5 2.9 3.0 >90’000 Lethal at 
100 i.p. 
 
DB 1236 Benz-
imidazole 
9.5 4.8 5.2 >90’000 Not toxic 
at 100 i.p. 
 
DB 1237 Aza-
terphenyl 
6.9 7.9 9.3 >90’000 Lethal at 
100 i.p. 
 
NNNH
NH2 NH2
NH
DB 1239 Aza-
naphtha-
lene 
13.2 3.2 4.7 >90’000 Lethal at 
100 i.p. 
Structure not shown 
due to patent reasons 
DB 1242 Aza-triaryl 3.7 5.7 5.7 >90’000 Not toxic 
at 100 i.p. 
 
DB 1250 Benz-
imidazole 
6.4 1.2 1.3 >90’000 Not toxic 
at 100 i.p. 
 
DB 1253 Aza-triaryl 3.2 5.7 4.3 >90’000 Not toxic 
at 100 i.p.  
DB 1255 Bithio-
phene 
5.6 7.8 6.0 >90’000 Not toxic 
at 100 i.p. 
DB 1258 Aza-
terphenyl 
8.3 9.5 7.5 >90’000 Not toxic 
at 100 i.p. 
DB 1265 Indene 8.2 4.1 4.0 >90’000 Not toxic 
at 100 i.p. 
 
DB 1266 Arylamide 8.0 7.7 9.8 >90’000 Lethal at 
100 i.p. 
Structure not shown 
due to patent reasons 
DB 1271 Arylamide 7.0 8.1 9.8 >90’000 Lethal at 
100 i.p. 
Structure not shown 
due to patent reasons 
DB 1272 Seleno-
phene 
5.7 5.1 6.8 >90’000 Not toxic 
at 100 i.p. 
Structure not shown 
due to patent reasons 
DB 1283 Di-aza 
furamidine 
6.5 2.4 2.7 >90’000 Not toxic 
at 100 i.p. 
DB 1288 Diaryl 
seleno-
phene 
5.4 0.9 0.7 >90’000 Not toxic 
at 100 i.p. 
Structure not shown 
due to patent reasons 
DB 1340 Seleno-
phene 
3.8 0.9 1.2 >90’000 Not toxic 
at 100 i.p. 
Structure not shown 
due to patent reasons 
DB 1342 Pyrrole 3.8 6.0 7.7 >90’000 Not toxic 
at 100 i.p. 
Table 3.2. continued… 
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DB 1370 Aza-
pyridine 
5.1 2.0 0.5 >90’000 Not toxic  
N
N
NH
NH2 NH2
NH
N N
at 100 i.p. 
DB 1371 Aza-
pyridine 
10.8 16.0 12.0 >90’000 Not toxic  
N
N
NH
NH2 NH2
NHN N
at 100 i.p. 
i.p. denotes an intra-peritoneal route was used 
 
In comparison, the IC50 values for the Tidwell compounds, tested against all three 
trypanosome strains, can be seen in Table 3.3. All the compounds produced IC50 values below 
30 ng/ml for the T. evansi and T. b. rhodesiense strains, yet forty-one of these compounds 
demonstrated higher activity for the T. evansi (STIB 806K) strain, with IC50 results below 10 
ng/ml. Again, compounds showing greater efficacy in vitro than the standard drugs are 
positively selected for continued investigation for an alternative compound against T. evansi 
infection. The IC50 values for the TbAT1 knock out strain for the Tidwell compounds ranged 
from 0.7 ng/ml to greater than 100 ng/ml. Since an important selective criterion is to avoid 
potential resistance occurring against new alternative compounds for T. evansi infection, only 
compounds with low IC50 values against the TbAT1 knock out strain will be pursued further. 
 
Table 3.3. Eighty-three new diamidine compounds, designed by Richard Tidwell, with their chemical families 
and structures depicted alongside the IC50 values obtained with a kinetoplastic T. evansi strain (STIB 806K), a T. 
b. rhodesiense strain (STIB 900) and a T. b. brucei P2 transporter knock out strain (TbAT1). Cytotoxicity IC50 
values (using L6 cells) and preliminary in vivo toxicity values (using NMRI mice) are also shown. 
 
Inhibitory concentration (IC50) in ng/ml Compound 
identity 
Chemical 
family STIB 
806K 
STIB 
900 
TbAT1 
(K.O.) 
Cytotoxicity  
(L6 cells) 
Preliminary 
toxicity 
(mg/kg) 
Chemical  
structure 
        
3 HXC 023 Benz-
imidazole 
9.5 13.0 4.2 >90’000 Not toxic 
at 100 i.p. 
Structure not shown 
due to patent reasons 
5 BGR 066 Benz-
imidazole 
14.6 17.2 5.7 >90’000 Lethal at 
100 i.p. 
Structure not shown 
due to patent reasons 
5 BGR 068 Benz-
imidazole 
7.5 14.4 6.9 >90’000 Lethal at 
20 i.p. 
Structure not shown 
due to patent reasons 
5 BGR 086 Benz-
imidazole 
5.6 5.5 2.4 >90’000 Lethal at 
20 i.p. 
Structure not shown 
due to patent reasons 
5 BGR 088 Benz-
imidazole 
10.3 8.8 5.5 >90’000 Lethal at 
20 i.p. 
Structure not shown 
due to patent reasons 
5 BGR 094 Benz-
imidazole 
24.7 16.1 7.9 >90’000 Lethal at 
20 i.p. 
Structure not shown 
due to patent reasons 
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5 BGR 096 Benz-
imidazole 
27.7 23.6 8.3 >90’000 Lethal at 
20 i.p. 
Structure not shown 
due to patent reasons 
6 BGR 012 Benz-
imidazole 
24.5 26.0 3.7 >90’000 Lethal at 
20 i.p. 
Structure not shown 
due to patent reasons 
1 SMB 015 Xylene 9.8 7.4 97.9 >90’000 Toxic at 
100 i.p. 
 
6 EVK 012 Isoxazole 21.4 26.2 20.6 >90’000 Lethal at 
100 i.p. 
Structure not shown 
due to patent reasons 
1 RRT 039 Xylene 2.9 0.9 30.7 >90’000 Lethal at 
50 i.p. 
 
6 MAA 143 Xylene 28.1 21.1 >100 >90’000 Not toxic 
at 100 i.p. 
Structure not shown 
due to patent reasons 
5 MAA 085 Pentamidine 
analogue 
22.6 26.2 >100 >90’000 Not toxic 
at 100 i.p. 
1 KAO 045 Pentamidine 
analogue 
14.9 16.9 55.8 >90’000 Lethal at 
100 i.p. 
 
3 STL 057 Pentamidine 
analogue 
4.4 4.4 18.7 >90’000 Not toxic 
at 100 i.p. 
 
5 MAA 083 Pentamidine 
analogue 
26.1 21.4 >100 >90’000 Not toxic 
at 100 i.p. 
 
5 MAA 101 Pentamidine 
analogue 
11.2 9.8 >92.8 >90’000 Not toxic 
at 100 i.p. 
 
5 MAA 121 Pentamidine 
analogue 
19.9 15.7 >100 >90’000 Not toxic 
at 100 i.p. 
 
5 MAA 123 Pentamidine 
analogue 
24.5 24.2 98.2 >90’000 Lethal at 
100 i.p. 
 
5 MAA 137 Pentamidine 
analogue 
26.1 22.2 86.2 >90’000 Lethal at 
50 i.p. 
Structure not shown 
due to patent reasons 
6 MAA 025 Pentamidine 
analogue 
2.4 3.1 27.3 >90’000 Not toxic 
at 100 i.p. 
 
2 SAB 087 Benzo-furan 25.8 22.3 85.4 >90’000 Lethal at 
50 i.p. 
Structure not shown 
due to patent reasons 
3 SMB 051 Bis-Benzo-
furan 
9.2 6.6 >100 >90’000 Not toxic 
at 100 i.p. 
Structure not shown 
due to patent reasons 
3 SMB 065 Bis-Benzo-
furan 
7.5 9.9 93.6 >90’000 Lethal at 
100 i.p. 
Structure not shown 
due to patent reasons 
3 SMB 079 Pentamidine 
analogue 
20.9 26.4 >100 >90’000 Not toxic 
at 100 i.p. 
Structure not shown 
due to patent reasons 
3 SMB 101 Pentamidine 
analogue 
6.4 4.2 63.8 >90’000 Not toxic 
at 100 i.p. 
Structure not shown 
due to patent reasons 
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4 SMB 058 Bis-Benzo-
furan 
24.1 24.5 >100 >90’000 Lethal at 
100 i.p. 
 
4 SMB 092 Bis-Benzo-
furan 
18.9 13.2 >100 >90’000 Not toxic 
at 100 i.p. 
O
NH2
NH
CC C
H
H
H
HO
NH
NH2 C
H
H
H
H
ONH2
NH
O NH
NH2
 
 
5 SMB 032 Bis-Benzo-
furan 
4.4 2.8 90.2 >90’000 Not toxic 
at 100 i.p. 
 
1 EVK 057 Pentamidine 
analogue 
6.0 6.2 34.4 >90’000 Lethal at 
100 i.p. 
Structure not shown 
due to patent reasons 
16 DAP 022 Carbazole 24.9 25.9 >100 >90’000 Lethal at 
100 i.p. 
Structure not shown 
due to patent reasons 
4 SAB 075 Isoxazole 2.6 3.5 28.5 >90’000 Not toxic 
at 100 i.p. 
Structure not shown 
due to patent reasons 
5 SMB 093 Isoxazole 22.2 11.5 17.3 >90’000 Not toxic 
at 100 i.p. 
Structure not shown 
due to patent reasons 
16 DAP 095 Isoxazole 15.5 5.8 12.7 51’150 Not toxic 
at 100 i.p. 
 
3 KEG 083 Pentamidine 
analogue 
8.2 11.5 36.3 >90’000 Not toxic 
at 100 i.p.  
3 NAN 027 Pentamidine 
analogue 
9.0 2.5 43.1 >90’000 Lethal at 
50 i.p. 
Structure not shown 
due to patent reasons 
6 SAB 038 Benzo-furan 11.8 11.4 6.1 >90’000 Lethal at 
100 i.p. 
Structure not shown 
due to patent reasons 
8 SMB 021 Isoxazole 4.2 4.8 0.9 >90’000 Lethal at 
100 i.p. 
Structure not shown 
due to patent reasons 
7 SAB 004 Benzo-furan 3.6 4.9 2.7 22’360 Not toxic 
at 100 i.p. 
7 SAB 015 Benzo-furan 10.3 8.1 5.9 >90’000 Lethal at 
100 i.p. 
Structure not shown 
due to patent reasons 
7 EVK 097 Isoxazole 2.1 2.1 13.8 >90’000 Not toxic 
at 100 i.p. 
Structure not shown 
due to patent reasons 
7 SAB 079 Isoxazole 3.1 2.4 1.9 >90’000 Lethal at 
100 i.p. 
Structure not shown 
due to patent reasons 
8 EVK 024 Isoxazole 2.7 2.8 42.3 >90’000 Not toxic 
at 100 i.p. 
Structure not shown 
due to patent reasons 
8 EVK 030 Isoxazole 2.1 4.8 58.7 >90’000 Not toxic 
at 100 i.p. 
Structure not shown 
due to patent reasons 
19 DAP 021 Isoxazole 10.9 6.1 3.9 >90’000 Not toxic 
at 100 i.p. 
Structure not shown 
due to patent reasons 
19 DAP 025 Naphthylene 1.8 1.5 1.8 >90’000 Not toxic 
at 100 i.p. 
Structure not shown 
due to patent reasons 
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1 FMS 034 Phenoxy 
amidine 
9.6 5.5 8.6 >90’000 Not toxic 
at 100 i.p. 
1 MCC 112 Phenoxy 
amidine 
2.4 2.3 2.7 >90’000 Not toxic 
at 100 i.p. 
1 MCC 179 Phenoxy 
amidine 
2.9 0.4 0.7 >90’000 Not toxic 
at 100 i.p. 
1 MCC 097 Phenoxy 
amidine 
14.5 9.0 26.6 >90’000 Not toxic 
at 100 i.p. 
O
H
I
NH2
NH
NH
NH2
O
NH
NH2
H
Br
NH2
NH
O
NH
NH2
I
I
NH2
NH
ONH
NH2
NH2
NH
 
1 MCC 128 Phenoxy 
amidine 
13.3 2.7 2.9 >90’000 Lethal at 
100 i.p. 
1 MCC 148 Phenoxy 
amidine 
3.3 1.1 1.8 >90’000 Not toxic 
at 100 i.p. 
1 MCC 184 Phenoxy 
amidine 
4.3 4.8 4.3 >90’000 Not toxic 
at 100 i.p. 
10 SMB 038 Isoxazole 18.7 10.1 11.2 >90’000 Not toxic 
at 100 i.p. 
Structure not shown 
due to patent reasons 
0 DWB 082 Biphenyl 12.5 3.5 3.1 24’740 Not toxic 
at 100 i.p. 
 
0 MXB 736 Phenoxy 
amidine 
25.3 28.2 24.3 >90’000 Not toxic 
at 100 i.p. 
 
0 MXB 767 Phenoxy 
amidine 
13.1 20.6 16.1 33’810 Not toxic 
at 100 i.p. 
 
0 MXB 864 Phenoxy 
amidine 
7.0 9.2 9.2 >90’000 Not toxic 
at 100 i.p. 
 
10 SMB 084 Isoxazole 35.9 31.9 47.6 >90’000 Not toxic 
at 100 i.p. 
Structure not shown 
due to patent reasons 
11 SMB 003 Pentamidine 
analogue 
13.4 10.5 32.3 >90’000 Not toxic 
at 100 i.p. 
Structure not shown 
due to patent reasons 
19 DAP 075 Isoxazole 15.0 12.7 12.1 >90’000 Not toxic 
at 100 i.p. 
Structure not shown 
due to patent reasons 
19 DAP 085 Naphthylene 22.0 16.7 24.0 >90’000 Not toxic 
at 100 i.p. 
Structure not shown 
due to patent reasons 
19 DAP 089 Isoxazole 6.7 10.7 13.7 >90’000 Not toxic 
at 100 i.p. 
Structure not shown 
due to patent reasons 
20 DAP 001 Isoxazole 7.6 8.4 9.6 >90’000 Lethal at 
100 i.p. 
Structure not shown 
due to patent reasons 
19 DAP 079 Isoxazole 17.6 12.3 10.7 >90’000 Lethal at 
100 i.p. 
Structure not shown 
due to patent reasons 
8 SAB 066 Isoxazole 3.9 1.3 1.1 >90’000 Not toxic 
at 100 i.p. 
Structure not shown 
due to patent reasons 
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8 SAB 068 Isoxazole 3.7 0.9 0.9 >90’000 Lethal at 
100 i.p. 
Structure not shown 
due to patent reasons 
8 SAB 072 Isoxazole 8.0 4.6 4.5 >90’000 Not toxic 
at 100 i.p. 
Structure not shown 
due to patent reasons 
20 DAP 055 Isoxazole 7.9 6.1 6.6 >90’000 Not toxic 
at 100 i.p. 
Structure not shown 
due to patent reasons 
20 DAP 059 Isoxazole 13.8 4.2 4.0 >90’000 Lethal at 
100 i.p. 
Structure not shown 
due to patent reasons 
12 SMB 003 Isoxazole 5.4 2.6 2.6 >90’000 Not toxic 
at 100 i.p. 
Structure not shown 
due to patent reasons 
12 SMB 028 Furan 2.5 8.9 7.0 >90’000 Lethal at 
100 i.p. 
Structure not shown 
due to patent reasons 
21 DAP 023 Pentamidine 
analogue 
5.0 2.0 2.0 >90’000 Lethal at 
100 i.p. 
Structure not shown 
due to patent reasons 
9 SAB 021 Isoxazole 13.3 11.6 11.0 >90’000 Not toxic 
at 100 i.p. 
Structure not shown 
due to patent reasons 
12 SMB 011 Isoxazole 28.5 26.0 97.0 >90’000 Lethal at 
100 i.p. 
Structure not shown 
due to patent reasons 
21 DAP 049 Isoxazole 7.4 5.4 9.8 >90’000 Lethal at 
100 i.p. 
Structure not shown 
due to patent reasons 
9 SAB 072 Phenoxy 
amidine 
11.3 10.1 12.1 >90’000 Toxic at 
100 i.p. 
9 SAB 076 Phenoxy 
amidine 
7.6 3.1 4.3 >90’000 Lethal at 
100 i.p. 
9 SAB 078 Phenoxy 
amidine 
7.1 3.5 7.1 >90’000 Lethal at 
100 i.p. 
8 SAB 070 Isoxazole 13.5 9.4 19.9 >90’000 Lethal at 
100 i.p. 
Structure not shown 
due to patent reasons 
21 DAP 046 Isoxazole 14.1 6.1 7.1 >90’000 Lethal at 
100 i.p. 
Structure not shown 
due to patent reasons 
10 SAB 037 Triazole 5.0 4.5 4.9 >90’000 Lethal at 
100 i.p. 
Structure not shown 
due to patent reasons 
10 SAB 055 Triazole 4.8 2.4 2.9 >90’000 Lethal at 
100 i.p. 
Structure not shown 
due to patent reasons 
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i.p. denotes an intra-peritoneal route was used 
 
Each of the 181 compounds, including the four standard drugs, was applied to an in 
vitro cell cytotoxicity assay using L6 cells. Their IC50 values in ng/ml are depicted in Table 
3.1 for the standard drugs, Table 3.2 for the Boykin compounds and Table 3.3 for the Tidwell 
compounds. Compounds which were considered non-cytotoxic to the L6 (rat myoblast) cells 
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had an IC50 value greater than 90’000 ng/ml (>90’000). The important exceptions to this were 
the standard drug, diminazene, the following Boykin compounds, DB 346, DB 545, DB 746, 
DB 994, DB 1052, DB 1152 and DB 1171 and the following Tidwell compounds, 16 DAP 
095, 7 SAB 004, 0 DWB 082 and 0 MXB 767. 
To evaluate the toxicity of these compounds within an in vivo system, preliminary in 
vivo toxicity tests were performed using an NMRI mouse model. Each compound was 
administered at an increasing accumulative dose using an intra-peritoneal application route in 
mg/kg. The mice were observed for signs of acute toxicity within a 48 hour period and then 
grouped accordingly. Compounds which caused death to the mouse were classed as lethal, 
whereas compounds showing no acute toxicity were defined as not toxic, up to a maximum 
accumulative dose of 100 mg/kg. Compounds that demonstrated some form of acute toxicity, 
but not enough to cause death, were labelled as toxic at that given accumulative dose, also up 
to a maximum accumulative dose of 100 mg/kg. 
In Table 3.1, the preliminary in vivo toxicity results show that three of the standard 
drugs (diminazene, cymelarsan and quinapyramine) are actually lethal when doses of 20 
mg/kg, 20 mg/kg and 5 mg/kg are given intra-peritoneally, respectively. The remaining 
standard drug, suramin, is not lethal, but toxic after an accumulative dose of just 50 mg/kg. 
The in vivo preliminary toxicity results for the Boykin compounds can be seen in more detail 
in Table 3.2. In total, twenty-eight of these compounds were lethal at 100 mg/kg, three were 
lethal at 50 mg/kg, only one was toxic at 100 mg/kg, four compounds were toxic at 50 mg/kg 
and seven were toxic at 20 mg/kg accumulative dose. Similarly, the in vivo preliminary 
toxicity results for the Tidwell compounds are shown in Table 3.3. In total, twenty-seven of 
these compounds were lethal at 100 mg/kg, four were lethal at 50 mg/kg, six were lethal at 
just 20 mg/kg and two compounds were toxic at 100 mg/kg accumulative dose. 
The toxicity of a compound in vivo remains another important criterion for selecting 
alternative compounds as potential leads against T. evansi infection. A compound which has 
the ability to treat infected animals without causing harm to the organism itself, would 
provide many ideal properties, hence compounds which demonstrate no preliminary toxicity 
in the mouse model used, are selected for further analysis within in vivo models. In total, fifty-
five compounds tested from David Boykin and forty-four compounds tested from Richard 
Tidwell were found to be not toxic, after the highest accumulated dose of 100 mg/kg was 
examined, in a mouse model. 
A compound capable of treating several strains of T. evansi would be an additional 
ideal property for an alternative novel drug against infection. Since high activity was seen by 
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these dicationic compounds against the reference Chinese T. evansi strain (STIB 806K), a 
select few were thus chosen to be tested against seven different T. evansi strains, obtained 
from geographically separate locations. The standard drugs were included to determine how 
sensitive each strain was to currently available drugs, whilst the six selected diamidine 
compounds were chosen based on their curative efficacy in a preliminary mouse model, the 
data of which can be viewed in the next chapter. 
The IC50 values (in ng/ml) obtained for the in vitro strain sensitivity study can be 
viewed in Table 3.4. The STIB 806K strain (marked in blue) represents the reference strain 
used for this study. All T. evansi strains tested (including the reference strain) showed similar 
sensitivities for diminazene, cymelarsan and quinapyramine. For suramin however, the IC50 
values fluctuated from 44.0 ng/ml to 87.6 ng/ml. 
 
Table 3.4. In vitro strain sensitivities (shown as IC50 values in ng/ml) of seven different T. evansi strains, 
originating from geographically separate locations, against the four standard drugs currently in use against T. 
evansi infection and six selected diamidine compounds. 
 
Trypanosoma evansi strains Compound 
Identity STIB 
   806K* 
CAN86/ 
Brazil Colombia Kazakhstan Philippines 
RoTat 
1.2 Vietnam 
Standard drugs        
Suramin 87.6 44.0 59.8 61.0 54.0 76.2 78.4 
Diminazene 12.5 12.2 13.3 13.1 12.2 12.6 12.5 
Cymelarsan 1.1 1.2 1.2 1.2 1.3 1.3 1.2 
Quinapyramine 0.1 0.1 0.1 0.1 0.1 0.1 0.1 
Diamidines        
DB 75 2.3 2.6 3.7 2.5 1.3 2.7 2.5 
DB 820 5.4 4.7 4.1 5.6 3.4 4.6 4.1 
DB 867 1.7 3.0 1.9 2.3 1.3 1.5 1.5 
DB 930 4.3 4.2 6.5 5.7 10.7 4.1 3.9 
DB 1192 10.5 9.6 8.2 10.7 10.4 9.9 10.3 
DB 1283 6.5 5.9 5.6 6.3 8.6 6.5 5.9 
     * The STIB 806K strain represents the reference T. evansi strain in this study. 
 
For the six diamidine compounds tested, the IC50 values of each compound (from each 
different strain), was compared with the IC50 value obtained using the reference STIB 806K 
strain. The strains Colombia, Kazakhstan, RoTat 1.2 (from Indonesia) and Vietnam, all 
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showed similar drug sensitivities to those seen with the Chinese reference strain. Slight 
variations were seen in the CAN86/Brazil strain with DB 867, where the IC50 value was 
approximately twice that of the reference strain and in the Philippines strain with DB 930, 
where the value was approximately two and a half times higher than that seen with STIB 
806K. Overall, the in vitro strain sensitivity IC50 values were found to range between 1.3 and 
10.7 ng/ml. 
 
 
 
Discussion 
 
The drug discovery and development pipeline expresses the various selective 
parameters which are required to be met in order to produce an effective and marketable drug. 
By screening large numbers of compounds, it is possible to select only those compounds 
presenting the given criteria important for an ideal drug. In this case, this study has enabled 
the screening of 181 novel diamidine compounds to be positively selected for compounds 
exhibiting high anti-trypanosomal activity against Trypanosoma evansi infection, reduced 
potential for drug resistance, low cytotoxicity against mammalian cells and of course low or 
no toxicity involved in an in vivo mouse system. 
The four standard drugs available for the treatment of T. evansi infection (suramin, 
diminazene, cymelarsan and quinapyramine) are inadequate in controlling the disease. An 
alternative compound for T. evansi infection should exhibit improved or greater activity 
against the pathogen than the standard drugs can currently provide. The selective IC50 cut-off 
point for this criterion therefore lies below 12 ng/ml. The 181 novel diamidine compounds 
tested in this study against T. evansi all produced inhibitory concentration (IC50) values less 
than 30 ng/ml, whilst 129 of these compounds had IC50 values between 1.2 ng/ml and 10 
ng/ml. It is evident from these results that these dicationic molecules are highly active against 
T. evansi in vitro. As was originally hypothesised, diamidine compounds found to be highly 
active against the human pathogenic T. b. rhodesiense strain are also highly effective against 
animal pathogenic T. evansi strains. 
To some extent, drug resistance has overcome any beneficial efficacy presented by the 
current drugs, especially suramin. By testing the novel diamidine compounds against a 
genetic knock out strain (TbAT1) lacking the gene encoding for the nucleoside P2 transporter, 
diamidine compounds relying mainly on this mode of action can be identified. An elevated 
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IC50 value, compared to the resulting IC50 value obtained for that compound against the 
respective trypanosome strain, demonstrates reduced trypanocidal activity due to a net 
reduction in drug uptake. The selective IC50 cut-off point for this criterion is thus placed at 
less than 20 ng/ml. Since drug resistance against dicationic diamidines tends to occur largely 
due to a lack in functional P2 transportation, any compounds demonstrating an elevated IC50 
value against the TbAT1 strain also reveal a susceptibility to potential drug resistance. In a 
wider context, such a compound would not achieve the advantages sought after in a new anti-
trypanosomal agent against T. evansi infection. 
As well as possessing high activity and reduced potential for developing drug 
resistance, the ideal anti-trypanosomal agent should also exhibit limited toxicity. Cymelarsan 
and quinapyramine both appear to be hindered through toxicity. Although both standard drugs 
are highly active against T. evansi, the toxicity these drugs display remains a major issue in 
their chemotherapeutic use. The in vitro cell cytotoxicity assay, together with the preliminary 
in vivo toxicity tests performed using NMRI mice, could be used in this study to eliminate 
compounds, which revealed harmful effects on either mammalian cells alone or within a 
living organism, in this case a mouse model. For the cytotoxicity criterion against mammalian 
(L6) cells, the selective cut-off point includes any compound demonstrating an IC50 value of 
greater than 90’000 ng/ml. As a new drug against T. evansi infection will most likely be 
administered to animals, the preliminary in vivo toxicity tests could be considered as one of 
the most important criterions assessed in this study. Therefore, all diamidine compounds 
found to be lethal or toxic within the preliminary in vivo toxicity mouse experiments, are 
negatively selected for, leaving only the non-toxic diamidine compounds present to continue 
along the drug pipeline and warrant further investigation. 
Although in vivo toxicity is an important criterion for drug discovery and 
development, another vital aspect in drug discovery is of course in vivo activity. Several of 
these compounds demonstrate high anti-trypanosomal activity in vitro, yet this activity is not 
necessarily displayed correspondingly when the compound is tested within a living organism. 
The next set of criteria to be investigated must essentially be performed in vivo and should 
include curative efficacy trials within a mouse model. For compounds that show no 
preliminary toxicity in the mouse, dose-response experiments could be carried out to 
determine primarily, the most active novel diamidine compounds and secondly, the lowest 
curative dose of those active compounds. 
Based on the results obtained in this initial in vitro study, including the preliminary 
toxicity data derived from the mouse model, a total of sixty-three compounds have been found 
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eligible for continued investigation in an in vivo mouse model. Although the compound, DB 
75 demonstrated toxicity at 50 mg/kg (i.p.) in the preliminary toxicity test and should not 
theoretically qualify for continued investigation, this compound will be included in all future 
experiments as an extra control compound, due to its current potential (together with its 
prodrug compound, DB 289) as a candidate drug against human sleeping sickness. 
An additional criterion investigated in this initial in vitro diamidine study was strain 
sensitivity. Six diamidine compounds were selected for in vitro strain sensitivity testing, due 
to their curative efficacy determined within an infected mouse model. The data of this study 
can be viewed in the next chapter. These six selected diamidine compounds, along with the 
four standard drugs, were thus first examined in vitro against seven different T. evansi strains. 
The STIB 806K strain (from China) acted as the reference strain, whilst the remaining six T. 
evansi strains were chosen on the basis of their geographical locations. This was done to 
determine whether dicationic compounds could demonstrate broader efficacy on separate 
strains of T. evansi found around the world. Although slight variations were seen in the 
CAN86/Brazil and Philippines strain, on the whole, the results depicted indicate that these six 
diamidine compounds are highly effective in vitro against all seven T. evansi strains tested. 
Moreover, all six compounds displayed greater activity than that of suramin and diminazene. 
Together with the criteria made apparent through this initial study, an effective, non-
toxic, economically designed diamidine compound could be produced as an alternative to the 
four standard drugs currently available against T. evansi infection. 
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Abstract 
 
Surra is an animal pathogenic protozoan infection, caused by Trypanosoma evansi, 
which develops into a fatal wasting disease. Control measures tend to rely on either treatment 
or prophylaxis. However, with the continuous emergence of drug resistance, this tactic is 
failing and the pressing need for new, alternative chemotherapeutic agents is becoming 
critical. With the introduction of novel aromatic diamidines, a new category of anti-
trypanosomal drugs was discovered. Nevertheless, their efficacy within an in vivo mouse 
model and the prophylactic nature of these compounds remains unknown. 
In total, 63 compounds were previously selected for eligibility for further in vivo 
investigations within a mouse model. However, only 48 of these selected compounds were 
ultimately tested, whilst fifteen compounds could not be investigated due to compound 
availability and synthesis. Six of the compounds were capable of curing T. evansi infected 
mice at drug doses as low as 0.5 mg/kg and 0.25 mg/kg and were more effective than the 
standard drugs, suramin, diminazene and quinapyramine. Moreover, three novel diamidines 
were then tested in vivo against various T. evansi strains to determine strain sensitivity. 
Strains isolated from China, the Canary Islands and Colombia demonstrated a 100 % cure rate 
with all three compounds at 0.5 mg/kg. In addition, the preliminary prophylactic activity of 
diamidines was examined, using doses of 3 mg/kg and 10 mg/kg of DB 75 (2,5-bis(4-
amidinophenyl)furan), which promoted 100 % survival of mice given prophylaxis up to six 
days before initial infection. 
After all selective criteria were applied only three diamidine compounds qualified as 
lead compounds, considered to have the potential to act as clinical candidates against T. 
evansi infection. These three compounds, DB 75, DB 867 and DB 1192, warrant further 
investigation in a larger animal model. 
 
Keywords: Trypanosoma evansi, diamidines, in vivo, dose-response, prophylaxis, mouse 
model, chemotherapy. 
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Introduction 
 
Surra is an animal pathogenic protozoan infection, caused by Trypanosoma evansi, 
which develops into a fatal wasting disease. It is mechanically transmitted by biting flies of 
the genera, Tabanus, Stomoxys and Lyperosia. No intermediate hosts and no insect 
developmental cycles have as yet been identified (Foil, 1989). Control measures for 
protozoan diseases, such as Surra, tend to rely on either treatment or prophylaxis. Treatment 
usually involves the use of anti-parasitic drugs, whereas prophylaxis can usually be 
accomplished by drugs or sometimes through vaccination. Whether “prevention is better than 
cure” depends on the parasite being dealt with, the type of drugs available, the occurrence and 
severity of the disease and the economics obtainable in such a situation (Ryley, 1982). 
In the case of Surra, drugs containing anti-parasitic properties are usually administered 
once an infection has already established itself, in the hope that such activity will render the 
parasite non-viable and the infection will clear (Davila and Silva, 2000; Seidl et al., 2001). 
However, with the continuous emergence of drug resistance, this tactic is failing and the 
pressing need for new, alternative chemotherapeutic agents is becoming critical (Touratier, 
2000; Reid, 2002). Moreover, the prospect of a vaccination against T. evansi infection appears 
non-existent, for which a large proportion of responsibility can be placed upon the 
phenomenon of antigenic variability of trypanosomes in general. 
With the introduction of novel aromatic diamidines, a new category of anti-
trypanosomal drugs was discovered (Francesconi et al., 1999; Wilson et al., 2005). Several of 
these dicationic compounds have shown great efficacy in vitro against both human and animal 
pathogenic trypanosome species. A previous study into these diamidine compounds against T. 
evansi enabled the positive selection of diamidine compounds exhibiting high anti-
trypanosomal activity, reduced potential for drug resistance, low cytotoxicity against 
mammalian cells and low or no toxicity involved within an in vivo mouse model. However, 
their efficacy within an in vivo mouse model and the prophylactic nature of these compounds 
remains unknown. 
In order to find an effective, non-toxic, economically designed diamidine compound, 
which could act as an alternative to the four currently used drugs (suramin, diminazene, 
cymelarsan and quinapyramine), it is important to investigate the most active compounds and 
to determine their efficacy in the treatment of mice infected with T. evansi. Hence, the aim of 
this study was to investigate 63 previously selected diamidine compounds in vivo within a 
mouse model. The selected compounds were chosen based on their in vitro activity against a 
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Chinese T. evansi reference strain, a P2 transporter knock out trypanosome strain, their low 
cytotoxicity and low in vivo toxicity. The cut-off values for each of these criteria were IC50 
values below 12 ng/ml, less than 20 ng/ml, greater than 90’000 ng/ml and not toxic at 100 
mg/kg within a mouse model, respectively. 
In response to the great efficacy produced by some of the diamidine compounds in 
vitro, several T. evansi strains isolated from various hosts and geographical locations were 
additionally tested in vivo using the mouse model. This was done to establish whether these 
compounds can provide curative efficacy against different T. evansi strains within living 
organisms. To explore any beneficial prophylactic properties contained within aromatic 
diamidines, one such compound called furamidine, or 2,5-bis(4-amidinophenyl)furan (also 
known as DB 75) (Figure 4.1), was further investigated, based on the high in vitro and in vivo 
activity seen by this compound against T. evansi strains. With curative doses of just 0.2 
mg/kg, DB 75 was used in a prophylactic mouse experiment to determine its ability to cure 
infected mice before infection as well as after infection. 
 
Figure 4.1. The chemical structure of 2,5-bis(4-amidinophenyl)furan (DB 75). 
 
ONH
NH2 NH2
NH
 
 
 
 
Materials and methods 
 
Trypanosome strains 
 
The reference STIB 806K strain was used for all in vivo experiments performed in this 
study. STIB 806K is a Chinese kinetoplastic Trypanosoma evansi strain, isolated from a water 
buffalo, by Lun in 1983. This strain was cloned and adapted to axenic culture conditions 
according to Baltz et al. (1985). In addition to the reference trypanosome strain, four further 
T. evansi strains, isolated from various geographical regions, were tested against a selection of 
diamidine compounds to determine in vivo strain sensitivity. Three of these strains (Colombia, 
Kazakhstan and Philippines) were originally obtained from the cryobank of the Institute of 
 70
Chapter 4: In vivo investigations into diamidines against T. evansi 
 
Tropical Medicine (ITM) in Antwerp, Belgium, whilst the fourth T. evansi (Canaries) strain 
was isolated from a dromedary camel in the Canary Islands, by Gillingwater in 2006. A fifth 
strain, designated as TbAT1 K.O., was furthermore included in the tests. This strain is a 
genetic knock out of a T. b. brucei strain (STIB 777S), which is missing the TbAT1 gene 
encoding the nucleoside P2 transporter. 
 
Mice 
 
Female NMRI mice weighing between 22 - 25 g were used for the in vivo 
experiments. All mice were specific pathogen free (SPF) and were maintained in standard 
Macrolon type II cages, at 22 °C and with a relative humidity of 60 - 70 %. Water and 
pelleted food was provided for the mice ad libitum. 
 
Standard trypanocidal drugs 
 
Suramin (Germanin® from Bayer, Leverkusen, Germany), diminazene aceturate (D-
7770, Sigma, St Louis, MO, USA), cymelarsan (MelCy®, Rhône Mérieux, Toulouse, France) 
and quinapyramine sulphate (Trypacide®, May & Baker, Lagos, Nigeria) were used as the 
standard drugs in this study. 
 
Diamidine compounds 
 
The diamidine compounds were originally designed and synthesised by the chemists, 
David Boykin and Richard Tidwell. For the in vivo experiments, the diamidine compounds 
were selected by means of their previously demonstrated in vitro activity against T. evansi 
strains and in vivo toxicity, which was determined in an earlier study, the data of which can be 
viewed in the previous chapter. 
 
Culture medium 
 
Bloodstream form trypanosomes were cultivated in Minimum Essential Medium 
(MEM) (powder, GIBCO/BRL, No: 11400-033) with Earle’s salts, supplemented with 25 mM 
HEPES, 1 g/l additional glucose, 2.2 g/l NaHCO3 and 10 ml/l MEM non-essential amino 
acids (50x concentration). The medium was then further supplemented by adding 1 % of a 2-
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mercaptoethanol stock (14 μl of 12 mM 2-mercaptoethanol was diluted in 10 ml of distilled 
water), 1 % of a stock consisting of 100 mM sodium pyruvate and 50 mM hypoxanthine and 
15 % heat inactivated horse serum, according to Baltz et al. (1985). The complete medium is 
called Baltz MEM (BMEM). 
 
Stock solutions and dilutions 
 
A 1.5 mg amount of each compound was weighed out in powder form and dissolved 
in 15 ml of sterile distilled water, to provide a 10 ml/kg bodyweight mouse stock solution. 
From these stock solutions, further compound dilutions were made if necessary, depending on 
the compound dose being tested. These compound dilutions were then used for the in vivo 
experiments. Additionally, a 15 mg amount of the diamidine compound, 2,5-bis(4-
amidinophenyl)furan (DB 75) was weighed out in powder form and dissolved in 15 ml of 
sterile distilled water, to provide a 100 ml/kg bodyweight mouse stock solution. From this 
stock solution, further compound dilutions were made for use in the in vivo prophylaxis 
experiment. Stock solutions and compound dilutions were made fresh on the day of 
administration and for each experimental procedure. 
 
In vivo experiments 
 
Female NMRI mice were divided into groups, each containing four mice. The mice 
were then infected with 104 parasites in 0.25 ml, from the STIB 806K T. evansi reference 
strain, using an intra-peritoneal (i.p.) route of infection. A parasitaemia was allowed to 
establish, before treatment was given (also using an i.p. route) on the following consecutive 
days: days 3, 4, 5 and 6 post-infection. Thereafter, the parasitaemia was checked twice a week 
using a tail blood examination technique, until day 60 post-infection. A two month 
experimental follow up period is used to account for any possible relapses, which may occur 
for inactive compounds. Subsequently, any surviving aparasitaemic mice are thus considered 
cured.  
A similar experimental procedure was followed for the in vivo strain sensitivity tests, 
with the exception that the mice were infected with 104 parasites in 0.25 ml from either the 
respective T. evansi strains (Canaries, Colombia, Kazakhstan, Philippines or STIB 806K) or 
from the knock out T. b. brucei strain (TbAT1). 
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Prophylactic in vivo experiment 
 
Thirty six mice were divided up into nine groups, each group consisting of four mice. 
The mice were then injected via an intra-peritoneal route (i.p.) with the respective DB 75 
compound dose (3 mg/kg or 10 mg/kg), according to the respective day, prior to or after 
infection, depending on the group (Figure 4.2). 
 
Figure 4.2. Time chart to show the number of days prior to infection (- #) and after infection (+ #) and the 
classification of the nine groups of mice (Groups A - I) 
 
- 10 - 6 - 3 + 1 0 
 
 
                                  Prior to infection                           Prior to infection        Prior to infection         Infection     After infection                          
                                   (Groups B + C)                              (Groups D + E)               (Groups F + G)         (Group A)    (Groups H + I) 
                                      Prophylaxis                                   Prophylaxis                         Prophylaxis           Infection       Treatment 
 
The volume of DB 75 given was dependent on the weight of each respective mouse, 
which was measured on the day of compound administration. On day 0 of the experiment, all 
nine groups of mice were infected with the STIB 806K strain. The mice were infected with 
104 parasites in 0.25 ml, using an i.p. route of infection. Subsequently, the parasitaemia was 
checked twice a week using a tail blood examination technique, until day 60 post-infection. 
Thereafter, any surviving aparasitaemic mice were considered cured. The experimental 
procedure was independently repeated a second time, using the same criteria and conditions. 
 
 
 
Results 
 
In total, the four standard drugs currently in use against Trypanosoma evansi infection 
and forty-eight selected novel diamidine compounds were tested in vivo within this study. 
Although 63 compounds were originally selected to qualify for in vivo testing within a mouse 
model, fifteen of these compounds were not obtainable for testing due to compound 
availability and production. Therefore, only forty-eight compounds and an extra control 
compound (DB 75) were ultimately tested in the in vivo mouse model. 
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The results of the in vivo investigations for the four standard drugs can be seen in 
Table 4.1. At a drug dose of 1 mg/kg, suramin was able to cure 4/4 mice for the required 
length of the experiment (>60 days). However, as the dose of suramin was reduced, the 
survival of the mice decreased to just 3/4 and finally to 0/4 at 0.5 mg/kg and 0.25 mg/kg, 
respectively. In comparison, the standard diamidine drug, diminazene, was only capable of 
curing 3/4 mice at a 1 mg/kg dose. Twice this amount (2 mg/kg) was actually required in 
order to achieve the lowest curative dose for diminazene. Cymelarsan demonstrated the 
highest efficacy with a lowest curative dose of just 0.0625 mg/kg. In contrast, this value is 
sixteen times lower than the curative doses of suramin and quinapyramine, as well as being 
thirty-two times lower than the curative dose of diminazene. With a further reduction in the 
dose for cymelarsan, only a quarter of the mice could survive at 0.03125 mg/kg. A similar 
pattern (to that of suramin) was observed with the standard drug quinapyramine, where a 1 
mg/kg dose was able to cure 4/4 mice, yet when reduced to 0.5 mg/kg and 0.25 mg/kg, only 
3/4 and 1/4 mice were cured, respectively. 
 
Table 4.1. In vivo investigations using the four standard drugs, against NMRI mice infected with T. evansi 
(STIB 806K), showing the number of mice cured over the number originally infected with the average survival 
of the mice (in days) depending on the drug dose, given four times (in mg/kg). The chemical families and 
structures of the drugs tested are also depicted. 
 
Drug  
identity 
Chemical 
family 
Dose tested 
(mg/kg x 4) 
Cured / 
Infected 
Survival 
(days) Chemical structure 
      
Suramin Naphtha- 
lene 
1 
0.5 
0.25 
4/4 
3/4 
0/4 
      >60* 
      >51 
        11 
NaO3S
NaO3S
NH
O
CH3
N
H
O
N
H
N
H
O
SO3Na
O
N
H
CH3
NH
O
SO3Na
NaO3S
NaO3S 
Diminazene Triazene 2 
1 
0.2 
4/4 
3/4 
0/4 
      >60* 
      >44 
          9 
N
NH2
NH2
NN
H
NH2
NH2  
Cymelarsan Melamino- 
phenyl 
arsenical 
1 
0.5 
0.25 
0.125 
0.0625 
0.03125 
4/4 
4/4 
4/4 
4/4 
4/4 
1/4 
      >60* 
      >60* 
      >60* 
      >60* 
      >60* 
      >37 
N
N
N
NH2
NH2
N
H
As
S
S C
H2
C
H2
C
H2
C
H2
NH2
NH2
 
Quinapyramine Quinoline 
pyrimidine 1 0.5 
0.25 
4/4 
3/4 
1/4 
      >60* 
      >57 
      >41 
N
NH2
CH3
CH3
N
H
N N
CH3
CH3
CH3
 
     * denotes all mice were cured at this dose (in bold, denotes the lowest curative dose of that drug) 
 
In summary, thirty-eight selected diamidine compounds, designed and synthesised by 
the chemist, David Boykin, were investigated for in vivo activity within a mouse model. The 
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extra standard control compound, DB 75, was also included. The various compound doses 
tested, showing the number of mice cured over the number originally infected and the average 
survival of the mice (in days), can be seen in Table 4.2. All thirty-eight diamidine compounds 
were selected based on their ability to produce in vitro activity against T. evansi strains and a 
knock out T. b. brucei strain, below 12 ng/ml and 20 ng/ml, respectively. Furthermore, all 
thirty-eight compounds had previously demonstrated no significant cytotoxicity against 
mammalian cell lines and more importantly, were not toxic when applied as accumulative 
compound doses in mice at 100 mg/kg, when an intra-peritoneal route of administration was 
used. 
 
Table 4.2. In vivo investigations using diamidine compounds, synthesised by the chemist, David Boykin, against 
NMRI mice infected with T. evansi (STIB 806K), showing the number of mice cured over the number originally 
infected with the average survival of the mice (in days) depending on the compound dose, given four times (in 
mg/kg). The chemical families and structures of the compounds tested are also depicted. 
 
Compound 
identity 
Chemical 
family 
Dose tested 
(mg/kg x 4) 
Cured / 
Infected 
Survival 
(days) Chemical structure 
      
DB 75 Diphenyl 
furan 
1 
0.5 
0.25 
0.20 
0.125 
0.0625 
4/4 
4/4 
4/4 
4/4 
3/4 
1/4 
      >60* 
      >60* 
      >60* 
      >60* 
      >55 
      >29 
ONH
NH2 NH2
NH
 
DB 211 Pyrimidine 0.5 0/4         15 
N
N
NH
NH2
O
CH3
NH2
NH
 
DB 320 Pyrrole 1 3/4       >49 NNH NH
NH2 NH2
CH3
 
DB 690 Diphenyl 
furan 1 0.5 
0.25 
4/4 
3/4 
1/4 
      >60* 
      >57 
      >41 
O
NH
NH2
NH2
NH
 
DB 820 Aza-furan 1 
0.25 
0.125 
4/4 
4/4 
2/4 
      >60* 
      >60* 
      >50 
NNH
NH2
O
NH2
NH
 
DB 828 
 
Diaryl 
furan 
1 0/4         23 
O
N
ONH
NH2
NH2
NH
 
DB 850 
 
Benz-
imidazole 
0.5 0/4         16 
N
NO
NH
NH
NH2 NH2
CH3
 
DB 853 
 
Benz-
imidazole 
1 0/4         18 
N
N
H
N
NH
NH2
NH2
NH
 
DB 867 Aza-furan 1 
0.5 
0.25 
0.125 
4/4 
4/4 
3/4 
2/4 
      >60* 
      >60* 
      >54 
      >46 
NH
NH2
O
NH2
NH
N
 
Table 4.2. continued… 
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DB 877 Biphenyl 1 
0.2 
1/4 
0/4 
      >35 
        12 N
N
NH
NH
NH2
NH2  
DB 930 Diphenyl 
furan 
1 
0.5 
0.25 
0.125 
4/4 
4/4 
1/4 
1/4 
      >60* 
      >60* 
      >38 
      >32 
O
OH
NH
NH2
NH2
NH
 
DB 989 
 
Benz-
imidazole 
0.5 0/4         27 
N
N
O
NH
NH
NH2
NH2F  
DB 1012 
 
Diaryl 
furan 
1 0/4         13 NNH
NH2
O
N
CH3
NH2
NH
 
DB 1017 
 
Diphenyl 
furan 
0.5 1/4       >43 
O
HH
NH2
NHNH
NH2
FF
 
DB 1019 Biphenyl 1 1/4         28 N
NH
NH2 O
NH2
NH
 
DB 1044 
 
Diaryl 
pyridine 
0.5 0/4         16 NNH
NH2 NH2
NH
 
DB 1046 
 
Benz-
imidazole 
1 0/4         11 
NH
N
NN
N
C
H2
C
H2
CH3 CH3
NH2
NH2
NH
 
DB 1052 Thiazole 1 3/4       >53 N
SNH2
NH NH
NH2
 
DB 1055 
 
Benz-
imidazole 
0.5 0/4         12 
H
H
N
H
N
NH2
NH
NH
NH2  
DB 1152 Cinnamide 
 
1 0/4         20 Structure not shown 
due to patent reasons 
    
DB 1171 Indole 0.5 1/4       >30 
N
H
NH
NH2
NH2
NH
DB 1172 Indole 1 1/4       >39 
N
N
H
N
H
N
N
H  
DB 1173 
 
Diaryl 
furan 
0.5 0/4         15 
NH
NH2 O
NH
NH2  
DB 1177 Biphenyl 0.5 0/4         13 NH2
NH
NH
NH2  
DB 1191 Indole 0.5 0/4           7 NH
N
N
H
CH3
N
H
N
 
DB 1192 Indole 1 
0.5 
0.25 
0.125 
4/4 
4/4 
2/4 
1/4 
      >60* 
      >60* 
      >51 
      >29 
NH
NH2
N
H
CH2
NH2
NH
 
DB 1194 Diaryl 
thiophene 
0.5 0/4         16 Structure not shown 
due to patent reasons 
   
DB 1213 Diaryl 
seleno-
phene 
0.5 0/4         27 Structure not shown 
due to patent reasons 
DB 1220 Terphenyl 0.5 0/4         13 NH N
H
NH
N
H
NH
N
H
CH3
CH3  
      
Table 4.2. continued… 
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DB 1237 Aza-
terphenyl 
0.5 
0.25 
2/4 
0/4 
      >47 
        16 
 
NNNH
NH2 NH2
NH
 
DB 1253 Aza-triaryl 0.5 0/4           7 
N N
NH
NH2
NH
NH2 
DB 1258 Aza-
terphenyl 
0.5 0/4           7 
NH2
NHNH
NH2
OMe
OMe  
DB 1272 Seleno-
phene 
0.5 0/4         18 Structure not shown  
due to patent reasons 
DB 1283 Di-aza 
furamidine 
1 
0.5 
0.25 
0.125 
4/4 
4/4 
2/4 
0/4 
      >60* 
      >60* 
      >46 
        23 
ON
NH
NH2 N NH2
NH
 
DB 1288 Diaryl 
seleno-
phene 
0.5 0/4         23 Structure not shown  
due to patent reasons 
DB 1340 Seleno-
phene 
0.5 0/4           8 Structure not shown  
due to patent reasons 
DB 1342 Pyrrole 0.5 1/4       >34 
NN
NNH
NH2 NH2
NH
Me
 
DB 1370 Aza-
pyridine 
0.5 0/4         21 
N
N
NH
NH2 NH2
NH
N N
 
DB 1371 Aza-
pyridine 
0.5 0/4         14 
 
N
N
NH
NH2 NH2
NHN N
 
     * denotes all mice were cured at this dose (in bold, denotes the lowest curative dose of that compound) 
 
In vivo, six selected diamidine compounds, designed and synthesised by David 
Boykin, out of the thirty-eight originally tested, demonstrated very high efficacy within the 
mouse model. The following compounds, DB 867, DB 930, DB 1192 and DB 1283, produced 
lowest curative compound doses of 0.5 mg/kg for curing mice infected with a reference T. 
evansi strain. In addition, the compounds DB 820 and DB 75 produced lowest curative 
compound doses of 0.25 mg/kg and 0.20 mg/kg, respectively. At these relatively small 
amounts, 4/4 mice could survive for >60 days and all six compounds were more effective at 
curing the T. evansi infected mouse model, than the standard drugs, suramin, diminazene and 
quinapyramine. The lowest curative dose of cymelarsan (0.0625 mg/kg) remains four to eight 
times lower than the lowest curative doses of these six diamidine compounds. A new selective 
criterion was thus applied, whereby only compounds capable of curing T. evansi infected 
mice at doses of 0.5 mg/kg (or lower) will be positively selected for further investigation as 
lead compounds in a larger animal model. 
Additionally, ten previously selected diamidine compounds, designed and synthesised 
by the chemist, Richard Tidwell, were also investigated for in vivo activity with a mouse 
model. The various compound doses tested, with the number of mice cured over the number 
originally infected together with the average survival of the mice (in days), can be seen in 
Table 4.3. All ten diamidine compounds were selected based on their ability to produce in 
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vitro activity against T. evansi strains and a knock out T. b. brucei strain, below 12 ng/ml and 
20 ng/ml, respectively. Furthermore, all ten compounds had previously demonstrated no 
significant cytotoxicity against mammalian cell lines and more importantly, were not toxic 
when applied as accumulative compound doses in mice at 100 mg/kg, when an intra-
peritoneal route of administration was used. 
 
Table 4.3. In vivo investigations using diamidine compounds, synthesised by the chemist, Richard Tidwell, 
against NMRI mice infected with T. evansi (STIB 806K), showing the number of mice cured over the number 
originally infected with the average survival of the mice (in days) depending on the compound dose, given four 
times (in mg/kg). The chemical families and structures of the compounds tested are also depicted. 
 
Compound 
identity 
Chemical 
family 
Dose tested 
(mg/kg x 4) 
Cured / 
Infected 
Survival 
(days) Chemical structure 
      
3 KEG 083 Pentamidine 
analogue 
1 0/4         29 
C O
H
H
H
NH2
N
H
O
N
NH2
C C C
H
H
H
H
H
H
C
H
H
CH3 CH3
 
4 SAB 075 Isoxazole 1 
0.5 
2/4 
0/4 
      >43 
        19 
Structure not shown  
due to patent reasons 
5 MAA 101 Pentamidine 
analogue 
1 1/4       >29 
NH
NH2
O
O C C C O
O
H
H
H
H H NH2
NHH
CH3 CH3
 
5 SMB 093 Isoxazole 0.5 0/4         20 Structure not shown  
due to patent reasons 
8 SAB 066 Isoxazole 0.5 2/4       >38 Structure not shown  
due to patent reasons 
9 SAB 021 Isoxazole 0.5 0/4           9 Structure not shown  
due to patent reasons 
12 SMB 003 Isoxazole 0.5 0/4           8 Structure not shown  
due to patent reasons 
16 DAP 095 Isoxazole 1 
0.5 
4/4 
1/4 
      >60* 
      >29 
N
NH
NH2 O
NH
NH2
 
19 DAP 021 Isoxazole 0.5 0/4         12 Structure not shown  
due to patent reasons 
19 DAP 025 Naphthylene 1 
0.5 
0.25 
4/4 
3/4 
1/4 
      >60* 
      >56 
      >36 
Structure not shown  
due to patent reasons 
     * denotes all mice were cured at this dose (in bold, denotes the lowest curative dose of that compound) 
 
Only two of the selected ten diamidine compounds demonstrated high in vivo efficacy 
against T. evansi infected mice. These two compounds, 16 DAP 095 and 19 DAP 025, are 
capable of curing 4/4 mice infected with T. evansi at 1 mg/kg doses. Both these compounds 
show better efficacy in the mouse model than the standard drug, diminazene. However, the 
cut-off value for the in vivo selective criterion is curative efficacy of T. evansi infected mice at 
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0.5 mg/kg doses. Since an alternative compound against T. evansi infection needs to show 
greater efficacy in vivo than the standard drugs, none of the diamidine compounds, designed 
and synthesised by the chemist Richard Tidwell, qualify for further in vivo investigation, 
based on this stringent criterion. 
Taking into account the selective criteria applied during the in vitro study (detailed in 
the previous chapter) and the selective criteria from this in vivo mouse model, only six 
diamidine compounds currently qualify for further investigation in a larger animal model. 
These compounds are DB 75, DB 820, DB 867, DB 930, DB 1192 and DB 1283. Given that 
an alternative compound against T. evansi infection would significantly benefit many 
communities within developing countries, an economical compound would be an ideal 
candidate. Therefore, an element of cost-effectiveness was applied as another selective 
criterion, to establish which compounds contain the most advantageous properties for large-
scale production. Any compounds, which require expensive raw materials or chemical 
components, as well as compounds involving complex and numerous synthetic steps, would 
in turn increase the cost of manufacture, hence the overall cost of the marketable compound. 
As a result, these compounds (DB 930 and DB 1283) were not selected for continued 
investigation. 
The aza-furan compound, DB 820, is currently under investigation as a potential 
clinical candidate for human trypanosomiasis. Consequently, DB 820 was not selected for 
continued investigation against T. evansi infection (which is only animal pathogenic), due to 
this compound having already been selected for continued investigation for human sleeping 
sickness. Although DB 75 is in a similar situation to that of DB 820, this compound (DB 75) 
was nevertheless selected for continued investigation against T. evansi as an extra standard 
control diamidine. Together with DB 75, the remaining compounds DB 867 and DB 1192, 
qualified for in vivo testing within a larger animal model. 
Three lead diamidine compounds (DB 75, DB 867 and DB 1192) were thus 
additionally tested in vivo against different T. evansi strains to determine strain sensitivity. 
The results obtained for the in vivo strain sensitivity mice experiments, for DB 75, DB 867 
and DB 1192, can be seen in Table 4.4. These three compounds were administered in the mice 
at 0.5 mg/kg doses only, since this was the selective cut-off value for the in vivo mouse model 
criterion used for the reference STIB 806K T. evansi strain. 
The T. evansi strains from the Canaries and Colombia demonstrated that all three 
compounds are capable of curing 4/4 mice at 0.5 mg/kg, which shows a similar pattern to that 
of the reference STIB 806K strain (marked in blue). The compound DB 75 was able to cure 
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4/4 mice infected with the Kazakhstan strain, unlike DB 867 and DB 1192, which were only 
able to cure 2/4 and ¼ mice, respectively, at the same dose. None of the compounds were able 
to provide complete survival of the mice, when they were infected with the Philippines strain, 
with the exception of DB 75, which managed to cure 2/4 mice only. 
 
Table 4.4. In vivo strain sensitivity tests using three selected diamidine compounds (DB 75, DB 867 and DB 
1192), against NMRI mice infected with either one of the five different T. evansi strains, isolated from various 
geographical locations, or the genetic knock out T. b. brucei strain (TbAT1 K.O.), showing the number of mice 
cured over the number originally infected with the average survival of the mice (in days), when each compound 
was tested against each strain, using a specific compound dose (in mg/kg) given four times. 
 
DB 75 DB 867 DB 1192 
Strain 
Identity 
Dose 
tested 
mg/kg x 4 
Cured / 
Infected 
Average 
survival     
(days) 
Dose 
tested 
mg/kg x 4 
Cured / 
Infected 
Average 
survival 
(days) 
Dose 
tested 
mg/kg x 4 
Cured / 
Infected 
Average 
survival 
(days) 
      
T. evansi strains         
Canaries 0.5 4/4 >60* 0.5 4/4 >60* 0.5 4/4 >60* 
Colombia 0.5 4/4 >60* 0.5 4/4 >60* 0.5 4/4 >60* 
Kazakhstan 0.5 4/4 >60* 0.5 2/4 >47 0.5 1/4 >45 
Philippines 0.5 2/4 >47 0.5 0/4   32 0.5 0/4   29 
STIB 806K 0.5 4/4 >60* 0.5 4/4 >60* 0.5 4/4 >60* 
T. b.  brucei  strain         
TbAT1 K.O. 0.5 1/4 >35 0.5 2/4 >45 0.5 3/4 >51 
  * denotes all mice were cured at this dose 
 
A Trypanosoma brucei brucei knock out strain (TbAT1) was also included in this 
panel of T. evansi strains to determine the in vivo effect of the three compounds in relation to 
their uptake mechanism and mode of action. As can be seen in Table 4.4, the compound DB 
75 only cured 1/4 mice, whereas DB 867 and DB 1192 were increasingly more effective, by 
curing 2/4 and 3/4 mice, infected with the T. b. brucei knock out strain. 
The number of mice cured over the number originally infected and the average 
survival (in days) of the nine groups of NMRI mice used in the prophylactic study are shown 
in Table 4.5. Group A acted as a negative control and therefore was given neither DB 75 
prophylaxis nor treatment. Group A demonstrates that without any preventative or curative 
measures, all mice die after an average of 5 days, when infected with the STIB 806K T. 
evansi strain. As a comparison, Groups H and I were given DB 75 treatment, one day after 
infection with STIB 806K. These two groups acted as a positive control to illustrate the fact 
 80
Chapter 4: In vivo investigations into diamidines against T. evansi 
 
that DB 75 can cure infection with STIB 806K at both 3 mg/kg (Group H) and 10 mg/kg 
(Group I) concentrations. Hence, as Table 4.5 clearly shows, 4/4 mice were cured in Groups 
H and I. 
 
Table 4.5. The number of mice cured over the number originally infected with the average survival (in days) of 
six groups of NMRI mice (Groups B - G), given 3 or 10 mg/kg doses of DB 75 prophylaxis, at 10, 6 or 3 days 
prior to infection with a kinetoplastic T. evansi strain. Two groups of NMRI mice (Groups H - I, positive 
control) were treated with 3 or 10 mg/kg doses of DB 75 respectively, one day after infection, whilst one group 
(Group A, negative control) was given neither prophylaxis nor treatment. 
 
 
Group 
DB 75  
 dose tested  
(mg/kg) 
Prophylaxis 
given 
(days) 
Cured / 
Infected 
Average  
survival 
(days) 
A n/a n/a 0/4 5 
B 3 - 10 2/4 >32.50 
C 10 - 10 2/4 >32.50 
D 3 - 6 4/4 >60 
E 10 - 6 4/4 >60 
F 3 - 3 4/4 >60 
G 10 - 3 4/4 >60 
H 3 + 1 4/4 >60 
I 10 + 1 4/4 >60 
     n/a denotes “not applicable” 
 
Groups B to G were given DB 75 as a prophylactic determinant, but at various time 
points before initial infection. Again two compound doses were used, namely 3 mg/kg and 10 
mg/kg. Starting with the smallest time difference, Groups F and G were given DB 75 
prophylaxis three days before infection. At both 3 mg/kg (Group F) and 10 mg/kg (Group G) 
doses, DB 75 was able to successfully protect against STIB 806K infection and a 100 % 
survival rate was seen for both groups. This encouraging result was also seen with Groups D 
(3 mg/kg) and E (10 mg/kg), when DB 75 was given six days before initial infection. The last 
two groups, Groups B and C were given DB 75 prophylaxis ten days prior to infection with 
STIB 806K. At this time period, the prophylactic efficacy of DB 75 was sufficient to protect 
only 2/4 mice in both groups. There was no difference seen between the higher and the lower 
DB 75 doses (3 mg/kg and 10 mg/kg, respectively) in terms of average survival of the mice in 
days (>32.50). 
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Discussion 
 
The aim of this study was to investigate sixty-three selected diamidine compounds, 
found to be highly effective in vitro against the reference STIB 806K Trypanosoma evansi 
strain. These diamidine compounds were not only chosen due to their antitrypanosomal 
activity against T. evansi strains, but also due to their reduced potential for drug resistance, 
determined by previous activity against a genetic P2 transporter knock out strain (TbAT1 
K.O.). The low cytotoxicity against mammalian cells and the absence of toxicity within an in 
vivo mouse model are also important criteria for the specific selection of these diamidine 
compounds. However, fifteen of these selected diamidine compounds were not tested within 
an in vivo mouse model, due to compound unavailability. By determining the in vivo 
chemotherapeutic efficacy of the remaining forty-eight compounds within an in vivo mouse 
model, it was possible to further select the most efficient, non-toxic compounds, which could 
act as alternatives to the four standard drugs currently in use. 
Using an in vivo mouse model, the compounds could be tested and observed for their 
efficacy within a living system. Although the in vitro results for these forty-eight compounds 
demonstrated potent activity against the parasite, T. evansi, the ability of these compounds to 
exert this same efficacy within a living system, such as an animal model infected with T. 
evansi strains, is a completely different matter. Factors such as absorption and metabolism 
start to play a role, enabling changes within the animal, the parasite or even the compound to 
occur and hence totally alter the resultant effect. 
The standard drugs were able to cure 4/4 mice at drug doses of 1 mg/kg (for suramin 
and quinapyramine), 2 mg/kg (for diminazene) and 0.0625 mg/kg (for cymelarsan). In this 
mouse model, the diamidine, diminazene, appears to have the least efficacy amongst all the 
standard drugs currently on the market. In contrast, cymelarsan demonstrates the greatest 
curative activity, yet the high costs of this drug coupled with its limited availability 
throughout the world, overshadow its beneficial properties. 
From the forty-eight compounds tested, 87.5 % of them demonstrated no significant in 
vivo activity at a 0.5 mg/kg compound dose given over four consecutive days. This stringent 
selection for active compounds at such a low dose is due to the in vivo activity observed by 
the four standard drugs against T. evansi. Since the general aim of this study is to discover 
potential lead compounds possessing greater activity than the standard drugs, only the 
remaining six compounds (providing high activity at 0.5 mg/kg given over four consecutive 
days) can be positively selected for in this case. Therefore 42 of the 48 compounds tested are 
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now removed from the drug pipeline, which expresses the various selective parameters 
required to be met in order to produce an effective and marketable drug. These six compounds 
(DB 75, DB 820, DB 867, DB 930, DB 1192 and DB 1283) will in turn continue onto the 
next step within the drug pipeline to determine whether they fit the next set of criteria. 
Another selection criterion for clinical candidate compounds capable of entering into 
clinical trials includes the cost assessment and large-scale production of a compound. It was 
recognized that some of the compounds included a lengthy and complicated synthesis and 
therefore for future large-scale production, this would pose problems of practicality and cost. 
Since the aim is to find an economical alternative, complicated synthetic steps would increase 
the overall costs of these compounds (in this case, DB 930 and DB 1283) and thus they were 
removed from the pipeline. In addition, any compound previously selected for (and currently 
undergoing) investigation against the human form of sleeping sickness (DB 820) was also 
removed from the pipeline. 
A further aspect investigated in this study was strain sensitivity and the ability of three 
lead compounds (DB 75, DB 867 and DB 1192) to cure mice infected with other T. evansi 
strains, isolated from various geographical locations. All three compounds cured mice 
infected with strains from the Canary Islands, Colombia and the reference STIB 806K 
Chinese strain. The Kazakhstan strain could be cured by DB 75, whereas DB 867 could cure 
only half of the mice and DB 1192, only a quarter. 
When compared to the genetic knock out (TbAT1 K.O.) strain, the following results 
were observed, whereby DB 75 cured only a quarter of the TbAT1 K.O.-infected mice, whilst 
DB 867 cured 2/4 mice and DB 1192, 3/4 mice. We know that DB 75 uptake relies on the P2 
transporter, which is missing in the TbAT1 K.O. strain and hence with a limited uptake rate, 
DB 75 was probably not able to cure all the mice. This may imply that DB 867 relies only 
partly on P2 transportation and thus could effectively cure only half the infected mice. 
Likewise, DB 1192 may not rely greatly on P2 transportation and thus strains missing this 
transporter may still be effectively cured by this compound (3/4 mice were cured for TbAT1 
K.O.). Whether different uptake transporters are involved and which ones these may indeed 
be, has not yet been completely investigated. 
Previously, the diamidine compound DB 75 demonstrated excellent in vitro 
chemotherapeutic properties. It produced an IC50 value of 2.3 ng/ml, when it was tested in 
various in vitro cell viability assays against a Chinese T. evansi strain (STIB 806K). 
Furthermore, this low IC50 value was seen to extend across a global panel of T. evansi strains, 
ranging from South America (Colombia and Brazil) through to Asia (Kazakhstan) and the 
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South East (Philippines, Indonesia and Vietnam). In vivo, DB 75 is capable of treating (and 
curing) mice infected with the reference T. evansi strain (STIB 806K) at overall treatment 
doses as low as 0.8 mg/kg. Similar to these results, a total dose of 2 mg/kg of DB 75 has 
shown curative efficiency in vivo within a mouse model against other T. evansi strains, 
namely from Colombia, Kazakhstan and the Canary Islands. Using DB 75, this study also 
provided a preliminary insight into the prophylactic nature of such dicationic molecules. The 
results reveal that DB 75 can remain effective within mice for up to six days, before that 
mouse is infected with T. evansi. This effect is capable of providing the mouse with 100 % 
protection. If the time period is extended until ten days prior to infection, only 50 % of the 
mice can be protected against T. evansi. This is seen at both 10 mg/kg and 3 mg/kg compound 
concentrations. Protection in a larger animal however, may last much longer than the six days 
observed for mice. 
The application of a prophylactic treatment against infection with T. evansi may not be 
the ideal situation for disease control. The financial costs involved in logistically moving from 
region to region, applying the prophylactic treatment and the labour time required, to carry 
out such a control programme, does not provide additional long term benefits than if only the 
infected animals were identified and respectively treated. To ensure continued success of such 
a prophylactic programme, constant maintenance and reapplication of the treatment would 
need to be pursued; a situation which is difficult to follow for a disease that can be 
(mechanically) transmitted with such ease in regions where meeting such highly economical 
demands would impart a continuous struggle on both communities and governments. 
With the selective criteria from a previous in vitro study, several in vivo (mouse 
model) criteria could be applied to these compounds within this study, to again select only 
those which have the ideal characteristics sought after. The remaining compounds are capable 
of curing T. evansi infected mice at doses of 0.5 mg/kg, more effectively than the standard 
drugs, suramin, diminazene and quinapyramine. In addition, these selected compounds are 
cost-efficient in terms of production, synthesis and manufacture and are not currently 
undergoing examination as lead compounds against human sleeping sickness. Although DB 
75 does not qualify for all the specified criteria, this diamidine compound is included in all 
investigations against T. evansi as an additional control standard. In summary, two selected 
diamidine compounds remain (DB 867 and DB 1192), which warrant continued investigation 
as potential clinical candidates against T. evansi infection in a larger animal model. 
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Abstract 
 
Chemotherapy is often the main method of control used to cure or prevent diseases. 
Since drugs usually produce undesirable effects, as well as desirable effects, successful 
chemotherapy is reliant on achieving a specific balance between the two. To conquer some of 
the limitations and problems involved in successful drug therapy, the events and effects 
occurring after drug administration can be investigated through pharmacokinetics and 
pharmacodynamics. The object of infectious disease drug therapy is to produce and maintain 
a therapeutic response, long enough to eliminate the disease causing agents, yet short enough 
to minimise toxicity and adverse effects. Investigations into a group of novel diamidine 
compounds found several to be highly effective against the protozoan parasite, Trypanosoma 
evansi, which causes Surra, a wasting disease affecting many domestic and wild animals 
worldwide. 
Initial toxicity profiles of three selected lead diamidine compounds (DB 75, DB 867 
and DB 1192) were evaluated in a goat model at a single administered compound dose of 4 
mg/kg and at multiple (four) compound administrations at 1 mg/kg, using an intramuscular 
route of application. A preliminary pharmacokinetic study was also included, whereby blood 
samples were taken at specific time points and then analysed using HPLC/MS-MS. Overall, 
no signs of acute toxicity were seen in any of the goats for either diamidine compound (DB 
75, DB 867 or DB 1192). In conclusion, all three compounds are considered safe to be 
investigated further in T. evansi experimentally infected goats and to determine their curative 
efficacy within such a model. 
 
Keywords: Toxicity; diamidines; goat model; Trypanosoma evansi; pharmacokinetics. 
 
 
 
Introduction 
 
Chemotherapy is often the main method of control used to cure or prevent diseases. 
Since drugs usually produce undesirable effects, as well as desirable effects, successful 
chemotherapy is reliant on achieving a specific balance between the two. It is important to 
realise that the extent of therapeutic and toxic responses are functions of the dose given and 
that the effect of drug therapy will decrease with time after a single drug dose has been 
 88
Chapter 5: Toxicity of diamidines in goats 
administered. Indeed, continuous drug administration can lead to increased costs, in terms of 
adverse effects, economics and toxicity, implying that the balance between all necessary 
factors is difficult to attain. To conquer some of the limitations and problems involved in 
successful drug therapy, the events and effects occurring after drug administration can be 
investigated through pharmacokinetics and pharmacodynamics. 
When a drug is administered, the rate at which it initially enters the body is greater 
than its rate of elimination. The concentration of the drug increases in the blood and in the 
tissues to gain the desired therapeutic effects; on the other hand, it can sometimes produce 
toxicity. Eventually, the rate of elimination will surpass the rate of absorption and hence the 
concentration of the drug in the blood and tissues (and of course the therapeutic effects) 
subsides. To apply drugs optimally, the mechanisms of absorption, distribution and 
elimination must be known, along with the kinetics included in such processes (Rowland and 
Tozer, 1989). The object of infectious disease drug therapy is to produce and maintain a 
therapeutic response, long enough to eliminate the disease causing agents, yet short enough to 
minimise toxicity and adverse effects. This important therapeutic window is illustrated in 
Figure 5.1, where if the drug dose administered is too high, toxicity may occur as the drug 
concentration in the body reaches the range in which adverse or toxic effects arise. Similarly, 
if the administered drug dose is too low, the period of time in which the required effective 
drug concentration remains within the therapeutic window may be too short, resulting in 
unproductive sub-therapeutic levels and unsuccessful treatment. The optimal drug dose to be 
administered is therefore a balance between the amount of drug present in the body and the 
length of time it remains there, before it is eliminated. 
A group of chemical compounds known as aromatic diamidines bind to the minor 
groove of DNA and display a broad spectrum of anti-parasitic activity. Pentamidine has found 
a current use in the treatment of early stage African trypanosomiasis, antimony-resistant 
leishmaniasis and AIDS associated Pneumocystis carinii (Boykin, 2002). Nevertheless, the 
beneficial effects of pentamidine are hindered, due to its toxicity causing hypotension, 
dysglycaemia and renal and hepatic dysfunction (Drake et al., 1985). Chemically, it has been 
shown that pentamidine-related toxicity is partly due to the cleaving of the linker during drug 
metabolism (Berger et al., 1992). 
With the introduction of synthalin, the first diamidine compound with anti-parasitic 
properties, a series of toxicity studies into such compounds was conducted within the 1920s 
(Blatherwick et al., 1927; Bodo and Marks, 1928). The ability of synthalin to produce 
hypoglycaemia, causing serious hepatic and renal damage, was considered to be derived from 
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malfunctions during normal glyconeogenesis. Synthalin caused a depletion of glycogen in the 
liver, hence leading to a breakdown of muscle glycogen and an increase in lactic acid within 
the blood. Many related compounds showed similar properties (Broom, 1936) and so, an 
attempt was eventually made to synthesise aromatic diamidines with improved properties and 
reduced toxicity (Boykin, 2002). 
 
Figure 5.1. Diagrammatic sketch to show the therapeutic window within which the amount of administered drug 
dose (drug concentration within the body) and the length of time (the drug remains within that therapeutic 
window) is important to ensure safe and successful drug therapy. 
Drug 
Level 
Time 
Toxic range 
Sub-therapeutic range 
Therapeutic  
   window 
High drug dose administered 
 
Optimal drug dose administered 
 
Low drug dose administered 
 
 
Amongst these new and improved dicationic compounds, several were found to be 
highly effective against the protozoan parasite, Trypanosoma evansi, which causes Surra, a 
wasting disease affecting many domestic and wild animals worldwide (Holland et al., 2004; 
Lun et al., 2004). Since chemotherapy is the main form of control management for Surra, 
existing drugs (troubled with drug resistance and unacceptable toxicity) need to be replaced 
with new and improved compounds providing a more economical, effective and safer 
alternative for chemotherapeutic action against T. evansi (El Rayah et al., 1999). 
Recent toxicity studies into these selected diamidine compounds have not yet been 
performed and before such compounds can enter clinical trials, the toxic effects of aromatic 
diamidines need to be fully examined. The compounds DB 867 and DB 1192 were previously 
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selected for their in vitro and in vivo activity (within a mouse model) against T. evansi strains, 
their reduced potential for drug resistance, as well as low cytotoxicity against mammalian 
cells and no preliminary toxicity in mice. In addition, these compounds were selected for 
further testing, due to their cost-effective manufacture as possible clinical candidates against 
T. evansi infection. The compound DB 75 has been included in these investigations as an 
extra standard control compound. The aim of this preliminary toxicity trial was therefore to 
determine whether the selected diamidine compounds, DB 75, DB 867 and DB 1192 produce 
signs of acute toxicity in goats, when administered at a single dose of 4 mg/kg or at 
accumulative multiple doses of 1 mg/kg. Should these compounds exert no toxic effects at the 
tested compound doses, it may be possible to formulate a safe and successful treatment 
schedule to determine the efficacy of these diamidines against T. evansi infected goats. 
 
 
 
Materials and Methods 
 
Study site and goats 
 
The toxicity study took place within the Veterinary Hospital of the University of Las 
Palmas in Arucas, Gran Canaria in June 2006 and was approved by the ethical committee of 
the Hospital Clinicó Veterinario, Gran Canaria. Six female Canarian goats, weighing between 
21 - 31 kg and no less than six months old were purchased from a local dairy farmer and then 
transported to the facility. Upon arrival, the goats were housed in enclosed pens and allowed 
to acclimatise to their new surroundings for one week. Thereafter, each goat was given a 
numbered ear tag, weighed and checked for current or previous infections. All six goats were 
confirmed to be clinically healthy at the start of the experiment. Throughout the experimental 
period, the goats were given food (pelleted nutrients, dried corn and hay) three times a day 
and water was provided ad libitum. 
 
Selected diamidine compounds 
 
The selected diamidine compounds were originally designed and synthesised by the 
chemist, David Boykin. The compounds DB 75, DB 867 and DB 1192 were used as the test 
compounds in these preliminary goat toxicity trials, based on their previous in vitro and in 
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vivo activity against Trypanosoma evansi and preliminary toxicity within a mouse model, 
which was assessed in previous chapters. 
 
Stock solutions 
 
A 160 mg amount of the compounds DB 75, DB 867 and DB 1192 were weighed out 
in powder form and dissolved in 4 ml of sterile distilled water with 10 % DMSO, to provide a 
40 mg/ml stock solution. In addition, a 300 mg amount of the compounds DB 75, DB 867 and 
DB 1192 were weighed out in powder form and dissolved in 30 ml of sterile distilled water 
with 10 % DMSO, to provide a 10 mg/ml stock solution. These stock solutions were then 
applied in the goat toxicity trials as 10 kg/ml working solutions and were made fresh on the 
day of the first administration. Thereafter, the stock solutions were kept stored at 4 °C. 
 
Toxicity trials 
 
At the start of the toxicity trials, the goats were divided into three groups of two goats. 
Each group was allocated to one selected diamidine compound as shown in Table 5.1. One 
goat from each group primarily underwent a single toxicity trial, where a single compound 
application of 4 mg/kg was given, whilst thereafter both goats in each group undertook a 
multiple toxicity trial, whereby four compound applications of 1 mg/kg were given at two 
hour intervals, over a total six hour period. All compound applications were administered 
using an intramuscular route into the lower third region of the neck muscles. The goats were 
individually observed and assessed for signs of acute toxicity after every compound 
application given. Signs of acute toxicity monitored included tremors, lacrimation, excess 
salivation, irritation (scratching at injection site or general discomfort), excess urination, 
diarrhoea, hypertension and hypotension. 
Blood samples (4 ml volumes) were taken for pharmacokinetic analysis from the goats 
at the following time points of 0.25, 0.50, 1, 2, 4, 8, 24 and 48 hours after the administration 
of the single 4 mg/kg compound application and at the following time points of 0.25, 0.50, 1, 
2, 4, 8, 24, 48, 72 and 96 hours after the administration of the fourth and final compound 
application of 1 mg/kg for the multiple compound application toxicity trials. In addition, 
blood samples were taken from all six goats before the toxicity trials began, to determine 
control plasma levels, as well as just before each compound application of 1 mg/kg was given 
during the multiple toxicity trials, to determine the trough levels. 
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Table 5.1. The allocation of lead compounds with the goat numbers and weights (in kg) along with the 
compound doses given (in mg/kg) for either the single or multiple application toxicity trials. 
 
Group Number of goats 
Lead 
compound 
Goat 
number 
Goat weight  
(kg) 
Dose given 
(mg/kg) 
Toxicity trial 
performed 
0823 27.0           4 
          1 (x 4) 
           single 
           multiple 
1 2 DB 75 
0865 21.5           1 (x 4)            multiple 
0866 31.0           4 
          1 (x 4) 
           single 
           multiple 
2 2 DB 867 
0850 21.0           1 (x 4)            multiple 
0818 29.0           4 
          1 (x 4) 
           single 
           multiple 
3 2 DB 1192 
Grey 24.5           1 (x 4)            multiple 
 
Blood sample collection 
 
Blood samples were collected at regular time intervals from each of the goats using 
clean, sterile Vacutainer® (Becton Dickinson, Plymouth, UK) tubes of 4 ml volume, 
containing the anticoagulant, ethylene diamine tetra acetic acid (EDTA). The tubes were 
inverted several times, immediately after blood was taken from the jugular veins of the goats, 
to ensure equal distribution of the anticoagulant throughout the blood sample taken. The tubes 
were then kept on ice until they reached the laboratory for plasma preparation. 
All blood samples taken at various time points, for either the single compound 
application or multiple compound application toxicity trials, were centrifuged at 3000 g for 
ten minutes. Subsequently, the plasma was removed and placed into sterile polypropylene 
cryotubes, before being stored away from light at -80 °C. 
 
Plasma sample preparation 
 
Plasma aliquots (25 μl volumes) were vortexed with 200 μl of a 12.5 nM internal 
standard (DB 103) dissolved in methanolic HCl (8:1 methanol: 1N HCl). Protein was 
precipitated by centrifugation (Beckman GS-6R) at 3000 rpm for 7 minutes at room 
temperature. The supernatant (120 μl) was then transferred to 96-well plates and evaporated 
under heated nitrogen (EVX Evaporator, Apricot Designs, USA). Thereafter, the samples 
were reconstituted in the plate, with 60 μl of high pressure liquid chromatography (HPLC) 
grade water (Fisher Scientific, USA), for analysis by mass spectrometry. Calibrators were 
prepared separately for each analyte. Stock solutions of DB 75, DB 867 and DB1192 were 
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prepared in water. Aqueous dilutions of each stock solution were prepared to provide the 
following spiking solutions: 0.5, 1, 2.5, 5, 10, 25, 50, 100, 250 and 500 μM. To produce the 
intended calibration solutions of 5, 10, 25, 50, 100, 250, 500, 1000, 2500 and 5000 nM, 0.6 μl 
of aqueous spiking solution was added to 60 μl of untreated commercial goat plasma. These 
calibrators were then treated in the same way as the plasma samples. Curves were then 
prepared and analysed in duplicate, at both the beginning and the end of the analytical run. 
 
Mass spectrometry analysis 
 
Concentrations of DB 75, DB 867 and DB 1192 were determined by Liquid 
Chromatography/Triple Quadrupole Mass Spectrometry (HPLC/MS-MS). The HPLC/MS-
MS system consisted of two solvent delivery pumps (Shimadzu Scientific, Colombia, MD, 
USA), a switching valve (Valco, Houston, TX, USA), a thermostated (6 °C) LEAP HTC auto-
sampler (Carrboro, NC, USA) and an API4000 triple quadrupole mass spectrometer (Applied 
Biosystems, Foster City, CA, USA). Reversed-phase gradient chromatography was used to 
elute the compounds from an analytical column (Aquasil, C18 5 µm, 50 × 2.1 mm) at a flow 
rate of 0.75 ml / minute, following an 8 µl injection. Starting conditions for each injection 
included 95 % water with 0.1 % formic acid (v/v) and 5 % methanol with 0.7 % formic acid 
(v/v). This was held constant for 1 minute while the column eluted to waste. After 1 minute, 
the eluent was directed to the mass spectrometer and the organic phase (methanol with 0.1 % 
formic acid, v/v) increased linearly, reaching 90 % organic, 3.25 minutes post-injection. This 
was held for 0.5 minutes to wash the column. The column was then re-equilibrated to starting 
conditions for the final 1 minute. The total run time was 4.75 minutes. 
The mass spectrometer was connected to the HPLC system by a TurboIon Spray® 
interface (MDS Sciex, San Francisco, CA, USA). Nitrogen, from a nitrogen generator (Peak 
Scientific, Bedford, MA, USA), was used as the curtain, nebulizer and collision gases. User 
controlled voltages, gas pressures and source temperature were optimised via direct infusion, 
for DB 103 (the internal standard), DB 75, DB 867 and DB 1192. All compounds were 
analysed in positive ion mode, using the following transitions preset in multiple reaction 
monitoring scans: DB 103 (internal standard) - 385.2 to 271.2, DB 75 - 305.2 to 288.2, DB 
867 - 306.3 to 289.2 and DB 1192 - 292.3 to 275.1. The calibration curves were generated 
based on peak area ratios (analyte: internal standard) from 5 to 5000 nM. Curves for all 
analytes followed a linear y = mx + b regression with a 1/x2 weighting. Typical r values were 
0.997 or greater and accuracy was between 80 and 120 %. Automated sample acquisition and 
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data analysis was performed using Analyst software (version 1.4.1, Applied Biosystems, 
Foster City, CA, USA). 
 
Pharmacokinetic parameters 
 
The pharmacokinetic parameters were determined using Microsoft® Excel software, 
with a functional set of add-ins applied, together with a graphical programme (GraphPad 
Prism 5, GraphPad Software Inc, USA). Pharmacokinetic parameters measured and calculated 
included the peak concentration (Cmax), time at which peak concentration occurs (Tmax), the 
area under the curve (AUC), the area under the first moment curve (AUMC), the mean 
residence time (MRT), the half life (t½) and the rate of elimination constant (Kelim). The MRT 
was calculated with the function, AUMC/AUC and the rate of elimination constant was 
obtained with the function, 1/MRT. 
 
 
 
Results 
 
The signs of acute toxicity seen in the goats for both the single and the multiple 
toxicity trials for the three selected lead compounds (DB 75, DB 867 and DB 1192) are 
shown in Table 5.2. None of the goats demonstrated any forms of hypotension or 
hypertension after application of the single or multiple injections for each of the three 
compounds. Similarly, no extreme lacrimation, tremors, excess urination or onset of diarrhoea 
were reported in any of the goats. All the goats demonstrated a slight excess in salivation, 
however, this was not considered to be directly related to the drug injections. 
For the goats within group 1 (DB 75) and group 2 (DB 867), some irritation was 
observed for both the single and multiple toxicity trials, by means of scratching at the 
injection site. These goats additionally showed a short phase of uncomfortability, immediately 
after each compound injection was applied. Nevertheless, these symptoms disappeared after 
ten minutes and the goats returned to their normal behaviour. 
Compound concentrations can be seen in Figure 5.2 for the compound DB 75, Figure 
5.3 for the compound DB 867 and Figure 5.4 for the compound DB 1192. The plasma 
samples taken were analysed by HPLC/MS-MS to determine the concentrations (in ng/ml) of 
each lead compound tested at each specific time point. From these values, concentration 
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versus time curves were plotted and the line of best fit applied to both the single and multiple 
compound application doses tested. 
 
Table 5.2. Signs of acute toxicity expected after the i.m. application of three selected diamidine compounds (DB 
75, DB 867 and DB 1192) in a single compound application (4 mg/kg) and a multiple compound application (4 x 
1 mg/kg) toxicity trial. The presence or absence of each sign is depicted as a (9) or as a (x), respectively. 
 
Signs of acute toxicity* 
Group Lead 
compound 
Toxicity 
trial 
Goat 
number Hypo Hyper (L) (S) (Tr) (Ir) (U) (D) 
x x x x x 9 x x single 
multiple 
0823 
x x x x x 9 x x 1 DB 75 
multiple 0865 x x x x x 9 x x 
x x x x x 9 x x single 
multiple 
0866 
x x x x x 9 x x 2 DB 867 
multiple 0850 x x x x x 9 x x 
x x x x x x x x single 
multiple 
0818 
x x x x x x x x 3 DB 1192 
multiple Grey x x x x x x x x 
   *Signs of acute toxicity: Hypo: Hypotension; Hyper: Hypertension; (L): Lacrimation; (S): Salivation (excess); (Tr): Tremors;  
           (Ir): Irritation; (U): Urination (excess); (D): Diarrhoea.   
 
For the lead compound DB 75, the peak concentration for both single and multiple 
trials occurred at the same time point (≤ 0.25 hours), yet was two-fold higher in the single 
toxicity trial (≥ 3690 ng/ml) compared to the multiple trial (≥ 1830 ng/ml). The area under the 
curve (AUC) was similar for both the single (159390) and multiple (138183) trials with DB 
75, whereas the AUMC differed between the two by a factor of 1.7 (3’715’369 and 
6’306’900, respectively). The MRT was twice as long in the multiple DB 75 trial and the 
elimination rate constant was twice as slow. 
The peak concentration for the single toxicity trial using DB 867 occurred at ≥ 2880 
ng/ml around ≤ 0.5 hours after the initial compound injection of 4 mg/kg. The multiple dose 
trial reached a peak concentration of ≥ 3390 ng/ml, at (≤) one hour after the fourth and final 
injection of 1 mg/kg DB 867. The AUC and the MRT for the multiple toxicity trial (300’997 
and 47.1 hours) were approximately double that of the single toxicity trial (114’853 and 25.0 
hours). The area under the first moment curve (AUMC) however, was five times greater in the 
multiple dose trial (14’162’688) than in the single (2’876’569). Similar to DB 75, the 
elimination rate constant of DB 867 was 0.04 for the single and 0.02 for the multiple toxicity 
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trials. The half life determined for the single toxicity trial with DB 867 was 120.5 hours, 
whilst the multiple toxicity trial produced a three-fold longer half life of 351.7 hours. 
 
Figure 5.2. Compound concentrations in plasma samples taken from goats for DB 75, with the single (4 mg/kg) 
dose and after the last application of the multiple (4 x 1 mg/kg) dose, against time. 
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Figure 5.3. Compound concentrations in plasma samples taken from goats for DB 867, with the single (4 mg/kg) 
dose and after the last application of the multiple (4 x 1 mg/kg) dose, against time. 
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Figure 5.4. Compound concentrations in plasma samples taken from goats for DB 1192, with the single (4 
mg/kg) dose and after the last application of the multiple (4 x 1 mg/kg) dose, against time. 
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The peak concentration of the single toxicity trial for DB 1192 (≥ 1980 ng/ml) was 2.5 
times higher than the peak concentration of the multiple toxicity trial (≥ 762 ng/ml). In 
addition, the time taken for the peak concentration to occur was twice as long for the multiple 
dose trial (≤ 0.5 hours) as for the single DB 1192 dose trial (≤ 0.25 hours). Both the AUC and 
the AUMC were smaller in the multiple dose trial (10’093 and 207’593 compared to the 
single trial with 12’694 and 215’167), whereas the MRT differed by only 3.6 hours between 
the two toxicity trials. The elimination rate constant was 0.06 for the single trial and 0.05 for 
the multiple. The half lives for the single and multiple toxicity trials using DB 1192 were 
relatively similar at 16.7 hours and 19.0 hours, respectively. 
 
 
 
Discussion 
 
The aim of this preliminary toxicity trial was to determine whether any of the three 
selected lead diamidine compounds were toxic at 4 mg/kg, given as either a single dose or as 
four 1 mg/kg applications every two hours within healthy goats. No signs of acute toxicity 
were reported for any of the goats, given either a single 4 mg/kg injection or four multiple 
injections of 1 mg/kg for the lead compounds, DB 75, DB 867 and DB 1192. Irritation was 
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evident in the goats given both the single and multiple compound regimens for the lead 
compounds, DB 75 and DB 867. Coupled with a short phase of uncomfortability, it was 
established that these symptoms were due to the painful method of compound application 
(intramuscular) rather than to the lead compounds themselves. 
Toxicity profiles were created based on the compound concentrations within plasma 
samples, taken from the goats at specific time points and then plotted against time, to give the 
concentration versus time curve. The compound concentrations established for DB 75 shows 
that both the single and multiple trials fall within the therapeutic range at 72 hours, with 
compound concentrations greater than 9.2 ng/ml. To remain within the therapeutic range, the 
minimal inhibitory concentration (MIC) for each compound must be exceeded for long 
enough to allow the compound to exert its biological activity. In this case, the MIC for DB 75 
can be calculated as approximately four times the in vitro IC50 value of this lead compound at 
72 hours against Trypanosoma evansi, based on previous in vitro experiments performed 
using cell viability assays (Chapter 3). Therefore, compound concentrations must exceed 
9.2ng/ml, which in this case is four times the IC50 for DB 75. Since the shape of the curve 
declines very slowly for at least 100 hours, it appears that DB 75 remains well within the 
therapeutic range for the compound doses tested. The same is seen for the compound DB 867, 
which has an MIC at 72 hours of 6.8 ng/ml. Both the single and multiple trials have 
compound concentrations higher than the MIC at 72 hours and with the shape of the curve 
declining so slowly for at least 100 hours, the probability of DB 867 remaining within the 
therapeutic range is high. 
The situation appears different for the third lead compound, DB 1192. With an MIC of 
42 ng/ml at 72 hours, the toxicity profile for this diamidine compound shows that the chosen 
dose of 4 mg/kg may not be sufficiently high enough to remain within the therapeutic range. 
However, the therapeutic efficacy of DB 1192 will be revealed after this compound has been 
tested in an experimentally infected goat model. 
In conclusion, all three selected lead diamidine compounds (DB 75, DB 867 and DB 
1192) displayed no forms of acute toxicity in healthy goats and are thus considered safe for 
use in a T. evansi experimentally infected goat model to determine the efficacy of these 
compounds in a larger animal. 
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Abstract 
 
Trypanosoma evansi, the causative agent of Surra, presents as a fatal wasting disease 
in domestic and wild animals, found on the South American, African and Asian continents. 
Effective control methods are hindered with resistant strains, high costs and unavailable and 
toxic drugs. Alternative chemotherapeutic agents are urgently required, of which diamidines 
are showing promising results. Three lead compounds (DB 75, DB 867 and DB 1192) were 
investigated in an experimentally infected T. evansi goat model in the Canary Islands. Various 
diagnostic methods, including the haematocrit centrifugation technique (HCT), the card 
agglutination test for trypanosomes (CATT / T. evansi) and the polymerase chain reaction 
(PCR), were used to determine efficacy of the diamidines against T. evansi infection, where 
the PCR method was considered the gold-standard. 
Complete curative efficacy of the experimentally infected goats was seen in the 
positive control group, treated with 5 mg/kg diminazene, and in the DB 75 and DB 867 
groups, where goats were treated with 2.5 mg/kg of the respective diamidine compounds. In 
addition, complete cure was also observed in the lower dose group of DB 75 (1.25 mg/kg). 
The group treated with DB 867 at 1.25 mg/kg relapsed after four months follow up, post 
treatment. The diamidine compound DB 1192 was not as effective and treatment failures were 
observed in the goats after just seven days in the 2.5 mg/kg group, whilst the 1.25 mg/kg 
group provided no efficacy whatsoever. In conclusion, two diamidine compounds (DB 75 and 
DB 867) have presented better efficacy than the standard drug (diminazene) and could be 
considered as potential clinical candidates against T. evansi infection. 
 
Keywords: Trypanosoma evansi, diamidines, goat model, chemotherapy, efficacy trial. 
 
 
 
Introduction 
 
Trypanosoma evansi is the causative agent of Surra, which presents itself as a fatal 
wasting disease in many domestic and wild animals, inhabiting the continents of South 
America, Africa and Asia (Davila and Silva, 2000; Reid, 2002; Delafosse and Doutoum, 
2004). Through mechanical transmission performed by biting flies (Tabanids), infection can 
quickly spread amongst close-living herds of cattle, water buffalo, horses and camels (Foil, 
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1989). With the hindrance of resistant strains, unavailable and toxic drugs and the great 
economical losses involved, controlling this disease is a complex process (Touratier, 2000), 
which could be simplified if alternative chemotherapeutic agents were obtainable. 
New diamidine analogues, one such alternative class of chemical compounds, were 
introduced (Wilson et al., 2005) and proved highly effective against Trypanosoma brucei 
rhodesiense, the causative agent of acute human sleeping sickness found mainly in Eastern 
Africa. As a comparison, these diamidine compounds were additionally tested against various 
T. evansi strains, yielding exceptionally good results in previously conducted experiments at 
an in vitro and in vivo (mouse model) level. The data for these experiments can be viewed in 
Chapter 3 and 4, respectively. Moreover, three selected diamidine compounds were examined 
for acute toxicity within a goat model, revealing promising prospects of diamidines as 
alternative chemotherapeutic representatives against Surra. To determine the potential of 
diamidines as clinical candidates against T. evansi infection, three selected lead compounds, 
DB 75, DB 867 and DB 1192 (Figure 6.1), were examined further to evaluate their ability to 
cure experimentally infected goats with T. evansi, in the Canary Islands, Spain. 
 
Figure 6.1. The chemical structures of a) DB 867 and b) DB 1192 
 
 
  
 
T. evansi is currently endemic on the Canary Islands, originally due to the importation 
and subsequent diagnosis of a male dromedary camel in 1997, from the neighbouring area of 
West Africa, where Surra is highly prevalent. Camels were primarily imported to the Canary 
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Islands for labour purposes, but are nowadays principally raised for the tourism industry 
(Gutierrez et al., 2005). Seroprevalences in camels have been calculated to be around 4.8 % to 
9 %, between 1997 and 1999 (Gutierrez et al., 2000). Although camels and horses are the 
major hosts affected on the Canary Islands, dissemination of the disease in other hosts has not 
yet been ruled out. Above all, goats may appear to play an important role in disease 
epidemiology, especially as potential reservoir hosts (Gutierrez et al., 2004). 
Therefore, the aim of this study was to determine firstly whether goats could be 
inoculated with a local T. evansi strain (and provide a constant parasitaemia) and if so, 
whether these experimentally infected goats could be effectively treated with the three 
selected lead compounds, DB 75, DB 867 and DB 1192, at compound doses of 2.5 mg/kg and 
1.25 mg/kg, given intramuscularly (i.m.). As a comparison, the standard drug, diminazene 
aceturate, would be included as a positive control compound, administered at 5 mg/kg i.m. 
Berenil® is the officially registered veterinary drug, yet it contains only 52.5 % of the active 
component, diminazene aceturate. A control group of goats receiving no compound treatment 
would also be established within the model. Thereafter, a five month follow up study is 
planned, to evaluate the curative efficacy of these compounds using various diagnostic 
methods. By means of such an efficacy study, potential new clinical candidates against T. 
evansi may be discovered. 
 
 
 
 
Materials and methods 
 
Parasite strain 
 
A Trypanosoma evansi strain, designated as the Canaries (Rubio) strain, was the 
parasite strain employed for goat infection in this pilot “proof of concept” study. This strain 
was originally isolated by K Gillingwater in 2006, from a twenty-two year old dromedary 
camel, in a farm on Gran Canaria, belonging to the Canary Islands, Spain. The camel blood 
was immediately inoculated into mice and after a single mouse passage, was then used for 
experimental infection of the goats. 
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Mice 
 
Female NMRI mice weighing between 25 - 30 g were used for strain isolation. All 
mice were specific pathogen free (SPF) and were maintained in standard Macrolon type II 
cages, at 22 °C and with a relative humidity of 60 - 70 %. Water and pelleted food was 
provided for the mice ad libitum. 
 
Goats 
 
This study was approved by the ethical committee of the Hospital Clinicó Veterinario, 
Gran Canaria. Twenty-seven female Canarian goats, weighing between 20 - 52 kg and older 
than 6 months, were purchased from a local dairy farmer. After transportation to the 
veterinary faculty, the goats were placed inside open pens and allowed to acclimatise for a 
week to their new surroundings. Thereafter, the goats were given numbered ear tags, weighed 
and checked for current or previous T. evansi infection using the diagnostic methods 
described within this study. Any goats showing positive results for previous T. evansi 
infection were removed from the project. The remaining goats were then divided into test 
groups, given oxytetracycline against nasal exudate and ivermectin as a standard anti-
helminthic, before being placed into fly-proof pens. Throughout the study period, the goats 
were given food (pelleted nutrients, dried corn and hay), three times a day and water was 
provided ad libitum. 
 
Standard trypanocidal compound 
 
Diminazene aceturate (D-7770, Sigma, St Louis, MO, USA), was used as the standard 
positive control drug in this goat efficacy study. Berenil®, the official veterinary drug, 
contains only 52.5 % of the active component, diminazene aceturate. 
 
Selected lead diamidine compounds 
 
The selected lead diamidine compounds were originally designed and synthesised by 
the chemist, David Boykin. The compounds DB 75, DB 867 and DB 1192 were used as the 
test compounds in this goat efficacy study, based on their previous in vitro and in vivo activity 
and preliminary toxicity within a mouse model, together with preliminary toxicity results 
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obtained from a goat toxicity trial. The data for these previous investigations can be reviewed 
in chapters 3, 4 and 5, respectively. 
 
Stock solutions 
 
A 900 mg amount of the compounds, DB 75, DB 867 and DB 1192 were weighed out 
in powder form and dissolved in 36 ml of sterile distilled water with 10 % DMSO, to provide 
a 25 mg/ml stock solution. In addition, a 450 mg amount of the compounds, DB75, DB 867 
and DB 1192 were weighed out in powder form and dissolved in 36 ml of sterile distilled 
water with 10 % DMSO, to provide a 12.5 mg/ml stock solution. A 1800 mg amount of the 
standard compound, diminazene aceturate was weighed out in powder form and dissolved in 
36 ml of sterile distilled water with 10 % DMSO, to provide a 50 mg/ml stock solution. These 
stock solutions were then applied in the goat efficacy study as 10 kg/ml chemotherapeutic 
solutions and were made fresh on the day of the first administration. Thereafter, the stock 
solutions were kept stored at 4 °C. 
 
Collection of blood samples 
 
Blood samples were collected at regular time intervals from each of the goats within 
each of the test groups, using clean, sterile Vacutainer® (Becton Dickinson, Plymouth, UK) 
tubes (4 ml and 10 ml volumes), containing the anticoagulant, ethylene diamine tetra acetic 
acid (EDTA). The tubes were inverted several times, immediately after blood was taken from 
the jugular veins of the goats, to ensure equal distribution of the anticoagulant throughout the 
blood sample taken. The tubes were then placed on ice whilst diagnostic tests were carried 
out. 
 
Haematocrit centrifugation technique 
 
To analyse whether parasites were present or absent in the blood of the goats, the 
haematocrit centrifugation technique, adapted to field conditions (Woo, 1970), was utilised as 
the standard parasitological test for this efficacy study. A small amount of whole blood (70 
μl), obtained directly after blood sampling of the goats, was taken up in a heparinised 
capillary and sealed with plasticine at one end. The capillary was then centrifuged for five 
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minutes at 9000 g and subsequently examined under light microscopy (x 10), for the presence 
of motile trypanosomes within the buffy coat layer. 
 
CATT / T. evansi test 
 
In addition, the CATT / T. evansi test was performed to act as a serological technique 
and determine the presence or absence of antibodies mounted specifically against T. evansi 
infections (Bajyana Songa and Hamers, 1988). Blood samples taken from the goats were 
centrifuged for ten minutes at 3000 g. All reagents, solutions and buffers required for the 
CATT test are already included within the commercially available kit (ITM, Antwerp, 
Belgium). Briefly, plasma dilutions were carried out, whereby 25 μl of goat plasma were 
mixed with 25 μl of buffer solution to give a ½ dilution. This step was then repeated to 
provide a ¼ plasma dilution, after which a 25 μl droplet was placed onto the corresponding 
circle on the card. Next, a drop (45 μl) of test reagent (antigen) was placed into the same 
circle and mixed carefully with a plastic spatula. The whole card was then placed onto a 
rotator and allowed to rotate for five minutes at seventy rotations per minute (rpm). 
Thereafter, the presence of agglutination within the circle determines a positive reaction. 
Furthermore, the positive reaction can be classified as strong (+++), intermediate (++), weak 
(+) or negative (-). 
 
Polymerase chain reaction 
 
As a validating molecular based technique, a PCR method (18S PCR for 
Trypanozoon) designed for the detection of parasite DNA was also applied. A 500 μl volume 
of whole goat blood was placed into a collection tube along with 500 μl of DNA stabilising 
buffer and mixed thoroughly. Thereafter, the PCR samples were stored at room temperature 
and in the dark, until they could be safely transported to the Institute of Tropical Medicine in 
Antwerp, Belgium, where the actual PCR procedures were completed. The PCR method was 
considered the overall gold-standard technique in this study. 
 
DNA extraction for PCR 
 
The DNA was extracted using the commercially available QIAamp® DNA blood mini 
kit from Qiagen® (Catalogue number: 51106, Qiagen®, Chatsworth, CA, USA). Briefly, 80 μl 
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of proteinase K (20 mg/μl) were added to the collection tube containing the goat blood 
sample. The sample was then incubated for 60 - 90 minutes at 58 °C and vortexed every 20 
minutes. A 40 μl volume of lysing buffer was added, vortexed for 15 seconds to ensure 
complete mixing and quickly spun down. Thereafter the whole mixture was incubated for ten 
minutes at 70 °C. After incubation, 210 μl of pure ethanol were added, mixed again by 
vortexing and quickly spun down. The solution was placed onto a QIAamp® spin column and 
centrifuged for two minutes at 15’700 g, after which the filtrate was removed, since the DNA 
binds to the Si-membrane on the spin column. This spin column was then transferred into a 
new collection tube and 500 μl of washing buffer 1 were added, followed by centrifugation 
for two minutes at 5900 g. Again the filtrate was removed and the spin column transferred to 
a new collection tube. This time, 500 μl of washing buffer 2 were added and the mixture 
centrifuged for three minutes at 15’700 g. Once the filtrate had been removed, the spin 
column was placed inside a previously labelled collection tube and 50 μl of elution buffer 
were added. This tube was then incubated for one minute at room temperature, followed by a 
two minute centrifugation step at 5900 g, before finally storing the tube at -20 °C, until further 
testing with PCR amplification could be carried out. 
 
PCR amplification 
 
For the polymerase chain reaction (PCR), a 25 µl reaction solution contained 1 x PCR 
buffer (Qiagen, Hilden, Germany), 2.5 mM final concentration of magnesium chloride 
(Qiagen, Hilden, Germany), 200 μM of each dATP, dTTP, dGTP and dCTP (Roche, 
Mannheim, Germany), 0.1 mg/ml acetylated bovine serum albumin (Promega, Madison, 
Wis.), 0.8 µM of each primer, 1 unit of HotStar Taq polymerase (Qiagen, Hilden, Germany) 
and 2.5 µl of sample DNA. Double distilled water acted as the negative control and 
Trypanosoma brucei as the positive control in all PCR reactions performed. PCR 
amplification was carried out in 200 µl thin-wall PCR tubes (Abgene, Epsom, United 
Kingdom) using a T3000 Biometra thermocycler (Westburg, Leusden, The Netherlands) with 
the following thermal cycling profiles: a 15 minute initial incubation at 94 °C followed by 40 
cycles of a 30 second dissociation phase at 94 °C, 30 seconds at 60 °C for the annealing 
process and 30 seconds at 72 °C for elongation, with a subsequent cooling down phase at 72 
°C for five minutes. The PCR product obtained was 100 bp (base pairs) long. 
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Gel electrophoresis 
 
Following PCR amplification of the sample DNA, 10 μl of the PCR product was 
mixed with loading buffer and placed into the available slots within a 2 % agarose gel 
(Eurogentec, Seraing, Belgium). A DNA ladder (37.5 ng/nl) was also placed into each gel at 5 
μl volumes. The samples were then allowed to migrate at 100 Volts for thirty minutes before 
being placed in ethidium bromide (1 μg/ml stock solution) for 15 to 20 minutes. The primary 
PCR results were subsequently identified after visualisation under UV light. 
 
Goat infection 
 
Fresh camel blood (400 μl) was collected from the jugular vein of the camel and 
inoculated (i.p.) into several NMRI mice. Once a high parasitaemia had established itself 
within a mouse, blood was collected via cardiac puncture and mixed with phosphate buffered 
saline with glucose (PSG) to provide the trypanosome suspension used for experimental goat 
infection. The isolated strain was also cryopreserved by mixing the camel blood 1:1 with a 
freezing solution, containing 20 % glycerine in PBS, followed by storage at -80 °C. 
Prior to experimental infection with T. evansi, a 4 ml blood sample from the jugular 
vein was taken from each goat and diagnostic methods were performed to ensure there was no 
previous evidence of T. evansi infection. Any goats demonstrating such evidence were 
removed from the project. Thereafter all goats were experimentally infected intravenously 
(i.v.), with 106 parasites in 1ml of a T. evansi strain, previously isolated from a dromedary 
camel in the south of Gran Canaria island. 
 
Goat treatment 
 
One month post-infection, a 4 ml blood sample was again taken from each goat via the 
jugular vein and diagnostic tests were carried out to establish that all goats were indeed 
infected with T. evansi. Following this, the goats were weighed and treatment was applied to 
the various groups of goats, according to the test compounds and treatment schedules depicted 
in Table 6.1. All test compounds were administered to the goats through an i.m. route and the 
goats were given four applications of their respective compound doses, 48 hours apart, on the 
following days: 32, 34, 36 and 38, post-infection. Thereafter, follow up diagnostic methods 
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were carried out for five months post treatment, to determine the curative efficacy of the 
compounds tested. 
 
Table 6.1. The test compounds and treatment schedules used for the different groups of goats along with the 
number of goats in each group for the T. evansi efficacy trial. 
 
Group Number of goats Test compound Treatment schedule 
(mg/kg x 4) 
1 4               None None 
2 3               Diminazene 5 
3 3               DB 75 2.5 
4 3               DB 867 2.5 
5 3               DB 1192 2.5 
6 3               DB 75 1.25 
7 3               DB 867 1.25 
8 3               DB 1192 1.25 
 
 
 
 
Results 
 
Table 6.2 demonstrates the results obtained, when goats were experimentally infected 
with Trypanosoma evansi and the parasitaemia was assessed using three different diagnostic 
methods. The results seen before initial infection was carried out, show that one goat (number 
7328) was weakly positive (+) for the CATT / T. evansi test. Any goats revealing evidence of 
previous or current infections with T. evansi were not used in this experimental efficacy study 
and therefore this goat (number 7328) was removed from the project and no further tests were 
performed with it. However, all remaining goats tested negative for all three diagnostic 
methods used and were thus divided up into their allocated groups before initial infection was 
carried out. 
Four days after infection, all goats were positive for the haematocrit centrifugation 
test, with motile trypanosomes seen in all blood samples taken from the goats. All the goats 
were similarly positive for PCR as would be expected, since a parasitaemia was present in all 
goats, thus parasite DNA was also present in all samples. Nevertheless, the CATT / T. evansi 
results were negative for all goats tested, since the sampling took place four days after the 
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goats had been experimentally infected, hence indicating that no antibodies could have 
developed in this short time to produce a positive antibody reaction. 
 
Table 6.2. Status of each goat, before experimental infection with T. evansi, four days post infection and one 
month after infection and before compound treatment, involving the haematocrit centrifugation technique 
(HCT), the card agglutination test for trypanosomes (CATT) and the polymerase chain reaction method (PCR). 
The results are depicted as negative (-) or positive (+) for the HCT and PCR methods and strongly positive 
(+++), intermediate (++), weak (+) or negative (-) for the CATT test, along with goats, which died (D) or were 
removed from the project (Rem). 
 
Before infection     Post infection     Before treatment 
Group Compound treatment 
Goat  
No.     HCT     CATT    PCR         HCT   CATT   PCR           HCT      CATT      PCR 
  7328 - + - Rem Rem Rem Rem Rem Rem 
  7399 - - - + - + D D D 
1 Control 2255 - - - + - + + +++ + 
  7397 - - - + - + + +++ + 
  7374 - - - + - + + +++ + 
  7314 - - - + - + + +++ + 
2 Diminazene 1773 - - - + - + + +++ + 
 5 mg/kg 7396 - - - + - + + +++ + 
  7388 - - - + - + + +++ + 
3 DB 75 7390 - - - + - + + +++ + 
 2.5 mg/kg 7324 - - - + - + + +++ + 
  5406 - - - + - + + +++ + 
4 DB 867 7319 - - - + - + + +++ + 
 2.5 mg/kg 5674 - - - + - + + +++ + 
  7386 - - - + - + + +++ + 
5 DB 1192 7379 - - - + - + + +++ + 
 2.5 mg/kg 7387 - - - + - + + +++ + 
  7361 - - - + - + + +++ + 
6 DB 75 5622 - - - + - + + +++ + 
 1.25 mg/kg 7366 - - - + - + + +++ + 
  7369 - - - + - + + +++ + 
7 DB 867 7372 - - - + - + + +++ + 
 1.25 mg/kg 7341 - - - + - + + +++ + 
  7339 - - - + - + + +++ + 
8 DB 1192 7384 - - - + - + + +++ + 
 1.25 mg/kg 7383 - - - + - + + +++ + 
  7360 - - - + - + + +++ + 
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The sampling procedure performed before compound treatment was applied, was 
carried out on day 31 post-infection. Unfortunately, one goat (number 7399) showed severe 
clinical signs of T. evansi infection and died (day 26, post-infection) before treatment could 
be applied. No further tests could be performed with this goat and it was removed from the 
project. The remaining twenty-five goats on the other hand, produced strongly positive (+++) 
antibody reactions to the CATT / T. evansi test, at one month post-infection. Positive results 
were still seen with the haematocrit centrifugation technique and the PCR test demonstrating 
that a constant parasitaemia was still present. 
After compound treatment, the goats were observed for a further five month follow up, 
using the same three diagnostic methods, to determine the curative efficacy of the three lead 
diamidine compounds, DB 75, DB 867 and DB 1192. The follow up results obtained, when 
using the haematocrit centrifugation technique (HCT), are shown in Table 6.3. A positive (+) 
result indicated that motile trypanosomes were seen within the buffy coat layer, after the 
blood samples had been centrifuged in the capillaries. A negative (-) result means that no 
motile trypanosomes were seen. The follow up part of the efficacy study lasted for 150 days 
(five months) and started 24 hours after the final compound application had been administered 
to those goats receiving treatment. Group 1 acted as the control group which received no 
compound treatment at all. All four goats within this group (numbers 2255, 7397, 7374 and 
7314) demonstrated motile trypanosomes in each of their blood samples. Two goats (numbers 
2255 and 7374) remained positive with a constant parasitaemia throughout the length of the 
follow up study (150 days). However, another two control goats (numbers 7314 and 7397) 
died during the study period on days 120 and 161 post-infection, respectively, due to severe 
clinical manifestation of T. evansi infection. Nevertheless, a constant parasitaemia was still 
observed in these two control goats. 
All three goats allocated to Group 2 (numbers 1773, 7396 and 7388) were given four 5 
mg/kg treatment applications of the positive control compound, diminazene. Thereafter, all 
three goats remained negative with the haematocrit centrifugation technique for the total 
length of the follow up study (150 days). A similar result was demonstrated by the 
compounds DB 75 and DB 867, both at the 2.5 mg/kg compound dose, where all goats in 
these two groups (Groups 3 and 4, respectively) produced negative findings for trypanosomes 
with the HCT. In Group 5, treatment with DB1192 at 2.5 mg/kg appeared insufficiently 
effective and motile trypanosomes were observed 2 weeks (14 days) after the final compound 
administration in two of the goats (numbers 7379 and 7387). These two goats were therefore 
removed from the project and no further tests were performed with them. The third goat
Chapter 6: Efficacy of diamidines in T. evansi infected goats 
 
 113
 
Table 6.3. A five month follow up of an efficacy study for a T. evansi experimentally infected goat model, using the haematocrit centrifugation technique (HCT), after treatment with  
Diminazene, DB 75, DB 867 or DB 1192 at various compound doses. The results are depicted as negative (-) or positive (+) for motile trypanosomes observed in goat blood samples,  
along with goats, which died (D) or were removed from the project (Rem) during the study period. 
 
Follow up goat efficacy using haematocrit centrifugation technique (HCT) post treatment (in days) 
Group Compound 
treatment 
Goat 
No. 1 7 14 21 28 35 42 49 56 70 84 98 112 126 140 150 
1 Control 2255 + + + + + + + + + + + + + + + + 
  7397 + + + + + + + + + + + + + D D D 
  7374 + + + + + + + + + + + + + + + + 
  7314 + + + + + + + + + + D D D D D D 
2 Diminazene 1773 - - - - - - - - - - - - - - - - 
 5 mg/kg 7396 - - - - - - - - - - - - - - - - 
  7388 - - - - - - - - - - - - - - - - 
3 DB 75 7390 - - - - - - - - - - - - - - - - 
 2.5 mg/kg 7324 - - - - - - - - - - - - - - - - 
  5406 - - - - - - - - - - - - - - - - 
4 DB 867 7319 - - - - - - - - - - - - - - - - 
 2.5 mg/kg 5674 - - - - - - - - - - - - - - - - 
  7386 - - - - - - - - - - - - - - - - 
5 DB 1192 7379 - - + Rem Rem Rem Rem Rem Rem Rem Rem Rem Rem Rem Rem Rem 
 2.5 mg/kg 7387 - - + Rem Rem Rem Rem Rem Rem Rem Rem Rem Rem Rem Rem Rem 
  7361 - - - - - D D D D D D D D D D D 
6 DB 75 5622 - - - - - - - - - - - - - - - - 
 1.25 mg/kg 7366 - - - - - - - - - - - - - - - - 
  7369 - D D D D D D D D D D D D D D D 
7 DB 867 7372 - - - - - - - - - - - - - - - + 
 1.25 mg/kg 7341 - - - - - - - - - - - - - - - + 
  7339 - - - - - - - - - - - - - - - + 
8 DB 1192 7384 - - + Rem Rem Rem Rem Rem Rem Rem Rem Rem Rem Rem Rem Rem 
 1.25 mg/kg 7383 - + + Rem Rem Rem Rem Rem Rem Rem Rem Rem Rem Rem Rem Rem 
  7360 - - + Rem Rem Rem Rem Rem Rem Rem Rem Rem Rem Rem Rem Rem 
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(number 7361) was left within the project however, since motile trypanosomes were not 
detected within the blood samples of this goat. Nonetheless, this third goat (number 7361) 
died on day 34 post treatment. 
Group 6 contained goats treated with DB 75, at half the dosage (1.25 mg/kg) used for 
Group 3 (2.5 mg/kg). One of the three goats (number 7369) was suffering from severe clinical 
symptoms of T. evansi infection before treatment even began, but was still included in the 
treatment schedule. Even so, the lead compound was not able to exert a beneficial effect quick 
enough and this goat died just 2 days post treatment. The two goats left in Group 6 (numbers 
5622 and 7366) on the other hand, remained negative for the complete duration of the follow 
up study with the haematocrit centrifugation technique. 
The goats in Group 7 were treated with DB 867 at half the dose (1.25 mg/kg) of that 
applied in Group 4 (2.5 mg/kg). All three goats in this group (numbers 7372, 7341 and 7339) 
remained negative for 149 days post treatment, when tested with the HCT. On the final day of 
the follow up study (day 150), all three goats presented motile trypanosomes in their blood. 
In the final group (Group 8) treated with 1.25 mg/kg of DB 1192, motile 
trypanosomes were detected after only 7 days post treatment in one of the goats (number 
7383). One week later (day 14), motile trypanosomes were seen in all three goats within 
Group 8 (numbers 7384, 7383 and 7360) and consequently, all three goats were removed 
from the project and no further tests were performed on them. 
The five month follow up results, obtained for the card agglutination test for 
trypanosomes (CATT / T. evansi), are shown in Table 6.4. The results are based on the 
intensity of an agglutination reaction, occurring between goat plasma samples together with 
an antigenic reagent, to determine the antibody response. The positive results are illustrated as 
a strong antibody reaction (+++), an intermediate (++) or weak (+) response or a negative (-) 
result, where no antibody reaction was observed. 
For the untreated control goats (Group 1), where a constant parasitaemia was 
established, all four goats (numbers 2255, 7397, 7374 and 7314) remained strongly positive 
with the CATT / T. evansi test for the duration of the follow up study. With the diminazene (5 
mg/kg) positive control goats (Group 2), a decreased intensity of antibody reactions 
throughout the follow up study were detected for all three goats (numbers 1773, 7396 and 
7388). In addition, two goats (numbers 7388 and 1773) produced negative CATT / T. evansi 
responses, 7 days and 56 days respectively, post treatment. 
In Groups 3 and 4, a similar trend was demonstrated and the CATT / T. evansi test 
results decreased in intensity from strongly positive to weakly positive. In the case of DB 75 
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Table 6.4. A five month follow up of an efficacy study for a T. evansi experimentally infected goat model, using a card agglutination test (CATT / T. evansi), after treatment with  
Diminazene, DB 75, DB 867 or DB 1192 at various compound doses. Results are depicted as strongly positive (+++), intermediate (++), weak (+) or negative (-) for agglutination,  
when goat plasma was mixed with an antigenic reagent, along with goats, which died (D) or were removed from the project (Rem) during the study period. 
 
Follow up goat efficacy using a card agglutination test (CATT/T. evansi) post treatment (in days) 
Group Compound 
treatment 
Goat 
No. 1 7 14 21 28 35 42 49 56 70 84 98 112 126 140 150 
1 Control 2255 +++ +++ +++ +++ +++ +++ +++ +++ +++ +++ +++ +++ +++ +++ +++ +++ 
  7397 +++ +++ +++ +++ +++ +++ +++ +++ +++ +++ +++ +++ +++ D D D 
  7374 +++ +++ +++ +++ +++ +++ +++ +++ +++ +++ +++ +++ +++ +++ +++ +++ 
  7314 +++ +++ +++ +++ +++ +++ +++ +++ +++ +++ D D D D D D 
2 Diminazene 1773 +++ +++ ++ ++ ++ + + + - - - - - - - - 
 5 mg/kg 7396 +++ +++ +++ +++ +++ +++ ++ ++ ++ ++ ++ ++ ++ ++ ++ ++ 
  7388 ++ - - - - - - - - - - - - - - - 
3 DB 75 7390 +++ +++ +++ +++ +++ ++ ++ ++ + + + + + + + + 
 2.5 mg/kg 7324 +++ +++ +++ +++ +++ ++ + + - - - - - - - - 
  5406 +++ +++ +++ +++ +++ ++ ++ ++ ++ ++ + + + + + + 
4 DB 867 7319 ++ ++ - - - - - - - - - - - - - - 
 2.5 mg/kg 5674 +++ +++ ++ + + + + + + + - - - - - - 
  7386 +++ +++ +++ ++ ++ + + + + + + + + + + + 
5 DB 1192 7379 +++ +++ +++ Rem Rem Rem Rem Rem Rem Rem Rem Rem Rem Rem Rem Rem 
 2.5 mg/kg 7387 +++ +++ +++ Rem Rem Rem Rem Rem Rem Rem Rem Rem Rem Rem Rem Rem 
  7361 +++ ++ ++ +++ +++ D D D D D D D D D D D 
6 DB 75 5622 +++ ++ + + + + + + - - - - - - - - 
 1.25 mg/kg 7366 +++ +++ +++ +++ +++ ++ ++ ++ ++ ++ ++ ++ ++ ++ ++ ++ 
  7369 +++ D D D D D D D D D D D D D D D 
7 DB 867 7372 +++ +++ +++ +++ +++ +++ +++ +++ +++ +++ ++ ++ ++ ++ ++ +++ 
 1.25 mg/kg 7341 +++ ++ ++ ++ ++ ++ ++ ++ + + + + + + ++ +++ 
  7339 +++ ++ + + + + + + + + + + + + ++ +++ 
8 DB 1192 7384 +++ +++ +++ Rem Rem Rem Rem Rem Rem Rem Rem Rem Rem Rem Rem Rem 
 1.25 mg/kg 7383 +++ +++ +++ Rem Rem Rem Rem Rem Rem Rem Rem Rem Rem Rem Rem Rem 
  7360 +++ +++ +++ Rem Rem Rem Rem Rem Rem Rem Rem Rem Rem Rem Rem Rem 
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at 2.5 mg/kg, one goat (number 7324) became negative on day 56 post treatment, as did two 
goats from DB 867 at 2.5 mg/kg (numbers 7319 and 5674), becoming negative on days 14 
and 84, respectively, post treatment. Group 5 goats (numbers 7379, 7387 and 7361), treated 
with DB 1192 at 2.5 mg/kg, expressed strong to intermediate positive antibody reactions and 
were removed from the project based on microscopic detection of the parasite. Equally so for 
the lower dose of DB 1192 of 1.25 mg/kg (Group 8), where all three goats (numbers 7384, 
7383 and 7360) displayed strong positive reactions and were subsequently removed from the 
project after two weeks follow up. 
For the goat suffering from severe clinical infection in Group 6 (DB 75 at 1.25 
mg/kg), a strong positive reaction was noted, before this goat died (number 7369) on day 2 
post treatment. The remaining two goats in Group 6 showed a negative reaction from day 56 
post treatment onwards (number 5622) and an intermediate response from day 35 onwards 
(number 7366), respectively. Interestingly, the three goats in Group 7 (numbers 7372, 7341 
and 7339), treated with DB 867 at a 1.25 mg/kg dose, revealed primarily a decrease from 
strongly positive to intermediate (and even to weak in goat numbers, 7341 and 7339), until 
approximately day 126 post treatment, after which an increase in antibody reaction (back to 
strongly positive) was subsequently detected. 
Table 6.5 shows the data obtained, when the PCR method was used for the five month 
efficacy follow up study. A positive reaction (+) for the PCR method confirmed the presence 
of parasite DNA within the goats’ blood, whereas a negative result (-) indicated that no 
parasite DNA was found in the goats’ blood at that point. As would be expected, all four 
untreated control goats (numbers 2255, 7397, 7374 and 7314) within Group 1, demonstrated a 
constant parasitaemia and hence positive PCR results for the duration of the follow up study. 
In comparison, Groups 2, 3 and 4, representing the positive control group, treated with 
diminazene (goat numbers 1773, 7396 and 7388), the 2.5 mg/kg dose group of DB 75 (goat 
numbers 7390, 7324 and 5406) and the 2.5 mg/kg dose group of DB 867 (goat numbers 7319, 
5674 and 7386), respectively, all produced negative PCR results. 
For the three goats in Group 5 (numbers 7379, 7387 and 7361), treated with 2.5 mg/kg 
of DB 1192, a positive PCR result was detected on days 7, 14 and 28 post treatment, 
respectively. Two of the goats within Group 5 (numbers 7379 and 7387) were removed on 
day 14 post treatment (based on microscopic detection of the parasite in the blood) and no 
further tests were performed on them. The third goat (number 7361), having died on day 34 
post treatment, had previously shown a positive result with the PCR method on day 28 post 
treatment, even though no parasites were seen in the blood at this time with the HCT method.
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Table 6.5. A five month follow up of an efficacy study for a T. evansi experimentally infected goat model, using the polymerase chain reaction (PCR), after treatment with  
Diminazene, DB 75, DB 867 or DB 1192 at various compound doses. The results are depicted as negative (-) or positive (+) for the presence of parasite DNA in goat blood  
samples, along with goats, which died (D) or were removed from the project (Rem) during the study period. 
 
Follow up goat efficacy using polymerase chain reaction (PCR) post treatment (in days) 
Group Compound 
treatment 
Goat 
No. 1 7 14 21 28 35 42 49 56 70 84 98 112 126 140 150 
1 Control 2255 + + + + + + + + + + + + + + + + 
  7397 + + + + + + + + + + + + + D D D 
  7374 + + + + + + + + + + + + + + + + 
  7314 + + + + + + + + + + D D D D D D 
2 Diminazene 1773 - - - - - - - - - - - - - - - - 
 5 mg/kg 7396 - - - - - - - - - - - - - - - - 
  7388 - - - - - - - - - - - - - - - - 
3 DB 75 7390 - - - - - - - - - - - - - - - - 
 2.5 mg/kg 7324 - - - - - - - - - - - - - - - - 
  5406 - - - - - - - - - - - - - - - - 
4 DB 867 7319 - - - - - - - - - - - - - - - - 
 2.5 mg/kg 5674 - - - - - - - - - - - - - - - - 
  7386 - - - - - - - - - - - - - - - - 
5 DB 1192 7379 - + + Rem Rem Rem Rem Rem Rem Rem Rem Rem Rem Rem Rem Rem 
 2.5 mg/kg 7387 - - + Rem Rem Rem Rem Rem Rem Rem Rem Rem Rem Rem Rem Rem 
  7361 - - - - + D D D D D D D D D D D 
6 DB 75 5622 - - - - - - - - - - - - - - - - 
 1.25 mg/kg 7366 - - - - - - - - - - - - - - - - 
  7369 + D D D D D D D D D D D D D D D 
7 DB 867 7372 - - - - - - - - - - - - - + + + 
 1.25 mg/kg 7341 - - - - - - - - - - - - - + + + 
  7339 - - - - - - - - - - - - - - + + 
8 DB 1192 7384 + + + Rem Rem Rem Rem Rem Rem Rem Rem Rem Rem Rem Rem Rem 
 1.25 mg/kg 7383 + + + Rem Rem Rem Rem Rem Rem Rem Rem Rem Rem Rem Rem Rem 
  7360 + + + Rem Rem Rem Rem Rem Rem Rem Rem Rem Rem Rem Rem Rem 
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Likewise, the severely affected goat (number 7369) in the lower dose group of DB 75 (Group 
6), presented a positive result for parasite DNA present in the blood, one day after treatment, 
before it eventually died and was removed from the project. The remaining two goats 
(numbers 5622 and 7366) however, were PCR negative for the rest of the follow up study 
(150 days post treatment). 
Unfortunately, the three goats (numbers 7372, 7341 and 7339) in Group 7 (DB 867 
treatment at 1.25 mg/kg), having shown negative PCR results until day 125 post treatment, 
relapsed and parasitic DNA was detected in all three goats on days 126 (for goat numbers, 
7372 and 7341) and 140 (for goat number, 7339) post treatment. They were not removed 
initially from the project, since motile trypanosomes were only observed on day 150, post 
treatment. All goats within Group 8 (goat numbers, 7383, 7384 and 7360), treated with 1.25 
mg/kg of the compound, DB 1192, never became PCR negative after compound treatment, 
thus demonstrating complete inefficacy at this dose. 
 
 
 
Discussion 
 
The aim of this study was to primarily establish a higher animal model using goats, 
which could be infected with Trypanosoma evansi. Thereafter, three selected lead diamidine 
compounds (DB 75, DB 867 and DB 1192) were to be investigated for their curative efficacy 
at several doses, in comparison with the standard compound, diminazene aceturate. 
Previous attempts to infect goats with T. evansi has lead to various problems, as seen 
in a goat study conducted in the Philippines using a local parasite strain (Dargantes et al., 
2005), where several goats developed an acute infection, the virulence of which ended in fatal 
consequences for the animals. Goat studies performed in the Canary Islands (Gutierrez et al., 
2004a; Gutierrez et al., 2004b; Morales et al., 2006) reported the onset of sub-clinical 
symptoms, when infection advances to the chronic form. However, severe clinical infection 
and specific pathological features have also been described in a study on small east African 
goats (Ngeranwa et al., 1993). Coupled with the limited availability of good diagnostic tests 
and a low or even intermittent parasitaemia, accurate detection of this parasite is complicated 
further. It was anticipated that, by using a less virulent parasite strain (endemic in the Canary 
Islands) at a higher parasite concentration (106/ml), a steady and constant parasitaemia could 
be achieved to ease the dilemma of accurate parasite detection. 
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Furthermore, a range of diagnostic methods were applied to measure the presence of 
T. evansi in the goats, using several approaches. A parasitological test (HCT) was applied to 
provide direct demonstration of the parasite itself, an approach that relies mainly on the 
existence of a regular parasitaemia. The standard serological test (CATT / T. evansi) was used 
to measure the level of antibodies during the course of the goat study. It is debatable as to 
whether an organism is considered completely cured, when antibody tests remain positive. 
Since most serological techniques are unable to differentiate between recent and past 
infections, the decision to use the CATT / T. evansi test in this study was essentially as a 
guide to disease progression, especially for understanding the five month follow up part of 
this investigation. The final diagnostic method used was a molecular based technique (PCR), 
which aims to detect the presence of parasitic DNA, even when a parasitaemia is too low to 
be detected by microscopy or when serological results are indecisive. Due to the specificity 
and sensitivity of such molecular based techniques, they tend to become the gold standard 
methods, which was also the case in this study. However, this PCR technique performed in 
this efficacy trial was used for the first time for diagnostic purposes. Nevertheless, the 
relationship seen between the PCR and the HCT method in this pilot study is considered to be 
accurate and well correlated. 
The resulting positive CATT / T. evansi result given by one goat (number 7328) at the 
start of the study, implied that this goat may have been previously exposed to T. evansi 
infection and was consequently removed from the project. After experimental infection, two 
goats (numbers 7399 and 7369) demonstrated severe clinical symptoms of infection and died 
subsequently. From the control group of goats, which received no compound treatment, a 
chronic, sub-clinical progression of T. evansi infection was observed. However, two control 
goats (numbers 7314 and 7397) died during the follow up study, demonstrating the fact that 
treatment is critical for the survival of infected animals. 
Complete curative efficacy was seen for the whole five month follow up trial in the 
positive control group, treated with a 5 mg/kg dose of diminazene. Additional complete 
curative efficacy was demonstrated in the goats treated with both 2.5 mg/kg and 1.25 mg/kg 
doses of the compound, DB 75. It may even be possible that this compound could effectively 
cure T. evansi infected goats at a lower dose than 1.25 mg/kg. However, another goat efficacy 
trial would need to be performed to confirm whether 1.25 mg/kg really is the lowest curative 
dose or not. With the compound DB 867, curative efficacy was seen in the higher treatment 
dose (2.5 mg/kg) for the entire five month follow up study and appeared similarly so for the 
lower (1.25 mg/kg) compound dose for the first four months. However, on day 140, all goats 
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treated with DB 867 at 1.25 mg/kg demonstrated positive PCR results, yet parasites were only 
visually detected in the blood after 150 days, post treatment. An interesting result was 
observed in the serological findings of these goats, which did not produce negative CATT / T. 
evansi results contrary to some of the goats treated with the higher dose (2.5 mg/kg). Instead 
an increased response in antibody level was noted from days 140 (post treatment) onwards. 
Since the goats were housed in fly-proof facilities, the potential risk of re-infection 
(experimental or natural) in this case is small, together with the knowledge that the control 
goats (which underwent no compound treatment) were also housed in a separate fly-proof pen 
within the research building. The exact reasons for understanding why this compound caused 
a relapse at this stage of the efficacy study may be made clearer after a pharmacokinetic 
investigation into DB 867 has been performed. 
The third lead diamidine compound tested in this efficacy trial (DB 1192) was not 
effective at either dose tested. Goats treated with 2.5 mg/kg of DB 1192 presented 
trypanosomes within the blood, 14 days after treatment was given. The antibody levels of 
these goats remained high (++ to +++) and DNA was detected earlier, between one and two 
weeks, post treatment. One goat (number 7361) remained PCR negative for just less than one 
month, yet this compound was still insufficient to provide comparable curative efficacy to that 
seen with the standard compound, diminazene. A treatment failure was also shown in the 
lower dose group (1.25 mg/kg) of DB 1192, where none of the goats ever became PCR 
negative and the serological results remained strongly positive (+++). 
In conclusion, this pilot efficacy trial into T. evansi infected goats has enabled three 
selected lead diamidine compounds to be evaluated, of which two (DB 75 and DB 867) 
demonstrated better efficacy than the standard compound (diminazene aceturate). The 
compound DB 75 was more effective at a quarter of the dose used (1.25 mg/kg), than 
diminazene and DB 867 was more effective at half the dose used (2.5 mg/kg). Therefore, two 
lead diamidine compounds (DB 75 and DB 867) have successfully been identified through 
this pilot “proof of concept” trial, as potential clinical candidates against T. evansi infection. 
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Abstract 
 
Pharmacokinetic analysis is important to create successful drug therapy and optimal 
treatment regimens, to enable the drug concentration within the body to remain within the 
therapeutic window, but at the same time prevent adverse or toxic effects. Three lead 
diamidine compounds were selected based on their previous activity in vitro and in vivo, as 
well as on preliminary toxicity results obtained from healthy goats. The curative efficacy of 
these lead diamidine compounds (DB 75, DB 867 and DB 1192) was further tested in an 
experimentally infected Trypanosoma evansi goat model and subsequently a pharmacokinetic 
study was carried out. Blood samples were collected at the following time points of 0.5, 1, 2, 
4, 8, 24, 48, 96 and 192 hours, after the intramuscular administration of the last compound 
injection. The plasma samples produced were analysed using an HPLC/MS-MS technique and 
pharmacokinetic profiles and parameters were determined. 
The pharmacokinetic results obtained in this study depict clearly the reasoning behind 
the compound treatment failures seen for DB 1192, when used in an experimentally infected 
T. evansi goat model. The low compound concentrations in goat plasma of DB 1192 fall far 
below the minimal compound concentrations required to reach therapeutic levels, whereas 
plasma concentrations for diminazene (standard compound), DB 75 and DB 867 remain well 
within therapeutic concentrations. Hence, curative efficacy is provided by diminazene at 5 
mg/kg, by DB 75 at 2.5 mg/kg and 1.25 mg/kg and by DB 867 at 2.5 mg/kg. Although the 
concentrations of DB 867 at 1.25 mg/kg were within the therapeutic window, other 
physiological factors may be responsible for the relapse seen at 4.5 months post treatment 
with this compound. 
 
Keywords: Trypanosoma evansi, pharmacokinetics, diamidines, goat model, chemotherapy. 
 
 
 
Introduction 
 
Pharmacokinetics is the quantitation of the time course of a drug and its metabolites in 
the body and the development of appropriate models to describe the observations. It can be 
applied in order to measure and understand the kinetics of drugs in the body, thus providing 
valuable data whilst following the processes involved after drug administration. Figure 7.1 
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shows a simple pharmacokinetic model, which diagrammatically depicts the different 
processes a drug goes through after it has been administered. Such pharmacokinetic 
information is required to carry out successful drug therapy and avoid the occurrence of 
adverse or toxic effects. 
 
Figure 7.1. Pharmacokinetic model to display the processes encountered after a drug is administered and how it 
moves to various compartments (boxes) via the processes of absorption, distribution, metabolism and excretion 
(shown by the arrows). 
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Drugs can be administered at different sites, which can be grouped as intravascular 
(directly into the blood, via an intra-venous or intra-arterial route) or extravascular, where the 
drug needs to be absorbed before it can enter the blood (via oral, sublingual, buccal, 
intramuscular, subcutaneous, dermal, pulmonary or rectal routes). Absorption of a drug is the 
process by which the unchanged drug proceeds from the administration site towards the 
measurement site within the body. However, drug can be lost at the site of administration 
before it reaches the measurement site, which would contribute to a decrease in the perceived 
absorption of that drug. This does not apply to intravascular routes of application, since the 
drug does not need to be absorbed. Nevertheless, monitoring the amount of drug in blood or 
plasma enables the assessment of entry of a drug into the body. Once a drug is in the blood, it 
is distributed (reversibly) to various tissues and organs around the body. The rate and extent 
of distribution is dependent on how well each tissue is supplied with blood, the size of the 
tissue, the binding of the drug to plasma proteins and DNA and the permeability of tissue 
membranes. If a drug leaves the measurement site and does not return, then it has undergone 
elimination and not distribution. Elimination (usually carried out by organs such as the liver 
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and kidneys) is the irreversible loss of drug from the measurement site and can occur via two 
processes: excretion and metabolism. Excretion can be defined as the irreversible loss of the 
chemically unaltered drug (usually performed by the kidneys) and metabolism is the 
conversion of one chemical species into another to create metabolites (usually performed by 
the liver). Together distribution and elimination are the components of disposition (Rowland 
and Tozer, 1989). 
Three lead diamidine compounds were selected for outstanding in vitro and in vivo 
efficacy against the animal pathogenic protozoan parasite, Trypanosoma evansi. The curative 
efficacy of these three compounds, DB 75, DB 867 and DB 1192, were assessed in an 
experimentally infected T. evansi goat model. A pharmacokinetic study was additionally 
carried out with the aim of providing preliminary pharmacokinetic profiles for the three 
compounds and to determine several pharmacokinetic parameters to establish a clearer 
understanding of the processes occurring after these compounds were administered to infected 
goats. An intramuscular route of application was chosen based on the practicalities and safety 
aspects of diamidine compounds given through this type of application. It was previously seen 
that intramuscular injections of DB 75, DB 867 and DB 1192 caused no acute signs of 
toxicity in healthy goats at a maximum compound dose of 4 mg/kg. The kinetics which occurs 
after compounds are given intramuscularly, rather than through an intravenous route directly 
into the blood, differ in several ways and must be taken into account, when analysing the 
results. 
 
 
 
 
Materials and methods 
 
Trypanosoma evansi strain 
 
A Trypanosoma evansi strain, designated as the Canaries (Rubio) strain, was 
originally isolated by K Gillingwater in 2006, from a twenty-two year old dromedary camel, 
in a farm on Gran Canaria, belonging to the Canary Islands, Spain. The camel blood was 
immediately inoculated into mice and after a single mouse passage, was then used for 
experimental infection of the goats. 
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Goats 
 
This study was approved by the ethical committee of the Hospital Clinicó Veterinario, 
Gran Canaria. Twenty-seven female Canarian goats, weighing between 20 - 52 kg and older 
than 6 months, were purchased from a local dairy farmer. After transportation to the 
veterinary research facility, the goats were placed inside open pens and allowed to acclimatise 
for a week to their new surroundings. Thereafter, the goats were given numbered ear tags, 
weighed and checked for current or previous T. evansi infection. Any goats showing positive 
results for previous T. evansi infection were removed from the project. The remaining goats 
were then divided into test groups, given oxytetracycline against nasal exudate and ivermectin 
as a standard anti-helminthic, before being placed into fly-proof pens. Throughout the study 
period, the goats were given food (pelleted nutrients, dried corn and hay), three times a day 
and water was provided ad libitum. 
 
Standard trypanocidal compound 
 
Diminazene aceturate (D-7770, Sigma, St. Louis, MO, USA) was used as the standard 
control compound in this pharmacokinetic goat study. Berenil®, the officially registered 
veterinary drug, contains only 52.5 % of the active component, diminazene aceturate. 
 
Lead diamidines 
 
The diamidine compounds were originally designed and synthesised by the chemist, 
David Boykin. The compounds DB 75, DB 867 and DB 1192 were used as the test 
compounds in this pharmacokinetic goat study, based on their previous in vitro and in vivo 
activity and preliminary toxicity within a mouse model, together with the initial toxicity 
results obtained from a goat toxicity trial. The data for these previous investigations can be 
viewed in chapters 3, 4 and 5, respectively. 
 
Stock solutions 
 
A 900 mg amount of the compounds, DB 75, DB 867 and DB 1192 were weighed out 
in powder form and dissolved in 36 ml of sterile distilled water with 10 % DMSO, to provide 
a 25 mg/ml stock solution. In addition, a 450 mg amount of the compounds, DB75, DB 867 
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and DB 1192 were weighed out in powder form and dissolved in 36 ml of sterile distilled 
water with 10 % DMSO, to provide a 12.5 mg/ml stock solution. A 1800 mg amount of the 
standard compound, diminazene aceturate was weighed out in powder form and dissolved in 
36 ml of sterile distilled water with 10 % DMSO, to provide a 50 mg/ml stock solution. These 
stock solutions were then applied in the pharmacokinetic goat study as 10 kg /ml 
chemotherapeutic solutions and were made fresh on the day of the first administration. 
Thereafter, the stock solutions were kept stored at 4 °C. 
 
Experimental infection of goats 
 
Prior to experimental infection with T. evansi, a 4 ml blood sample from the jugular 
vein was taken from each goat and diagnostic methods were performed to ensure there was no 
previous evidence of T. evansi infection. Any goats demonstrating such evidence were 
removed from the project. Thereafter all goats were experimentally infected intravenously 
(i.v.), with 106 parasites in 1 ml of a T. evansi strain, previously isolated from a dromedary 
camel in the south of Gran Canaria island. 
 
Goat treatment 
 
One month post-infection, a 4 ml blood sample was again taken from each goat via the 
jugular vein and diagnostic methods were carried out to establish that all goats were indeed 
infected with T. evansi. Following this, the goats were weighed and treatment was applied to 
the various groups of goats, according to the compounds and treatment schedules depicted in 
Table 7.1. All test compounds were administered to the goats through an i.m. route and the 
goats were given four applications of their respective compound doses, 48 hours apart, on the 
following days: 32, 34, 36 and 38, post-infection. 
 
Blood samples (4 ml volumes) were taken for pharmacokinetic analysis from the goats 
at the following time points of 0.50, 1, 2, 4, 8, 24, 48, 96 and 192 hours after the 
administration of the fourth (and final) compound injection. In addition, blood samples were 
taken from all the goats, shortly before each compound injection was applied, to determine 
the trough levels. 
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Table 7.1. The test compounds and treatment schedules used for the different groups of goats along with the 
number of goats in each group for the pharmacokinetic study. 
 
Group Number of goats Test compound Treatment schedule 
(mg/kg x 4) 
1 4               None None 
2 3               Diminazene 5 
3 3               DB 75 2.5 
4 3               DB 867 2.5 
5 3               DB 1192 2.5 
6 3               DB 75 1.25 
7 3               DB 867 1.25 
8 3               DB 1192 1.25 
 
Collection of blood samples 
 
Blood samples were collected using clean, sterile Vacutainer® (Becton Dickinson, 
Plymouth, UK) tubes of 4 ml volume, containing the anticoagulant, ethylene diamine tetra 
acetic acid (EDTA). The tubes were inverted several times, immediately after blood was taken 
from the jugular veins of the goats, to ensure equal distribution of the anticoagulant 
throughout the blood sample taken. The tubes were then kept on ice until they reached the 
laboratory for plasma preparation. 
All blood samples taken at various time points, for each goat and each test compound, 
were centrifuged at 3000 g for ten minutes. Subsequently, the plasma was removed, placed 
into sterile polypropylene cryotubes and stored away from light at -80 °C. 
 
Preparation of plasma samples 
 
Plasma aliquots (25 μl volumes) were vortexed with 200 μl of a 12.5 nM internal 
standard (DB 103) dissolved in methanolic HCl (8:1 methanol: 1N HCl). Protein was 
precipitated by centrifugation (Beckman GS-6R) at 3000 rpm for 7 minutes at room 
temperature. The supernatant (120 μl) was then transferred to 96-well plates and evaporated 
under heated nitrogen (EVX Evaporator, Apricot Designs, USA). Thereafter, the samples 
were reconstituted in the plate, with 60 μl of high pressure liquid chromatography (HPLC) 
grade water (Fisher Scientific, USA), for analysis by mass spectrometry. 
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Calibrators were prepared separately for each analyte. Stock solutions of diminazene, 
DB 75, DB 867 and DB1192 were prepared in water. Aqueous dilutions of each stock 
solution were prepared to provide the following spiking solutions: 0.5, 1, 2.5, 5, 10, 25, 50, 
100, 250 and 500 μM. To produce the intended calibration solutions of 5, 10, 25, 50, 100, 
250, 500, 1000, 2500 and 5000 nM, 0.6 μl of aqueous spiking solution was added to 60 μl of 
untreated commercial goat plasma. These calibrators were then treated in the same way as the 
plasma samples. Curves were then prepared and analysed in duplicate, at both the beginning 
and the end of the analytical run. 
 
Mass spectrometry analysis 
 
Concentrations of diminazene, DB 75, DB 867 and DB 1192 were determined by 
Liquid Chromatography/Triple Quadrupole Mass Spectrometry (HPLC/MS-MS). The 
HPLC/MS-MS system consisted of two solvent delivery pumps (Shimadzu Scientific, 
Colombia, MD, USA), a switching valve (Valco, Houston, TX, USA), a thermostated (6 °C) 
LEAP HTC auto-sampler (Carrboro, NC, USA) and an API4000 triple quadrupole mass 
spectrometer (Applied Biosystems, Foster City, CA, USA). Reversed-phase gradient 
chromatography was used to elute the compounds from an analytical column (Aquasil, C18 5 
µm, 50 × 2.1 mm) at a flow rate of 0.75 ml / minute, following an 8 µl injection. Starting 
conditions for each injection included 95 % water with 0.1 % formic acid (v/v) and 5 % 
methanol with 0.7 % formic acid (v/v). This was held constant for 1 minute while the column 
eluted to waste. After 1 minute, the eluent was directed to the mass spectrometer and the 
organic phase (methanol with 0.1 % formic acid, v/v) increased linearly, reaching 90 % 
organic, 3.25 minutes post-injection. This was held for 0.5 minutes to wash the column. The 
column was then re-equilibrated to starting conditions for the final 1 minute. The total run 
time was 4.75 minutes. 
The mass spectrometer was connected to the HPLC system by a TurboIon Spray® 
interface (MDS Sciex, San Francisco, CA, USA). Nitrogen, from a nitrogen generator (Peak 
Scientific, Bedford, MA, USA), was used as the curtain, nebulizer and collision gases. User 
controlled voltages, gas pressures and source temperature were optimised via direct infusion, 
for DB 103 (the internal standard), diminazene, DB 75, DB 867 and DB 1192. All compounds 
were analysed in positive ion mode, using the following transitions preset in multiple reaction 
monitoring scans: DB 103 (internal standard) - 385.2 to 271.2, diminazene - 282.2 to 254.1, 
DB 75 - 305.2 to 288.2, DB 867 - 306.3 to 289.2 and DB 1192 - 292.3 to 275.1. The 
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calibration curves were generated based on peak area ratios (analyte: internal standard) from 5 
to 5000 nM. Curves for all analytes followed a linear y = mx + b regression with a 1/x2 
weighting. Typical r values were 0.997 or greater and accuracy was between 80 and 120 %. 
Automated sample acquisition and data analysis was performed using Analyst software 
(version 1.4.1, Applied Biosystems, Foster City, CA, USA). 
 
Pharmacokinetic parameters 
 
The pharmacokinetic parameters were determined using Microsoft® Excel software, 
with a functional set of add-ins applied, together with a graphical programme (GraphPad 
Prism 5, GraphPad Software Inc, USA). Pharmacokinetic parameters measured and calculated 
included the peak concentration (Cmax), time at which peak concentration occurs (Tmax), the 
area under the curve (AUC), the area under the first moment curve (AUMC), the mean 
residence time (MRT), the half life (t1/2) and the rate of elimination constant (Kelim). The MRT 
was calculated with the function, AUMC/AUC and the rate of elimination constant was 
obtained with the function, 1/MRT. 
 
 
 
Results 
 
The pharmacokinetic profiles and results for the pharmacokinetic analysis can be seen 
in Figure 7.2 for the standard compound diminazene, Figure 7.3 for the compound DB 75, 
Figure 7.4 for the compound DB 867 and Figure 7.5 for the compound DB 1192. The plasma 
samples taken were analysed by HPLC/MS-MS to determine the concentrations (in ng/ml) of 
each compound tested at each specific time point. From these values, the averages from the 
experimental goats in each group were calculated and concentration versus time curves were 
plotted with a line of best fit applied, corresponding to either the high or low compound dose 
tested. 
In addition, the pharmacokinetic parameters calculated can be viewed in Table 7.2 for 
Trypanosoma evansi experimentally infected goats, given four treatment doses of 2.5 mg/kg 
and in Table 7.3 for T. evansi experimentally infected goats, given four treatment doses of 
1.25 mg/kg. In both tables, the pharmacokinetic parameters for the standard compound, 
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diminazene, given to T. evansi experimentally infected goats at four treatment doses of 5 
mg/kg, has also been included as a comparison. 
 
Figure 7.2. Pharmacokinetic profile obtained from the average compound concentrations in plasma samples, 
taken from all three goats in Group 2 for diminazene, when treated with four applications of 5 mg/kg, against 
time. 
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The peak concentration (Cmax) for goats treated with diminazene, with four 
applications of 5 mg/kg doses, reached ≥ 8637 ng/ml after just ≤ 0.5 hours (Tmax) after the 
fourth (and final) compound injection was given. The area under the curve was 193’589, 
whilst the area under the first moment curve was calculated as 13’683’170. The mean 
residence time (MRT) for diminazene was 70.7 hours, with an elimination rate constant 
(Kelim) of 0.01 hrs-1. With this pharmacokinetic profile, the half life of diminazene was 
determined to be 59.1 hours. 
The peak concentration produced for goats treated with the compound DB 75, with 
four applications of 2.5 mg/kg, was lower (≥ 2530 ng/ml) than the Cmax produced by goats 
treated with four applications of DB 75 at 1.25 mg/kg (≥ 3115 ng/ml). However, it took 
longer for the lower dose (1.25 mg/kg) goats to reach this higher peak with a Tmax of ≤ 1.0 
hour, as compared to the Tmax of the 2.5 mg/kg treated goats (≤ 0.5 hours). In addition, the 
peak concentration of goats treated with DB 75 at both doses was approximately three times 
lower than that seen with diminazene. 
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Figure 7.3. Pharmacokinetic profiles obtained from the average compound concentrations in plasma samples, 
taken from all three goats in Group 3 and both goats in Group 6 for DB 75, when treated with four applications 
of 2.5 mg/kg or four applications of 1.25 mg/kg, respectively, against time. 
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The AUC for both groups of goats treated with DB 75 were similar to one another 
(358’215 and 394’305, respectively), yet twice as large as the AUC calculated for 
diminazene. Again, the AUMC for both groups of DB 75 goats were similar to one another 
(33’469’105 and 35’295’790, respectively), but greater than the AUMC of diminazene by a 
factor of 2.5. The MRT for the 2.5 mg/kg group was 93.4 hours and the MRT for the 1.25 
mg/kg group was 89.5 hours. The rate of elimination constant was equal for the DB 75 high 
and low dose treated goats and to that of diminazene (0.01 hrs-1). The half life of the 1.25 
mg/kg treated goats was determined to be 279.3 hours, whilst the half life of the 2.5 mg/kg 
treated goats was approximately 1.7 times longer at 473.7 hours. This is approximately five 
and eight times longer than the half life of diminazene. 
The pharmacokinetic parameters measured for the goats treated with DB 867 at 2.5 
mg/kg and 1.25 mg/kg doses show similar results to the pharmacokinetic parameters 
determined for DB 75, at the same 2.5 mg/kg and 1.25 mg/kg doses. The peak concentration 
achieved was higher in the 1.25 mg/kg group (≥ 3663 ng/ml), than in the 2.5 mg/kg group for 
DB 867 (≥ 3310 ng/ml). The time at which peak concentration occurred for both treatment 
schedules of DB 867 was the same (≤ 0.5 hours). The AUC and AUMC were similar, yet 
slightly larger in the 1.25 mg/kg group. The mean residence time for both groups was also 
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comparable (90.0 and 87.9 hours) and slightly longer than that of diminazene. The elimination 
rate constant was 0.01 hrs-1 for both DB 867 treatment groups and identical to the elimination 
rate constants for DB 75 treatment groups and diminazene. The half lives of DB 867 for the 
2.5 mg/kg and 1.25 mg/kg doses were similar (221.4 hours and 202.5 hours, respectively) and 
were approximately four times greater than that of diminazene. 
 
Figure 7.4. Pharmacokinetic profiles obtained from the average compound concentrations in plasma samples, 
taken from all three goats in Group 4 and from all three goats in Group 7 for DB 867, when treated with four 
applications of 2.5 mg/kg or four applications of 1.25 mg/kg, respectively, against time. 
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The Cmax for DB 1192 was much lower for the 2.5 mg/kg (≥ 1563 ng/ml) and 1.25 
mg/kg (≥ 836 ng/ml) treated goats compared to the peak concentrations of DB 75 and DB 867 
compounds. Nevertheless, Tmax remained the same at ≤ 0.5 hours. The AUC and AUMC for 
DB 1192 at 2.5 mg/kg (9’861 and 378’645) were smaller than the AUC and AUMC for DB 
1192 at 1.25 mg/kg (4’809 and 251’434) and immensely small compared to the AUC and 
AUMC values of DB 75, DB 867 and diminazene. The MRT was longer in the lower dosed 
DB 1192 treatment schedule (52.3 hours) than in the higher dosed group (38.4 hours). The 
elimination rate constants were 0.03 hrs-1 and 0.02 hrs-1 for the 2.5 mg/kg and 1.25 mg/kg 
groups, respectively, making them also two times and three times greater than the elimination 
rate constants seen in DB 75, DB 867 and diminazene. The half lives of DB 1192 were 
determined to be around 30.5 hours and 37.0 hours for the high and low dosed groups. 
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Figure 7.5. Pharmacokinetic profiles obtained from the average compound concentrations in plasma samples, 
taken from all three goats in Group 5 and from all three goats in Group 8 for DB 1192, when treated with four 
applications of 2.5 mg/kg or four applications of 1.25 mg/kg, respectively, against time. 
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Moreover, pharmacokinetic profiles were created to show the correlation between the 
different lead compounds, compared with the standard compound diminazene, at the 
treatment doses of 2.5 mg/kg (depicted in Figure 7.6) and at 1.25 mg/kg (depicted in Figure 
7.7). Both Figures 7.6 and 7.7 clearly show the high concentration of diminazene in the 
plasma of the goats after the final compound injection was given, followed by its rapid 
decline as time increases. In comparison, the relatively low compound concentrations of DB 
1192 within the goats’ plasma can also be clearly seen on the pharmacokinetic profile. 
Although DB 75 and DB 867 did not produce such high compound concentrations in contrast 
to diminazene at 5 mg/kg, the curves of best fit for these two compounds remain above that of 
diminazene. 
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Table 7.2. Pharmacokinetic parameters determined for the standard compound (diminazene) at 5 mg/kg and 
each of the three lead diamidine compounds (DB 75, DB 867 and DB 1192) at 2.5 mg/kg, used as a treatment 
schedule for T. evansi experimentally infected goats. 
 
Diminazene DB 75 DB 867 DB 1192 
Parameter 
(4 x 5 mg/kg) (4 x 2.5 mg/kg) (4 x 2.5 mg/kg) (4 x 2.5 mg/kg) 
Cmax (ng/ml) ≥ 8637 ≥ 2530 ≥ 3310 ≥ 1563 
Tmax (hrs) ≤ 0.5 ≤ 0.5 ≤ 0.5 ≤ 0.5 
AUC 193589 358215 360895 9861 
AUMC 13683170 33469105 32471327 378645 
MRT (hrs) 70.7 93.4 90.0 38.4 
Kelim (hrs-1) 0.01 0.01 0.01 0.03 
T½ (hrs) 59.1 473.7 221.4 30.5 
 
 
 
 
 
Table 7.3. Pharmacokinetic parameters determined for the standard compound (diminazene) at 5 mg/kg and 
each of the three lead diamidine compounds (DB 75, DB 867 and DB 1192) at 1.25 mg/kg, used as a treatment 
schedule for T. evansi experimentally infected goats. 
 
Diminazene DB 75 DB 867 DB 1192 
Parameter 
(4 x 5 mg/kg) (4 x 1.25 mg/kg) (4 x 1.25 mg/kg) (4 x 1.25 mg/kg) 
Cmax (ng/ml) ≥ 8637 ≥ 3115 ≥ 3663 ≥ 836 
Tmax (hrs) ≤ 0.5 ≤ 1.0 ≤ 0.5 ≤ 0.5 
AUC 193589 394305 381604 4809 
AUMC 13683170 35295790 33558186 251434 
MRT (hrs) 70.7 89.5 87.9 52.3 
Kelim (hrs-1) 0.01 0.01 0.01 0.02 
T½ (hrs) 59.1 279.3 202.5 37.0 
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Figure 7.6. Pharmacokinetic profiles showing the correlation between diminazene at 5 mg/kg and DB 75, DB 
867 and DB 1192 at 2.5 mg/kg treatment doses, with the corresponding curves of best fit. 
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Figure 7.7. Pharmacokinetic profiles showing the correlation between diminazene at 5 mg/kg and DB 75, DB 
867 and DB 1192 at 1.25 mg/kg treatment doses, with the corresponding curves of best fit. 
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Discussion 
 
The aim of this pharmacokinetic study was to collect information for three lead 
diamidine compounds (DB 75, DB 867 and DB 1192) within an experimentally infected 
Trypanosoma evansi goat model. Thereafter, pharmacokinetic parameters were determined 
and the pharmacokinetic profiles for each compound, including the positive control (standard) 
compound, diminazene, were established by plotting the compound concentration values (in 
ng/ml) from the plasma samples against time. Based on these results, it is possible to 
understand how each compound underwent the processes of absorption, distribution and 
elimination after they were administered. 
Absorption is an important process when intramuscular injections are given, which 
delays and reduces the magnitude of the peak compared to that seen with an intravenous dose. 
Therefore, all peak plasma concentrations (Cmax) seen in this study are expected to be lower 
(and of course the time periods for Tmax, longer) than those seen if the study was repeated 
using an intravascular route of compound application. In the case of intramuscular compound 
application, the time at which peak compound concentration occurs (Tmax and Cmax, 
respectively), some of the compound will remain at the absorption site and some will have 
already been eliminated; unlike an intravenous injection, where the entire dose enters the 
body immediately. However after such a peak, the Cmax (intramuscular) will exceed the Cmax 
(intravenous), due to the continual entry of the compound into the body from the muscles (Ali 
et al., 2003b). The compound concentrations obtained from the plasma samples provided 
information about the levels present, yet the first sample taken was at 0.5 hours after the last 
compound application. This limits the accuracy with which Cmax and Tmax can be defined, 
since had more samples been taken between T0 (the time point at which the last compound 
application was given) and T30 (thirty minutes after T0), then Tmax may have been shorter 
(than 30 minutes) and Cmax may have been higher than the values seen for each compound. 
Therefore, the values obtained for Cmax and Tmax in this study are attributed to either greater 
than or equal to that value (≥), in the case of Cmax and less than or equal to that value (≤), in 
the case of Tmax. 
Once the compound has been absorbed, it needs to be distributed around the body to 
various organs and tissues. The distribution phase primarily accounts for the early rapid 
decline in plasma concentration. This decline relates to movement of the compound within the 
body and the rate a compound is distributed depends on factors such as plasma protein and 
DNA binding, tissue size and membrane permeability. It is not yet known exactly which 
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plasma proteins diamidines bind to, but basic compounds tend to bind with lipoproteins or 
alpha-1-acid glycoproteins. The absorption of compounds in solution from muscles is 
invariably perfusion rate-limited, so an increase in blood flow would speed up absorption (Ali 
et al., 2003a). 
For compounds given extravascularly, the absorption process is critical in terms of 
therapeutic activity (Elsheikh et al., 1997). Increasing the dose produces a proportional 
increase in the plasma concentration at all times, unless the absorption half life or the 
availability (completeness of absorption) is changed. Therefore, if a dose is doubled, then at 
any given time, the amount of compound absorbed is doubled and with twice as much 
compound entering the body, twice as much compound needs to be eliminated. The difference 
between the amount of compound absorbed and the amount of compound eliminated is 
therefore also double. The reverse holds true for DB 1192, which was tested in the goats at 
2.5 mg/kg and then at half this dose (1.25 mg/kg). The time for the peak should remain the 
same, but its magnitude should decrease proportionally with the dose. For DB 1192, Tmax 
remained the same (≤ 0.5 hours), yet the Cmax (≥ 836 ng/ml) was approximately half that of 
the higher dose (≥ 1563 ng/ml). In addition, the total area under the curve (AUC) should also 
be half, which is shown for the 1.25 mg/kg dose as 4’809 and for the 2.5 mg/kg dose as 
9’861. However, DB 1192 failed to treat the infected goats at both doses tested. This can be 
explained when the compound concentrations in goat plasma are compared with the in vitro 
IC50 values for DB 1192. At 192 hours after the final compound injection was applied to goats 
treated with 2.5 mg/kg, the compound concentration in plasma was only 10 ng/ml. Through 
previous in vitro testing of DB 1192 against T. evansi, an IC50 value of 10.5 ng/ml was 
obtained after 72 hours. The minimal inhibitory concentration (MIC) of such a compound is 
at least four times greater than the IC50, so for DB 1192, the estimated MIC (at 72 hours) 
would be around 42 ng/ml. To establish curative efficacy of an infected animal, the level of 
the compound in plasma must exceed the MIC for a certain time period. If the compound 
level in plasma falls below the MIC threshold too quickly, the compound provides only sub-
therapeutic concentrations, which in turn will be insufficient to remove the parasites. At 72 
hours, the compound concentration in the plasma (of the infected goats) was only 32 ng/ml. 
This value is already below the MIC threshold to ensure successful therapeutic activity of DB 
1192. In fact, at 24 and 48 hours, the compound concentrations in goat plasma were 78 and 40 
ng/ml, respectively. This shows that between 24 and 48 hours, the level was already below the 
MIC level required. In addition, 42 ng/ml is the MIC for 72 hours, which increases as time 
decreases; therefore the MIC at 48 hours alone would be much higher than 42 ng/ml and 
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probably is larger still than the mere 78 ng/ml seen at 24 hours. Thus, there is strong and clear 
evidence why DB 1192 could not ensure curative therapeutic activity at 2.5 mg/kg against 
goats experimentally infected with T. evansi. Furthermore, this relates to the lower dose of 
DB 1192 tested (1.25 mg/kg), where compound concentrations in goat plasma at 72 hours 
were only 18 ng/ml. Additional information demonstrates the compound concentration levels 
in plasma for 8, 24 and 48 hours to be 69, 23 and 18 ng/ml, respectively. Again with a 42 
ng/ml value for the MIC of DB 1192 at 72 hours, the low compound concentration value of 
69 ng/ml for 8 hours is far below the required therapeutic threshold. 
For the standard control compound (diminazene), the in vitro IC50 value obtained for 
72 hours is 12.5 ng/ml, with a corresponding MIC of 50 ng/ml. At 72 hours after compound 
treatment of 5 mg/kg doses to infected goats, the concentration of diminazene in goat plasma 
was 1112 ng/ml, which is a 22-fold greater concentration than the 50 ng/ml MIC value. Even 
after 192 hours, the diminazene concentration in goat plasma was 568 ng/ml, which still 
remains well within the therapeutic range; hence all goats treated with the standard compound 
were effectively cured. A similar pattern was seen in DB 75 at 2.5 mg/kg and 1.25 mg/kg, 
where the plasma concentrations derived at 72 hours were 1923 ng/ml and 2223 ng/ml, 
respectively. DB 75 has an IC50 of 2.3 ng/ml at 72 hours and an MIC of 9.2 ng/ml. At 192 
hours, the plasma concentrations of DB 75 for both the high and low doses were 1600 ng/ml 
and 1540 ng/ml, respectively and well within the therapeutic range. Treatment of infected 
goats with DB 75 at both doses provided an effective cure. 
Lower Cmax values were seen for the higher 2.5 mg/kg dose for the compounds, DB 75 
and DB 867. Both these compounds appear to accumulate within the body, as determined 
through their long half lives. If accumulation is high, then these compounds probably have a 
large affinity for tissue-binding. Since no differences were seen between the high (2.5 mg/kg) 
and low (1.25 mg/kg) doses tested, it may be that a point of saturation within the body has 
occurred at a specific compound dose. If a higher dose is administered, a larger amount of 
compound will be absorbed and bound to tissue, yet the amount which is unbound and free in 
the body may be the same amount, irrespective of whether the high or low dose is given. 
However, it is difficult to support such a theory with only plasma concentration data and 
would therefore require more detailed analysis and in-depth research into the accumulation 
and tissue-binding properties of diamidines in general. 
In the case of DB 867, the in vitro IC50 at 72 hours was calculated as 1.7 ng/ml and the 
MIC as 6.8 ng/ml. Both the 2.5 mg/kg and 1.25 mg/kg DB 867 treated goats demonstrated 
compound concentrations in plasma at 72 hours of 1852 ng/ml and 2014 ng/ml, respectively. 
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After 192 hours, the compound concentration levels were still within the therapeutic range, 
being 1683 ng/ml and 1637 ng/ml, respectively. Goats treated with the higher dose (2.5 
mg/kg) of DB 867 produced a curative efficacy, whereas goats treated with the lower dose of 
1.25 mg/kg were seen to relapse after 4.5 months post treatment. 
The phenomenon of relapse cases in both human and animal trypanosomiasis is not 
fully understood and many factors, such as drug resistant strains, reinfection or insufficient 
drug levels at a given site of the body, can be attributed as possible explanations for this. One 
aspect to consider would be the blood supply to various tissues, organs and compartments 
within the body. If trypanosomes have an ability to enter compartments or specific tissues (for 
example, cartilage), which have a reduced blood flow passing these areas, then insufficient 
drug levels may permeate these compartments/tissues, hence “hidden” trypanosomes will not 
receive the full therapeutic (trypanocidal) levels of the drug, enabling them to survive. 
Thereafter, once the drug concentrations within the body have been eliminated completely, 
these trypanosomes would then be free to reinvade different tissues and body compartments, 
thus building up a new population, which would produce the high parasitaemia observed in 
the goats after 4.5 months post treatment with DB 867 at 1.25 mg/kg. Whether other 
physiological factors play a vital role in this phenomenal situation would have to be further 
investigated. 
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Chapter 8: Fluorescent uptake of diamidines in T. evansi 
Abstract 
 
How a drug can be taken up into parasitic cells, without harming host cells and without 
causing adverse effects, is important when designing new drugs to combat infection. 
Diamidines can be transported into trypanosomes using the same carrier proteins as those 
necessary for trypanosomal salvaging of purines. Once inside a parasitic cell, the bound 
complexes and target areas affected by the drug can reveal its mode of action. Even though 
the exact mode of action for novel diamidine compounds is not currently understood, they are 
believed to bind to the minor groove of AT-rich DNA sites and inhibit transcription. 
Based on the efficacy of three lead diamidine compounds (DB 75, DB 867 and DB 
1192) against Trypanosoma evansi, an investigation into their natural fluorescent properties 
was carried out. The rate of uptake and the areas within the cell, where the compounds bound 
and accumulated, could be visualised using fluorescent microscopy. The uptake of the 
compound DB 1192 took longer, than the uptake of the compounds DB 75 and DB 867. 
Nevertheless, all compounds demonstrated a similar pattern of uptake, whereby blue 
fluorescence occurred first in the kinetoplast, followed by the nucleus and then the 
acidocalcisomes. Thirty minutes after incubation, the acidocalcisomes gave off a yellow 
fluorescence for the compounds DB 75 and DB 867. The slower uptake of DB 1192 may shed 
some understanding as to why this compound produced the least therapeutic activity against 
T. evansi infection in mice and goats. 
 
Keywords: Fluorescence; diamidines; Trypanosoma evansi; drug uptake. 
 
 
 
 
Introduction 
 
When discovering or designing new drugs, the mechanisms involved in getting that 
drug into a parasite is an important factor for eventually destroying the parasitic organism. In 
addition, the ideal outcome of a new drug would enable destruction of the parasite with 
minimal or no harm towards host cells. Nowadays, medicinal chemists have the ability to alter 
synthesised compounds, providing compounds with favourable properties, such as 
compounds with greater lipophilic features, enabling them to cross cell membranes easier, or 
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to provide compounds with less toxicity, hence limiting the adverse effects seen when host 
cells are harmed. 
The diamidine drug, pentamidine, has found great use in the treatment of Pneumocystis 
carinii pneumonia, leishmaniasis and early stage human African trypanosomiasis, but is 
hindered by toxic effects such as hypotension, hypoglycaemia and renal failure (Pepin and 
Milord, 1994), to name a few. The uptake of pentamidine into trypanosomes relies on three 
specific transporters (de Koning, 2001), the high affinity pentamidine transporter (HAPT), the 
low affinity pentamidine transporter (LAPT) and the P2 transporter (coded by a TbAT1 gene) 
(Mäser et al., 1999), also responsible for the uptake of adenosine and adenine. Since 
trypanosomes cannot produce purines de novo, they must salvage them from the host and 
actively transport them into the cell. Drugs, showing a similar motif (especially diamidines 
and melaminophenyl arsenicals) are also actively taken up by the P2 transporter (Carter et al., 
1995; de Koning and Jarvis, 1999; de Koning et al., 2004). Recent investigations however, 
suggest there may be additional transporters involved, such as a P1 transporter (de Koning, 
personal communication), but it is not yet known to what extent these transporters may be 
involved in drug uptake. 
Another interesting factor about drugs (whether new or old) is their mode of action. 
This involves the respective target, which the active part of a drug will attack and thus cause 
the ultimate destruction of the parasite, either directly or indirectly. Diamidines are known to 
favour AT-rich regions and can bind to the minor groove of DNA, before exerting their effect 
on the transcription process, either directly or indirectly by inhibiting DNA dependent 
enzymes, for example, nucleases or topoisomerases (Wilson et al., 2005). All the same, the 
exact mode of action of these compounds has not been fully elucidated. 
Since the three selected lead diamidine compounds, DB 75, DB 867 and DB 1192 
were chosen based on their in vitro and in vivo efficacy and low or no preliminary toxicity in 
mice and goats against Trypanosoma evansi, the causative agent of a worldwide animal 
pathogenic wasting disease called surra, an attempt was made to determine whether all three 
compounds contain similar fluorescent properties and whether they are taken up into T. evansi 
in the same way. Once taken up by the trypanosomes, a clearer insight into where these 
compounds bind or accumulate may be additionally revealed. 
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Materials and Methods 
 
Trypanosomes 
 
Trypanosoma evansi (STIB 806K) is a kinetoplastic strain and was isolated from a 
water buffalo in China in 1983. This strain was used to perform the fluorescent uptake 
studies. 
 
Lead diamidine compounds 
 
The selected diamidine compounds were originally designed and synthesised by the 
chemist, David Boykin. The compounds DB 75, DB 867 and DB 1192 were used as the test 
compounds in this fluorescent uptake study, based on their previous in vitro and in vivo 
activity within a mouse model and in vivo activity within an experimentally infected T. evansi 
goat model. 
 
Stock solutions 
 
Stock solutions of 10 mg/ml of each compound were prepared, dissolved in DMSO 
and then stored frozen at -20 °C. From these stock solutions, further compound dilutions were 
made for use in the fluorescent uptake study, together with culture medium as a solvent. 
Compound dilutions were made fresh on the day of each experimental procedure. 
 
Culture medium 
 
Bloodstream form trypanosomes were cultivated in Minimum Essential Medium 
(MEM) (powder, GIBCO/BRL, No: 11400-033) with Earle’s salts, supplemented with 25 mM 
HEPES, 1 g/l additional glucose, 2.2 g/l NaHCO3 and 10 ml/l MEM non-essential amino 
acids (50x concentration). The medium was then further supplemented by adding 1 % of a 2-
mercaptoethanol stock (14 μl of 12 mM 2-mercaptoethanol was diluted in 10 ml of distilled 
water), 1 % of a stock consisting of 100 mM sodium pyruvate and 50 mM hypoxanthine and 
15 % heat inactivated horse serum, according to Baltz et al., 1985. The complete medium is 
called Baltz MEM (BMEM). 
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Fluorescent uptake studies 
 
Microscopic slides were labelled and prepared ready for the study. The slides were 
cleaned beforehand with 70 % ethanol to remove any dust residue. Trypanosome cultures 
previously cultivated, with an approximate parasite concentration of 105/ml, were taken and 
99 μl of these cultures were mixed with 1 μl of a 1 mg/ml solution of the lead diamidine 
compounds, DB 75, DB 867 or DB 1192, respectively. The stopwatch was immediately 
started as soon as the compound was mixed with the trypanosome culture. 
Thereafter, 5 μl droplets of each incubated culture were placed onto clean microscopic 
slides and a cover slip placed on top. This cover slip was then sealed onto the microscopic 
slide using Vaseline. This was done for the following time points after initial incubation with 
DB 75, DB 867 or DB 1192: 1, 5, 10, 20 and 30 minutes. The slides were then observed using 
a Leica DC200 fluorescent microscope (Leica Microsystems AG, Glattbrugg, Switzerland) at 
a magnification lens of x 50 with oil immersion and pictures were taken using an imaging 
programme (IM500, Version 1.20, Image Manager from Leica IM) for each time point and for 
each diamidine compound. 
 
 
 
Results 
 
The selected lead diamidine compounds DB 75, DB 867 and DB 1192 all 
demonstrated fluorescent properties, allowing them to be visualised under a fluorescent 
microscope at an excitation wavelength of 350 nm. Photo images were taken for each 
diamidine compound at 1, 5, 10, 20 and 30 minutes after incubation with Trypanosoma 
evansi, STIB 806K. These images can be seen in Figure 8.1 for the compound DB 75, Figure 
8.2 for the compound DB 867 and Figure 8.3 for the compound DB 1192. 
All three compounds showed a similar pattern as they were taken up by the 
trypanosomes. The kinetoplast structure showed blue fluorescence first, followed by blue 
fluorescence within the nucleus. These two structures (kinetoplast and nucleus) then suddenly 
fluoresced at a peak point, after which small, circular structures within the cytoplasm gave off 
a blue fluorescence. These small, circular structures are known as acidocalcisomes. Thereafter 
a general equilibrium of fluorescence was seen throughout the whole trypanosome, before the 
acidocalcisomes gave off a yellow fluorescence, whilst the nucleus and kinetoplast remained 
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faintly blue. Although the process was similar for all three lead diamidine compounds, the 
times at which the various stages occurred were different between DB 1192 and the remaining 
two compounds. 
 
Figure 8.1. Fluorescent images taken for T. evansi incubated with DB 75 at the time points of 1, 5, 10, 20 and 30 
minutes. 
 
           
 
Figure 8.2. Fluorescent images taken for T. evansi incubated with DB 867 at the time points of 1, 5, 10, 20 and 
30 minutes. 
 
            
 
Figure 8.3. Fluorescent images taken for T. evansi incubated with DB 1192 at the time points of 1, 5, 10, 20 and 
30 minutes. 
 
           
 
The kinetoplast was seen fluorescing at one minute after incubation in Figures 8.1 and 
8.2 for the compounds DB 75 and DB 867, respectively. The image for DB 1192 in Figure 
8.3 at one minute shows no kinetoplast fluorescence and it is only after five minutes that an 
appearance of the kinetoplast is finally seen. By this time, DB 75 and DB 867 already 
demonstrated strong fluorescence within the kinetoplast and nucleus. Again this stage 
happened slightly slower in DB 1192 and occurred after ten minutes incubation only. The 
acidocalcisomes appear after ten minutes incubation with DB 75 and DB 867, yet with DB 
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1192, they were not so prominent. After twenty minutes incubation, there was an immense 
fluorescence in the nucleus of the trypanosomes, seen more clearly in DB 1192 on the thirty 
minute image rather than the twenty minute photograph. Ultimately the acidocalcisomes 
produced a yellow fluorescence with DB 75 and DB 867 after thirty minutes, which was not 
yet evident in DB 1192 at the same time point. 
 
 
 
Discussion 
 
The aim of this fluorescent uptake study was primarily to determine whether DB 75, 
DB 867 and DB 1192 displayed sufficient fluorescent properties to visualise and track the 
compounds and whether the uptake of these three selected lead diamidines could shed some 
light on their mode of action. 
Indeed, all three compounds did fluoresce at an excitation wavelength of 350 nm. In 
addition, the uptake of these compounds could be observed in Trypanosoma evansi at various 
time points, after incubation with DB 75, DB 867 or DB 1192, respectively. Both, DB 75 and 
DB 867 appeared to be fairly similar during the uptake process, whereas DB 1192 was much 
slower, showing longer time delays between itself and the other two compounds. The P2 
transporter, which has been reported to be involved in the active uptake of many diamidines 
and melaminophenyl arsenicals, remains one of the most predominant purine transporters and 
is responsible for the majority of DB 75 uptake visualised in trypanosomes. Since DB 867 is 
fairly similar to DB 75, both in structure and in efficacy against T. evansi (in vitro and in 
vivo), it would be reasonable to expect DB 867 to act in a comparable way to DB 75. From 
the fluorescent images produced, there appear to be no significant differences between DB 
867 and DB 75 uptake. Whether the slower DB 1192 uptake into the parasite is by another 
predominant transporter, rather than by the TbAT1-coded P2 nucleoside transporter, remains 
to be further investigated. 
Another possibility for the time delays seen in DB 1192 could result from compound 
binding complexes. As DB 75 and DB 867 are taken up into the trypanosome, they rapidly 
bind to AT-rich regions within trypanosomal DNA. Such areas include organelles such as the 
kinetoplast and nucleus. Once bound to these structures, the drugs are stored and no longer 
freely available in the cell cytoplasm. This allows more drug compound to be actively 
pumped in, until an equilibrium is obtained. The large affinity of DB 75 to bind to the minor 
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groove of trypanosomal DNA is believed to be as a result of non-bonded interactions between 
the furan active group and the walls of the AT-rich minor groove. If this is seen with DB 75, a 
diphenyl furan, then a similar binding could be occurring with DB 867, an aza-furan, hence 
explaining the strong fluorescence seen in Figure 8.2. 
In the case of DB 1192 (an indole, however) these non-bonded interactions might not 
be so potent, thus reducing the ability of DB 1192 to bind strongly to the minor groove of 
trypanosomal DNA, resulting in less compound taken up and stored in the organelles, hence a 
slower activity against the parasite, which in turn could account for the extra time needed 
before fluorescence began to appear. Furthermore, if DB 1192 takes longer to cross over the 
cell membranes of these organelles and form these non-bonded DNA complexes, then the 
compound will take much longer before it can exert its biological activity and hence its 
therapeutic potential. This may be a suggestion as to why DB 1192 showed decreased efficacy 
against T. evansi in previous in vivo studies compared to DB 75 and DB 867. 
Fluorescence for these three selected lead diamidines was not just detected in DNA-
containing organelles (blue fluorescence), yet also in small, circular structures called 
acidocalcisomes. Over time, these acidocalcisomes changed from blue to yellow fluorescence. 
Acidocalcisomes are acidic calcium storing organelles, characterised by their high density, 
acidic nature and large content of pyrophosphate, polyphosphate (polyP), calcium and 
magnesium (Moreno and Docampo, 2003). They have been found in many microorgansims, 
ranging from both prokaryotic to eukaryotic types, yet are not present in mammalian cells. 
Acidocalcisomes are believed to be involved in certain metabolic pathways and tend to be 
randomly distributed, usually located at the anterior end of trypanosomes (De Souza, 2002). 
Although acidocalcisomes have also been reported to be involved in the osmoregulation of 
Trypanosoma cruzi (Rohloff et al., 2004), their function in T. evansi has not yet been fully 
investigated. 
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General Discussion 
 
The overall aim of this thesis was to investigate novel diamidine compounds against 
the animal pathogenic protozoan, Trypanosoma evansi, to determine whether any had the 
potential to become clinical candidates and hence offer a more effective, less toxic, cheaper 
alternative to the current standard drugs available. 
Firstly, a panel of drug sensitivities was established from previously isolated T. evansi 
and Trypanosoma equiperdum strains, to understand the extent of drug resistance occurring 
for the four standard drugs currently in use. The results revealed that reduced drug 
sensitivities are present in many of the strains tested and that a new drug against infection is 
desperately needed. Since debates are still open as to whether T. equiperdum is a separate 
species or may be misidentified T. evansi strains (Claes et al., 2003; Claes et al., 2006), both 
were tested in this case and an in vitro profile of drug sensitivities was created for future 
reference purposes. 
Through in vitro screening of around 200 diamidine compounds, using cell viability 
and cytotoxicity assays, a large quantity of compounds could be tested in a fairly short period 
of time. A vast amount of reproducible information was generated for each respective 
compound from this process. Most importantly though, the selective criteria being sought 
after could be adjusted or modified to adhere to those specific requirements desired. Of all the 
compounds tested, the majority demonstrated activity against T. evansi (with IC50 values 
below 30 ng/ml), but selection was narrowed for lead identification through the cytotoxicity 
assays and the investigations with the knock out TbAT1 strain. As previously mentioned in 
the respective chapter, compounds relying less on P2 transportation would be advantageous 
considering the information we know about resistant strains (Mäser et al., 1999; De Koning, 
2001). However, more research needs to be conducted on a molecular level to fully identify 
and elucidate all possible transporters and uptake mechanisms, which diamidines may use to 
enter trypanosomes. 
From here, preliminary in vivo toxicity studies provided another source of crude 
selection and many compounds were removed based on their resulting acute toxic effects 
within a mouse model. Thereafter, the in vivo chemotherapeutic efficacy was investigated, 
allowing us to observe how these compounds behaved within a living system, especially in 
the presence of certain biochemical factors, which cannot be mimicked under in vitro 
conditions. Similarly to lead identification in vitro, the majority of the 48 diamidine 
compounds tested, were seen to be active against T. evansi infection in mice. Due to the 
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relatively low curative doses demonstrated by the four standard drugs against mice infected 
with T. evansi (between 2 mg/kg for diminazene and 0.0625 mg/kg for cymelarsan), the 
selective criteria, which are based on finding a superior compound to that of the standard 
drugs, were so stringently specific, it meant that many of the in vivo active compounds were 
not positively selected for further investigation in this project. It should be noted here 
however, that these compounds are not complete failures, since the curative treatment of 
infected mice with doses as small as 2 mg/kg are still incredibly active, especially when 
compared to other trypanosomal infections (such as with Trypanosoma brucei rhodesiense), 
where curative efficacy of infected mice can require treatment doses of up to 20 mg/kg. So, 
for the purposes of this project, only those diamidines demonstrating very low curative doses 
were optimised and further examined for pre-clinical assessment in larger animals. 
Six selected diamidine compounds were further assessed, based on in vitro and in vivo 
experiments. With treatment doses of just 0.5 mg/kg, given over four consecutive days, mice 
were effectively cured from T. evansi infection. This effect was also seen in different strains 
from various geographical locations. As T. evansi infection is found on the majority of the 
world’s continents, a compound capable of exerting its curative efficacy on several strains can 
only benefit its marketable portfolio. So too can the costs involved in the manufacturing of a 
new drug. By reducing the costs involved in compound synthesis, be it in the raw materials or 
in the complex stepwise conditions utilised, the overall cost of the developed compound will 
also decline. This is critical for successfully targeting those poorer communities, 
economically dependent on their livestock, yet unable to find the means to purchase over-
priced drugs. 
This project enabled drug discovery against T. evansi infection to enter pre-clinical 
(and in some aspects clinical phase) trials. A higher animal model provides specialised data 
on the toxicological, biological and pharmacological qualities of the chemical compound(s) 
being analysed and developed. To follow the experimental processes carried out in this 
project, a PhD pipeline (Figure 9.1) was generated to reveal the different stages covered, with 
their related outcomes. The risky and unstable business of drug discovery and development is 
clearly shown in this PhD pipeline, where we began with 600 active compounds, yet only 
three progressed to pre-clinical evaluation (DB 75, DB 867 and DB 1192). 
A goat model was chosen to act as the higher animal model against T. evansi infection, 
partly due to the size of such an animal and partly due to the biology behind this disease. To 
synthesise a specific amount of the test compound(s) takes time and financial resources, 
which were tailored for the resources available in this project. To undertake such pre-clinical 
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trials within cattle or camels for example, would require kilogramme quantities of test 
compound(s), requiring in turn approximately one and a half years for the manufacture of one 
compound alone. Coupled with the cost of performing, maintaining and analysing such a 
cattle/camel model, one can begin to understand why pharmaceutical entities are usually at 
the forefront of such experimental investigations. Nevertheless, within a three month period, a 
total of two grams were synthesised for each test compound, which was sufficient to perform 
all the goat-related investigations described within this project. 
 
Figure 9.1. A PhD project pipeline depicting the different levels of drug discovery and development, according 
to the investigations carried out, with the outcomes for diamidine compounds, as potential clinical candidates 
against T. evansi infection. 
 
1 2 3 4 5 6 7 8 9 
1. Original compounds (Early explorative discovery) 
2. In vitro screening (Lead identification) 
3. In vivo (mouse) preliminary toxicity (Lead identification) 
4. In vivo (mouse) curative efficacy (Lead identification) 
5. In vivo (mouse) strain sensitivity (Lead optimisation) 
6. Cost evaluation of synthetic manufacture (Lead optimisation)  
7. In vivo (goat) toxicity trials (Pre-clinical trials) 
8. In vivo (goat) pharmacokinetic study (Pre-clinical trials) 
9. In vivo (goat) curative efficacy (Clinical phase trials) 
600 
Active 
181 
Hits 
49 
Leads 
6 
Leads 
6 
Leads 
3 
Leads 
3 
Leads 
3 
Leads 
2 
Clinical 
 
 
Although many domestic and wild animals have been reported susceptible to T. evansi 
infection, some demonstrate acute infection, whilst others demonstrate a chronic progression 
of disease. Goats tend to develop the sub-clinical, chronic version of Surra, although severe 
clinical symptoms, acute disease and rapid death have also been accounted for in infected 
goats. Additionally, there have been no known attempts, where goats have been 
experimentally infected with T. evansi, followed by subsequent treatment with new 
chemotherapeutic compounds. Therefore, it was decided to use a goat model to determine the 
efficacy of selected diamidine compounds at treating not just experimentally infected goats, 
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but the chronic animal model of disease, as well as a potential reservoir host of T. evansi 
infection. 
Before DB 75, DB 867 and DB 1192 could be investigated for curative efficacy, the 
toxicit
ted lead diamidine compounds were considered safe to use in 
goats, 
e goats were infected, it was important that the control goats (receiving no 
compo
y of these compounds within goats needed to be analysed. Although the in vivo mouse 
model had shown no immediate or low toxic effects for these three compounds, drug 
metabolism in higher animals can be remarkably different and complex to that shown by 
mice. In addition, higher compound doses and multiple compound applications would be 
administered in the efficacy study, so the extent of accumulation by these compounds was not 
yet entirely known. One of the dangers presented by compound accumulation is the 
possibility of compound concentrations in plasma exceeding the therapeutic window 
threshold, thus entering the toxic range. No acute signs of toxicity were seen in goats tested 
with single or multiple applications of 4 mg/kg doses of DB 75, DB 867 and DB 1192. 
Various tissue and organ samples were collected for each compound from the respective goats 
and prepared for histological examination. These samples remain available for future 
examination, which could possibly reveal in-depth toxicological effects and findings, 
especially for the organs of compound elimination (liver and kidneys) and for critical regions, 
such as the site of injection. 
Once the three selec
an efficacy study was planned and conducted in the Canary Islands. T. evansi infection 
is currently endemic there with seroprevalances of 4.8 % to 9 % (1997-1999), after the initial 
importation of a male dromedary camel from West Africa in 1997. The primary task of 
finding a highly parasitaemic camel infected with T. evansi, enabled us to isolate the local 
strain and use it to experimentally infect the goats. In this way, no new strains of T. evansi 
were introduced onto the island and the infected goats closely represented the case of 
naturally infected animals from the area, due to the limited adaptation of the isolated strain 
through mice. 
After th
und treatment) revealed a constant parasitaemia, which is why the parasite 
concentration for infection (106) was quite high. This improved our probability of finding 
trypanosomes within the peripheral blood system, hence supporting the parasitological 
detection method used (HCT). However, three different diagnostic methods were applied in 
this efficacy study, to provide complete assessment of curative efficacy based on various 
arguments. Although demonstrating the causative agent through visual detection is an 
undisputable fact of infection, the absence of the parasite in this case, does not necessarily 
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imply cure or complete eradication. Therefore, a specific and sensitive method used to support 
the parasitological point of view usually involves the application of molecular DNA-based 
techniques, capable of detecting parasite DNA even if the parasite cannot be visually 
observed. The PCR technique, although new in this study, proved to be highly effective in 
demonstrating infection within the control goats (given no compound treatment), in goats 
where compound treatment failed completely (DB 1192 at 2.5 mg/kg and 1.25 mg/kg) and in 
goats which appeared to relapse at a later stage (DB 867 at 1.25 mg/kg). The positive 
detection of T. evansi shown by the PCR method was so sensitive, that in several situations, 
the PCR results became positive much earlier than the HCT did. However, this is expected 
since the PCR technique is more sensitive at detecting parasitic DNA in a small volume of 
blood, than the HCT can detect live parasites in the same amount of blood. The third 
diagnostic method used was the serological CATT / T. evansi test, to determine the antibody 
response of the infected goats to the RoTat 1.2 antigen. Like all serological tests, the CATT / 
T. evansi cannot differentiate easily between a recent or past infection. Although antibody 
responses in some diseases are considered an immunological benefit, they can be misleading 
in trypanosomal infections. Antibodies from previous trypanosome infections may not 
provide a protective effect, because trypanosomes have the ability to undergo antigenic 
variation. Consequently, the trypanosomes may display a new variant antigenic type (VAT) 
on their surfaces, which in turn will not be recognised by the previous antibodies, which may 
have been mounted against a different VAT. The CATT / T. evansi test was mainly used in 
the goat efficacy trial to assess the conditions of the goats during the follow up study. 
Diminazene aceturate was used as a positive control in the goat efficacy study. Not 
only is
ising and two lead 
compounds have been selected as potential clinical candidates against T. evansi infection. The 
 it also a diamidine compound, but it is the standard compound used for treating goats 
infected with T. evansi at compound doses of around 5 mg/kg. To continue the main aim of 
the project and find a more efficient novel diamidine compound than the standard, the dosing 
of the test compounds (DB 75, DB 867 and DB 1192) were based on this figure. Hence, half 
and a quarter of the dose used by diminazene were selected, with the added knowledge that at 
2.5 mg/kg and 1.25 mg/kg doses, these compounds should not exert any adverse or toxic 
effects within the goats, since doses of up to 4 mg/kg had been previously assessed in the goat 
toxicity trials. These figures also coincided well with the in vivo activity data from the mouse 
model, where approximately five-fold less compound doses of 0.5 mg/kg (of DB 75, DB 867 
and DB 1192) had provided curative efficacy in T. evansi infected mice. 
The results obtained from the goat efficacy study are very prom
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most a
ons of DB 1192 in the plasma of 
the ex
ctive compound, DB 75, was capable of curing the goats at 2.5 mg/kg and 1.25 mg/kg 
compound doses, just a quarter of the dose required by the standard compound, diminazene. 
In comparison, DB 867 was also very active and cured goats at 2.5 mg/kg compound doses 
(half that required by the standard compound). Treatment failures were seen with the third 
compound, DB 1192, at both compound doses tested and DB 867 relapsed at the lower 
compound dose of 1.25 mg/kg at 4.5 months post treatment. 
The pharmacokinetic study carried out in parallel with the goat efficacy study, clearly 
demonstrated the presence of very low compound concentrati
perimental goats. At these levels, DB 1192 was not within the therapeutic range and 
consequently could not effectively treat and cure the T. evansi infected goats. A different 
pattern was seen for DB 867, given at compound doses of 1.25 mg/kg however. The 
compound concentrations within plasma were high enough to remain within the therapeutic 
range, yet after nearly five months, these goats relapsed and infection was made apparent 
through the diagnostic methods used in the efficacy study. The phenomenon of relapse cases 
in trypanosomal infections can be caused by several factors, such as drug resistant strains, re-
infection or insufficient drug levels at a given site of the body. The likelihood of re-infection 
in the goats treated with DB 867 at 1.25 mg/kg for example, was minimised in our study by 
keeping the infected control goats separate from the treated goats, plus all experimental goats 
were housed within fly-proof facilities. Furthermore, the potential of resistance for the T. 
evansi strain used to infect the goats is also considered unlikely, partly due to the fact that 
these three selected diamidine compounds have never before been investigated or released for 
use on a veterinary market. With no realistic possibility of prolonged exposure of this specific 
strain to these selected diamidines, the absence of a P2 transporter is also unlikely. Since 
diminazene is highly dependent on P2 transportation, one would also have expected to see 
reduced sensitivities for this compound, in both the mouse and goat in vivo studies previously 
performed. Since the pharmacokinetic profile of DB 867 demonstrated high compound 
concentrations in plasma, it seems doubtful that there were insufficient compound levels 
present. However, with a fairly long half life (~ 200 hours), DB 867 is believed to accumulate 
within tissues. Given that the amount of unbound compound is the active part, which 
correlates to the therapeutic activity, it may well be that DB 867 was present in insufficient 
concentrations in certain sites within the body, hence eventually leading to a possible relapse. 
It cannot be concluded for certain how or why such a relapse may have occurred in infected 
goats, treated with a low dose of DB 867, but with half the dose of that used for the standard 
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compound (diminazene), DB 867 remains one of the most active clinical candidates against T. 
evansi infection. 
 
 
 
Future Perspectives 
 
This PhD project has provided the basic scientific and investigative data for diamidines 
as pote
, a programme involving treatment of all infected camels and 
horses
ntially alternative chemotherapeutic agents against T. evansi. This class of compounds 
demonstrated higher efficacy against the parasite, than the majority of the standard drugs and 
were shown to be less toxic and economically beneficial for large scale production and 
manufacture. Two compounds, DB 75 and DB 867, have been brought through the discovery 
stages of early explorative discovery, lead identification and lead optimisation, into the 
developmental levels, involving pre-clinical trials and a pilot “proof of concept” efficacy 
study in a higher animal model. The scope of discovering and developing a new drug (from 
start to finish) cannot be covered completely within a PhD project. However, the promising 
results and analysis already performed and collected on DB 75 and DB 867, warrant their 
continued investigation, development and marketable potential as serious candidate molecules 
against T. evansi infection. Such a novel compound is desperately required on the 
international veterinary market. 
Within the Canary Islands
 is currently underway, yet it does not take into account small ruminants, such as goats. 
Camel farms placed near to or within close proximity to goat herds presents a possible 
epidemiological catastrophe, especially if natural infection of T. evansi can occur in goats, 
which in turn can act as chronic reservoirs of the parasite. This was seen in our study, 
whereby one goat had previously been exposed to T. evansi infection and control goats could 
survive up to six months post-infection, with plenty of viable parasites circulating in the 
blood. Should such a programme successfully treat all infected camels and horses, the 
potential possibility of re-infection is incredibly high, if animals acting as disease reservoirs 
are not equally investigated and treated. Based on the results of our goat efficacy study, it 
would be advisable to use all three diagnostic methods when seeking out infected animals in 
such a programme, since parasitological methods can identify recent infections, serological 
methods can determine the immunological state of the animal and molecular based techniques 
can confirm the presence of parasite DNA in re-infected or relapsed animals at an early stage. 
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In addition, the situation of insect vectors as potential disease transmitters on the island 
should also be assessed and follow up studies should be conducted after the programme has 
terminated. 
The pharmacokinetic goat study revealed that the pharmacokinetic profiles of DB 75 
and DB
eferences 
laes F, Verloo D, De Waal DT, Majiwa PAO, Baltz T, Goddeeris BM and Büscher P (2003) The expression of 
laes F, Dujardin JC, Touratier L, Büscher P and Goddeeris BM (2006) Response to Li et al. and Shaw: Return 
e Koning HP (2001) Transporters in African trypanosomes: role in drug action and resistance. International 
tterlin C, Kralli A and Kaminsky R (1999) A nucleoside transporter from Trypanosoma brucei 
 867 were quite similar, producing very high compound concentrations within plasma 
samples. With such long half lives for these two compounds, the extent of compound 
accumulation within the goats may be a critical factor required to fully understanding the 
absorption, metabolism and elimination of diamidines. Preliminary investigations, focused on 
compound uptake and accumulation, were performed for DB 1192, DB 867 and DB 75, using 
the compounds natural fluorescent properties. Detailed examination into the accumulative 
affinity of these compounds however to trypanosomes and to various tissues within the body, 
need to be performed to fully comprehend the processes going on between compound, 
parasite and host. The specifics for DNA and protein binding of diamidine molecules within 
the body, the distribution phases involved and the clearance of such compounds, are all areas 
of pharmacological interest, that could reveal much wanted knowledge about diamidines. In 
conclusion, the beneficial effects seen for DB 75 and DB 867 against T. evansi infection 
support the opinion that these two compounds have a stable advantage against other standard 
drugs and should be developed further for productive use on the international veterinary 
market. 
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Appendix 1: Raw data for Chapter 2 
 
1. Growth curves for several Trypanosoma sp. to determine optimal starting 
concentrations for different in vitro cell viability assays 
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2. Plate layout for the 3H-hypoxanthine incorporation assay 
 
Trypanosoma equiperdum Trypanosoma equiperdum 
  1 x 105   1 x 104   1 x 103   
Canadian strain BoTat strain 
 
 
 
 
        1       2       3       4
 
       5       6       7       8       9      10    
    
B            1000 
 
C             333 
 
D             111 
 
E              37.0 
 
F             12.4 
 
G             4.12 
 
H             1.37 
        Drug 1      Drug 2      Drug 3      Drug 4       Drug 5      Drug 6 
 11     12  
A  
 
       
Control well Background well 
 to 3-fold drug dilutions (from highest to lowest) in ng/ml  
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3. SOP: Trypanosoma brucei species in vitro Assay (3H-hypoxanthine incorporation) 
Standard parasite strains
 
 
: Trypanosoma brucei rhodesiense strains (STIB 900) 
 Trypanosoma evansi strains (STIB 806 K) 
  oma equiperdum st
 
 
Standard drugs
   
  Trypanos rains 
: Suramin (10 mg/ml stock solution; start conc. 10 μg/ml) 
   Diminazene (10 mg/ml stock solution; start conc. 10 μg/ml) 
   Cymelarsan (10 mg/ml stock solution; start conc.100 ng/ml) 
   Quinapyramine (10 mg/ml stock solution; start conc. 100 ng/ml) 
 
 
Standard conditions: 
 
 
Medium:   Minimum essential media (MEM) 
    Earle’s balanced salt solution 
    Horse 
   Baltz solution (without Hypoxanthine) 
adioactive hypoxanthine: 500 μl 3H-hypoxanthine stock + 500 μl EtOH + 24.5 ml 
medium (these 1 ml aliquots are stored at -20 °C, medium 
added fresh) 
 
Plates:    CostarTM 96-well microtitre plates 
 
 
Incubation:   37 °C and 5 % humidified CO2
 
 
Drug preparation
serum (inactivated) 
 
 
 
R
 
: Compounds are prepared as advised by the supplier. If not specified, 
DMSO is used. Stock solutions of 10 mg/ml are made, which may be kept at room 
temperature or at -20 °C if an alternative solvent is used. (Since DMSO is toxic, care has to be 
taken not to exceed a final concentration of 0.5 % DMSO). 
 
 
 
Assay Procedure: 
 
Day 1 
 
1. Into all wells of a 96 well microtitre plate, 50 μl of BMEM (containing no hypoxanthine) 
are added, with the exception of those wells in row B. 
2. An additional 50 μl of BMEM (containing no hypoxanthine) is placed in the last four wells 
of row A (columns 9, 10, 11 and 12), to produce a total volume of 100 μl, as these wells 
act as a negative background. 
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3. Into the wells of row B, 75 μl of two times the highest drug concentration (previously 
calculated and mixed with BMEM medium containing no hypoxanthine) are placed 
according to the number of drugs being tested. 
 columns 3 - 4, Drug 
mns 11 - 12. 
. Then 25 μl of each well from row B are removed and using a multi-channel pipette, the 
 B are mixed 
with ow C then 2 d again 25 
rom row 
H ar  then d scarde
. Using the CASY cell counter system, the correct trypanosome suspension can be achieved, 
EM medium (containing no hypoxanthine). A total concentration of 
2x10 / ml of the required trypanosome suspension is calculated, where approximately 4.6 
ml of medium are required for one 96 well microtitre plate. 
ed to all wells, with the 
mns 9 - 12. Therefore, a total 
. The plates are then placed into the incubator at 37 °C and 5 % humidified CO2 for 24 
 
 
ay 2 
. After the 24 hour incubation period, the plates are removed and 20 μl of a 1 μCi 
radioactive 3H-hypoxanthine solution (freshly mixed with 24.5 ml of BMEM medium, 
 n  prev us hypoxanthine) are added to all wells on the 96 well microtitre plate, 
including the four negative control wells. 
ay 3 
. After a total incubation time of 40 hours, the plates are removed from the incubator and 
arvester machine. 
s for using the cell harvester can be found on the corresponding protocol sheet.  
oxanthine counts are then evaluated 
and stored onto a floppy disk. 
4. 
 
4. Per plate, six drugs can be tested - Drug 1 in columns 1 - 2, Drug 2 in
3 in 5 - 6, Drug 4 in 7 - 8, Drug 5 in 9 - 10 and Drug 6 in colu
 
5
drugs are diluted using a 3-fold serial dilution step, in that 25 μl from row
 r , 5 μl of row C are removed and placed into row D, mixed an
μl removed and put into row E, and so on until row H is reached. The final 25 μl f
e i d. 
 
6
accompanied by BM
6 
 
7. Finally, 50 μl of this trypanosome suspension are then add
exception of the four negative control wells in row A, colu
volume of 100 μl should be found in each well of the plate. 
 
8
hours. 
 
D
 
1
containing o io
 
2. The plates are then incubated for a further 16 hours under the same conditions. 
 
 
 
D
 
1
read in the cell h
 
2. Step
 
3. Once harvested, the plates are placed into the beta counter (using the protocol cassettes) 
and the machine is started, whereby the radioactive hyp
 
The data can then be analysed using a template sheet in a graphics programme (Microsoft 
Excel) and IC50 values determined and obtained for the drugs tested. 
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4. SOP: Trypanosoma brucei species in vitro Assay (Alamar Blue® assay) 
 
 
tandard parasite strainsS : Trypanosoma brucei rhodesiense strains (STIB 900) 
   Trypanosoma equiperdum strains 
 
Sta
    Trypanosoma brucei gambiense strains (STIB 930) 
Trypanosoma evansi strains (STIB 806 K) 
 
 
ndard drugs:  Melarsoprol (Main standard for STIB 900) 
Suramin (10 mg/ml stock solution) 
TM 
    Diminazene (10 mg/ml stock solution) 
   Cymelarsan (10 mg/ml stock solution) 
 
 
Sta
 
    Quinapyramine (10 mg/ml stock solution) 
ndard conditions: 
 
 
dium:   Minimum essential media (MEM) 
   Earle’s balanced salt solution 
Me
 
   Horse serum (inactivated) 
    Human serum for T. b. gambiense strains 
   Baltz solution 
   CostarTM 96-well microtitre plates 
 
 
r
 
    Foetal calf serum (inactivated) for T. b. gambiense strains 
 
 
Plates: 
 
 
Incubation:   37 °C and 5 % humidified CO2
D ug preparation: Compounds are prepared as advised by the supplier. If not specified, 
t at room 
re has to be 
ken not to exceed a final concentration of 0.5 % DMSO). 
rocedure: 
drugs can be tested (drug 1 column 1-3, drug 2 column 
3. 
lace it into row G and mix well. Next, 25 µl are taken out of 
DMSO is used. Stock solutions of 10 mg/ml are made, which may be kep
emperature or at -20 °C if an alternative solvent is used. (Since DMSO is toxic, cat
ta
 
 
ssay PA
 
1. Into the wells of row H, add 75 µl of medium that contains two times the highest drug 
concentration desired. Per plate, 4 
4-6, etc.) 
 
2. Add 50 µl of medium at room temperature to rows A to G of a 96-well plate. 
 
Serial drug dilutions are prepared by using a 12-channel multi-pipette. First, remove 25 µl 
from the wells of row H and p
row G and placed into row F and so on until row B. The last 25 µl of row B are discarded. 
A serial dilution factor of 1:3 is thus obtained. The wells in row A serve as controls 
without drugs. 
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4. Thereafter, 50 µl of medium without trypanosomes are added to columns 3, 6, 9 and 12; 
these columns serve as background. 
t usted with 
ocytometer.  
(The trypanosome density used should be adjusted depending on the current growth 
. Per plate, allow for the use of 3.5 ml of the trypanosome stock. 
7. Into the remaining wells, . 
O2. 
valuation: 
. The plates are inspected under an inverted microscope to ensure that growth is normal. 
Additional information may be recorded, such as drug insolubility or contamination, etc. 
cubate for an additional 3 
length of 536 nm and 
o 3.1.2) and are evaluated to 
5. Plate layout for the Alamar Blue® assay 
 
5. Dilute the trypanosomes o 4x104 parasites / ml.  The trypanosome density is adj
a Cell Analyser System (CASY, Schaerfe System) or by a count on the haem
characteristics of the corresponding cultures) 
 
6
 
add 50 µl of trypanosome suspension
 
8. The plates are then incubated for 69 hours at 37 °C and 5 % humidified C
 
 
E
 
1
 
2. Add 10 µl of the fluorescent dye Resazurin to each well and in
hours (until a subtle colour change is observed). 
 
3. To determine an IC50 value, the plate is read at an excitation wave
emission wavelength of 588 nm. 
 
4. Data are transferred into a graphics programme (SOFTmax Pr
determine the IC50 values. 
 
 
 
        1       2       3       4       5       6       7       8       9      10     11     12  
 
A 
 
B      
 
       0.14 
C             0.41 
 
D             1.23 
 
E             3.70 
 
H             100 
 
F             11.1 
 
G             33.3 
         Drug 1                Drug 2                Drug 3               Drug 4 
Control well Background well 
3-fold drug dilutions (from lowest to highest) in ng/ml  to 
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6. SOP: In vitro sensitivity assay for compound toxicity (Cytotoxicity assay) 
 
 
Standard cell lines:  L-6 (rat skeletal myoblast cells) 
HT-29 (human bladder carcinoma) 
 
 
tandard drugsS :  Suramin (10 mg/ml stock solution) 
) 
   Cymelarsan (10 mg/ml stock solution) 
on) 
tandard conditions
    Diminazene (10 mg/ml stock solution
 
    Quinapyramine (10 mg/ml stock soluti
 
 
S : 
edium:   Roswell park memorial institute media (RPMI 1640) 
 
 
 
M
    Foetal calf serum (inactivated) 
   L-Glutamine (1.7 µM) 
 
Plates:    CostarTM 96-well microtitre plates 
 
 
Incubation:   37 °C and 5 % humidified CO2
 
 
Drug preparation: Compounds are prepared as advised by the supplier. If not specified, 
SO is used. Stock solutiDM ons of 10 mg/ml are made, which may be kept at room 
mperature or at -20 °C if an alternative solvent is used. (Since DMSO is toxic, care has to be 
ken not to exceed a fin
Assay procedure: 
 
1. Add 100 µl of medium to wells of columns 3, 6, 9 and 12 of a microtitre plate. These 
wells serve as controls. 
  
2. Next, 100 µl of a cell suspension of 4x104 cells / ml is added into the remaining columns 
(1 and 2, 4 and 5, 7 and 8, and 10 and 11). Cells are allowed to attach overnight. 
 
3. Per plate, allow for 6.5 ml of cell suspension to be used. 
 
4. The following day, the medium is removed from row H (do this for half of the plates and 
go to step 4 and return to step 3 for the second half, so that the cells do not dry out). 
 
5. Thereafter, 150 µl of medium containing the highest drug concentration is added to the 
wells of row H. Four drugs can be tested on one plate (drug 1 column 1-3, drug 2 column 
4-6, etc.). 
te
ta al concentration of 0.5 % DMSO). 
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6. Serial drug dilutions are prepared by using a 12-channel multi-pipette. First, remove 50 µl 
from wells of row H and put into row G and mix well. Next, 50 µl are taken out of row G 
and put into row F and so on until row B. The last 50 µl of row B are discarded. A serial 
serve as control wells without 
drugs. 
midified CO2. 
ected under an inverted microscope to ensure that growth is normal. 
Additional information may be recorded, such as drug insolubility or contamination, etc. 
plates for 
tation wavelength of 536 nm and 
emission wavelength of 588 nm. 
o 3.1.2) and are evaluated to 
determine the IC50 values. 
 
 
dilution factor of 1:3 is thus obtained. Wells in row A 
 
7. The plates are then incubated for 69 hours at 37 ºC and 5 % hu
 
 
Evaluation: 
 
1. The plates are insp
2. Add 10 µl of the fluorescent dye Resazurin to each well and incubate the 
another 2 hours (until a colour change is observed). 
3. To determine an IC50 value, the plate is read at an exci
4. Data are transferred into a graphics programme (SOFTmax Pr
 
 
 
7. Plate layout for the L6 Cytotoxicity assay 
 
        1       2       3       4       5       6       7       8       9      10     11     12  
 
A 
 
B             0.12 
           1.11 
 
G              30 
 
        90 
g 4 
 
C             0.37 
 
D  
E             3.33 
 
F              10 
 
H      
           Drug 1               Drug 2               Drug 3               Dru
Control well Background well 
3-fold drug dilutions (from lowest to highest) in μg/ml  to 
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8. SOP: In vivo preliminary acute toxicity test (mouse model) 
ndard parasite strains
 
 
Sta : None 
 
 
Standard conditions: 
 
 
Mice:    NMRI female mice, 22 - 25 g 
   
ages:    Macrolon, type II cages 
 
 
Tes
     
 
C
 
Maintenance:   22 °C and 60 - 70 % relative humidity 
    Pelleted food and water ad libitum 
 
t procedure:   
 
Day 1: A mouse is injected (i.p.) with the compound being tested, at a 
starting concentration of 5 mg/kg. Thereafter, the doses then 
increase to 15 mg/kg, 30 mg/kg and 50 mg/kg with two hour 
intervals. The cumulative dose corresponds to the injection 
dose; hence 15 mg/kg has an accumulation dose of 20, 30 
ctively. The mouse is 
constantly observed for any toxic or sub-toxic signs in order to 
determine the highest tolerated dose (HTD).  
 
Day 2: The mouse is checked again after 24 hours for any signs of 
toxicity or sub-toxicity. If none are present, the highest tolerated 
dose can be recorded. 
 
mg/kg of 50 and 50 mg/kg of 100, respe
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9. Raw data for the Alamar Blue® assay 
 
Trypanosoma brucei rhodesiense (STIB 900): 
 
Standard drugs 
Boykin compounds 
 
  Alamar Blue Assay for STIB 900     Alamar Blue Assay for STIB 900 
 
 
 
Compound IC50 IC50 IC50  Compound IC50 IC50 IC50
  (ng/ml) (ng/ml) (ng/ml)    (ng/ml) (ng/ml) (ng/ml) 
      Average        Average 
75 8 0.824 0.85 0.841  828 5.634 5.769 5.702 
103 4 7.938 10.35 9.146  832 3.332 3.821 3.577 
201 8.465 9.29 8.878  841 7.388 10.046 8.717 
210 10.725 8.437 9.581  846 10.983 10.457 10.720 
211 1.98 5.833 3.907  849 4.01 3.498 3.754 
217 2.968 3.523 3.246  850 5.305 5.353 5.329 
242 7.815 9.385 8.600  851 13.474 12.389 12.932 
262 4.606 4.584 4.595  853 13.427 13.918 13.673 
320 1.129 3.051 2.090  866 2.022 2.798 2.410 
325 5.668 2.633 4.151  867 0.639 0.943 0.791 
346  1.61 3.23 2.420  877 0.137 0.319 0.228 
351 0.895 0.502 0.699  902 6.439 8.425 7.432 
417 1.89 3.923 2.907  911 1.371 3.336 2.354 
427 2.047 6.156 4.102  930 1.487 2.069 1.778 
484 1.561 1.523 1.542  935 5.001 9.653 7.327 
497 13.43 11.043 12.237  943 3.069 5.898 4.484 
508 1.96 2.795 2.378  945 2.199 3.498 2.849 
544 3.263 3.553 3.408  988 3.563 3.37 3.467 
545 4.355 3.257 3.806  989 3.187 5.764 4.476 
560 1.765 1.814 1.790  994 1.049 1.146 1.098 
609 6.03 6.411 6.221  1012 3.283 3.303 3.293 
690 1.837 1.783 1.810  1016 4.304 9.536 6.920 
746 9.129 8.964 9.047  1017 2.409 3.422 2.916 
763 6.238 6.923 6.581  1019 0.245 0.583 0.414 
773 4.279 4.777 4.528  1023 5.11 3.518 4.314 
820 1.414 1.281 1.348  1044 3.901 9.542 6.722 
 
Alamar Blue Assay for STIB 900   
Drug IC50 IC50 IC50 IC50
  (ng/ml) (ng/ml) (ng/ml) (ng/ml) 
      Average   
Suramin 85.28 91.946 50.215 75.814 
Diminazene 3.067 2.357 2.917 2.780 
Cymelarsan 1.544 2.838 1.443 1.942 
Quinapyramine 0.209 0.566 0.193 0.323 
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Ti ell com ds 
  Alamar Blue Assay for STIB 900     Alamar Blue Assay for STIB 900 
Compound IC50 IC50 IC50  Compound IC50 IC50 IC50
  (ng/ml) (ng/ml) (ng/ml)   (ng/ml) (ng/ml) (ng/ml)  
      Average        Average 
1046 4.759 3.6 1210 1.353 1.862 1.608 74 4.217  
1 11.493 6.901 9.197 121 1.007 0.802 0.905 049  3 
1050 2.061 1.616 12 7.693 4.159 5.926 1.839  14 
1052 4.808 9.566 7.187  1 9.774 157 14.540 12.220 
10. 23 754 1228 3.539 272 13. 6 11.  2.229 2.884 1055 
1065 0.716 0.91 813 12 5.686 3.928 4.807 0.  36 
1077 2.533 4.33 432 12 10.145 5.648 7.897 3.  37 
1114 4.767 3.471 119 1239 4.509 1.866 3.188 4.  
1149 5.359 3.235 297 4.  1242 6.510 4.925 5.718 
1152 0.464 0.461 0.463  1250 1.145 1.267 1.206 
1157 15.034 10.216 12.625  1253 3.435 7.936 5.686 
1159 10.162 10.153 10.15 8.091 7.540 7.816 8  1255 
 1164 0.240 0.256 0.248 1258 13.051 6.046 9.549 
 1165 1.357 1.212 1.285 1265 3.806 4.291 4.049 
1171 1266 0.534 1.126 0.830  9.534 5.834 7.684 
1172 5.743      3.489 4.616  1271 6.551 9.577 8.064
1173 1272 12.338 10.490 11.414  5.667 4.578 5.123 
1177 2.104 3.378 1283 3.311 1.424 2.741  2.368 
1191 6.918 9.644 8.281  1288 0.809 0.969 0.889 
1192 0.371 0.504 0.438  1340 0.857 0.862 0.866 
1194 3.160 1.134 2.147  1342 6.045 5.933 5.989 
1197 8.828 11.051 9.940  1370 1.721 1.848 1.850 
1206 0.957 0.769 0.863  1371 1  6.107 16.485 16.296 
dw poun
 
 
 
 
  ar Blue Assay for S   amar Blue Assay for 0 Alam TIB 900   Al STIB 90
Co nd  pound 50 50mpou IC50 IC50 IC50 Com IC IC IC50
  l) l) l) /ml) /ml) l) (ng/m (ng/m (ng/m    (ng (ng (ng/m
  e ge     Averag        Avera
3 H 023 3 3 3 A 143 .93 249 90 XC 10.83 15.13 12.98  6 MA 20 21. 21.0
5 B 066 9 5 2 A 085 037 25.412 25 GR 16.80 17.67 17.24  5 MA 27. 26.2
5 B 068  3 7 O 045 572 327 50 GR 14.26 14.51 14.38  1 KA 18. 15. 16.9
5 B 086 8  L 057 687 2.064 6 GR 5.155 5.80 5.482  3 ST 6. 4.37
5 BG   187 661 R 088 8.294 9.308 8.801  5 MAA 083 22. 20. 21.424 
5 B 094 5 9 2 A 101 502 95 9 GR 16.26 15.85 16.06  5 MA 12. 7.0 9.79
5 B 096 1 1 1 A 121 287 078 83 GR 24.20 23.06 23.63  5 MA 16. 15. 15.6
6 B 012 1 1 1 A 123 .068 381 25 GR 28.97 23.03 26.00  5 MA 25 23. 24.2
1 SMB 015    A 137 632 671 52 6.082 8.703 7.393  5 MA 20. 23. 22.1
6 EVK 012 24.498 27.867 26.183  6 MAA 025 3.639 2.622 3.131 
1 RRT 039 0.982 0.843 0.913  2 SAB 087 21.735 22.95 22.343 
 173
Appendix 2: Raw data for Chapter 3 
 
 
  Alamar Blue Assay for STIB 900    Alamar Blue Assay for STIB 900 
Compound IC50 IC50 50 nd IC50 IC50 IC50IC  Compou
  (ng/ml) l) ) ml) l) l) (ng/m (ng/ml    (ng/ (ng/m (ng/m
             e Average  Averag
3 SMB 051 7 4  C 184 85 35 0 6.51 6.70 6.611  1 MC 6.1 3.4 4.81
3 SMB 065  7  B 038 595 99 97 9.889 10.00 9.948  10 SM 13. 6.5 10.0
3 SMB 079 3 8 7 B 082 52 62 7 23.31 29.3 26.34  0 DW 3.8 3.0 3.45
3 SMB 101 5 9  B 736 .29 68 9 4.13 4.24 4.192  0 MX 28 28.1 28.22
4 SMB 058 5 6  B 767 261 984 23 27.72 21.23 24.481  0 MX 25. 15. 20.6
4 SMB 092 4 49 2 B 864 634 01 8 13.91 12.4 13.18  0 MX 10. 7.8 9.21
5 SMB 032 8 5 75 909 3.49 2.04 2.772  10 SMB 084 29.8 33. 31.892 
1 57 4 2   B 003 52 282 17 EVK 0 6.02 6.41 6.218 11 SM 8.7 12. 10.5
16 7 7 7 P 075 774 659 17  DAP 022 24.14 27.58 25.86  19 DA 13. 11. 12.7
4 SAB 075    P 085 873 14.45 62 3.638 3.437 3.538  19 DA 18. 16.6
5 SMB 093 8   P 089 38 796 17 12.64 10.27 11.459  19 DA 9.6 11. 10.7
16 2 2   P 001 84 23 4  DAP 095 6.64 4.99 5.817 20 DA 10.4 6.2 8.35
3 83 9 9 4  P 079 955 25 40 KEG 0 12.23 10.68 11.46 19 DA 15. 8.7 12.3
3 NAN 027 7 2   066 77 96 7 3.19 1.76 2.480  8 SAB 1.6 0.9 1.33
6 SAB 038 9 7 8  068 08 65 5 11.74 11.08 11.41  8 SAB 1. 0. 0.86
8 SMB 021 3   072 54 3.637 9 4.818 4.78 4.801  8 SAB 5. 4.58
8 SMB 044 6 1 9 P 055 02 14 8 14.25 13.10 13.67  20 DA 6.5 5.7 6.10
7 SAB 004 8 9  P 059 98 05 2 5.19 4.65 4.929  20 DA 5.1 3.1 4.15
7 SAB 015 4 8  B 003 12 38 5 7.32 8.77 8.051  12 SM 3.6 1.5 2.57
7 97 1   B 028 14 5 EVK 0 1.45 2.783 2.117  12 SM 6.609 11. 8.87
7 SAB 079 2 5  P 023 13 37 5 1.34 3.35 2.349  21 DA 2.4 1.6 2.02
8 EVK 024 4.036 1.598 2.817  9 SAB 021 13.522 9.768 11.645 
8 EVK 030 3.165 6.365 4.765  12 SMB 011 27.439 24.529 25.984 
19 DAP 021 9.132 2.969 6.051  21 DAP 049 7.637 3.191 5.414 
19 DAP 025 1.809 1.238 1.524 2 13.426 6.858 10.142  9 SAB 07
1 FMS 034 5.419 5.627 5.523 4.506 1.674 3.090  9 SAB 076 
1 MCC 112 3.163 1.424 2.294  9 SAB 078 4.07 2.973 3.522 
1 MCC 179 0.514 0.264 0.389  8 SAB 070 11.736 6.972 9.354 
1 MCC 097 8.51      9.433 8.972  21 DAP 046 7.101 5.184 6.143
1 MCC 128 3.489 1.961 2.725  10 SAB 037 5.715 3.351 4.533 
1 MCC 148 1.237 0.926 0 SAB 055 2.735 2.108 1.082  1 2.422 
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Stan ugs dard dr
Boy mp
0. Raw data for the Alamar Blue® assay 
 
Trypanosoma ST K)
 
 
 
 
 
  Alam IB 806K     ar Blue Assay f  806K 
kin co ounds 
1
evansi ( IB 806 : 
ar Blue Assay for ST Alam or STIB
Co IC IC  Com IC50 IC50 IC50mpound 50 50 IC50 pound 
  (ng/m (ng/m (ng/m    (ng/ml) ng/ml) ng/ml)l) l) l)  (  (  
      Average        Average 
75 3. 1.  972 5.676 5.324 324 245 2.285 828 4.
103 5. 807 6.  0.254 7.107 8.681 192 6. 000 832 1  
201 3. 209 4.  913 8.414 7.164 783 5. 496 841 5.
210 0. 757 1.  415 10.565 9.990 659 1. 208 846 9.
211 9. 1  432 1.113 1.773 215 11.609 0.412 849 2.
217 3. 271 2.  8 4.319 4.574 4.447 131 1. 201 50 
242 7. 9.  997 9.763 7.380 036 12.585 811 851 4.  
262 7. 251 8.  483 7.965 7.224 186 9. 219 853 6.
320 3.306 6.69 4.998  866 4.113 2.742 3.428 
325 1.838 3.729 2.  867 1.488 2.003 1.746 784 
346 5.089 6.523 5.  8 5.635 1.18 3.408 806 77 
351 3. 3. 3.  9 4.785 2.28 3.533 22 33 275 02 
417 3. 965 3.239 3. 602  9 3.406 3.978 3.692 11 
427 5.788 8.509 7.149  930 3.211 5.389 4.300 
484 7. 435 6.  164 4.925 4.545 602 5. 519 935 4.
497 9. 732 8.  916 2.682 2.799 278 7. 505 943 2.
508 9.871 9.271 9.571  945 2.713 3.74 3.227 
544 3.207 4.161 3.684  988 4.167 7.014 5.591 
545 8.879 8.299 8.589  989 9.265 4.968 7.117 
560 3.82 3.515 3.668  994 9.719 3.405 6.562 
609 8.121 8.498 8.310  1012 8.894 5.557 7.226 
690 5.65 8.884 7.267  1016 9.648 11.327 10.488 
746 6.345 14.886 10.616  1017 6.21 9.873 8.042 
763 3.199 2.278 2.739  1019 2.09 3.598 2.844 
773 4.061 3.423 3.742  1023 6.819 6.096 6.458 
820 4.596 6.217 5.407  1044 10.221 12.913 11.567 
 
r Blue for STIB 806K   Alama  Assay 
Drug IC50 50 50IC IC IC50
  (ng/ml) l (ng/ml) (ng/m ) (ng/ml) 
        Average 
Suramin 88.253 .181 88 69 86 .2 87.568 
Diminazene 19 1.85 11 47 13.6 1 .9 12.472 
Cymelarsan 43 .124 1. 9 0.7 1 36 1.079 
Quinapyramine 0.134 .124 0. 7 0 09 0.118 
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Ti ell com nds 
  Alamar Blue Assay for STIB 806K     Alamar Blue Assay for STIB 806K 
50  Compound IC50 IC50 IC50Compound IC50 IC50 IC
  (ng/ml) (ng/ml) (ng/ml)    (ng/ml) (ng/ml) (ng/ml) 
      Average        Average 
1046 2.532 3. 210 1.281 1.29 1.286 941 3.237  1
1 6.849 7.188 7.019 1213 10.881 8.801 9.841 049  
1050 5.619 6.914 267 12 1.008 1.572 1.290 6.  14 
1052 1 652 10.151  12 7.179 0.65 9. 20 4.572 5.876 
12.431 10.342 .387 122 13.84 9.11  8 049 11.445 1055 
1065 3.546 1.155 351 123 9.919 9.082 9.501 2.  6 
1077 8.132 8.348 240 123 8.612 5.08 6.846 8.  7 
1114 1.758 1.597 678 123 13.548 12.817 13.183 1.  9 
1149 6.351 5.926 139 1242 4.148 3.276 3.712 6.  
1152 2.549 4.909 3.729  1250 5.638 7.062 6.350 
1157 3.346 3.698 3.522  1253 2.095 4.223 3.159 
1159 3.045 4.579 3.812 6.42 4.84 5.630  1255 
1164 10.77 7.077 8.924  1258 7.805 8.878 8.342 
1165 3.392 1.377 2.385  1265 7.199 9.272 8.236 
1171 1266 1.365 1.193 1.279  7.376 8.633 8.005 
1172 3.378      3.124 3.251  1271 8.199 5.837 7.018
1173 1272 5.707 6.592 6.150  6.99 4.498 5.744 
1177 6.303 3.642 1283 7.954 5.011 4.973  6.483 
1191 1.787 5.775 3.781  1288 5.86 4.859 5.360 
1192 10.886 10.03 10.458  1340 3.671 3.945 3.808 
1194 1.095 1.631 1.363  1342 3.633 4.027 3.830 
1197 3.214 2.549 2.882  1370 5.276 4.899 5.087 
1206 11.575 5.743 8.659  1371 13.205 10.832 12.019 
dw pou
 
 
 
 
  ar Blue Assay for ST   ar Blue Assay f  806K Alam IB 806K   Alam or STIB
Co nd  pound 50 50 IC50mpou IC50 IC50 IC50 Com IC IC
   ( g/ml) l) ng/ml) (ng/ml) ng/ml) (ng/ml)    (n (ng/m (
    Average          Average 
3 023 A 143 .805 29.363 28.084 HXC 9.565 9.384 9.475  6 MA 26
5 066  A 085 .584 21.663 22.624 BGR 14.064 15.205 14.635  5 MA 23
5 068 O 045 .058 14.748 14.903 BGR 7.85 7.133 7.492  1 KA 15
5 086  L 057 .581 4.133 4.357 BGR 4.245 6.987 5.616  3 ST 4
5 BG 10. 71 24.406 26.058 R 088 9.692 10.887 290  5 MAA 083 27.
5 094  A 101 2.565 9.799 11.182 BGR 24.466 25.007 24.737  5 MA 1
5 096  A 121 9.185 20.578 19.882 BGR 26.714 28.678 27.696  5 MA 1
6 012  A 123 .819 22.208 24.514 BGR 23.661 25.425 24.543  5 MA 26
1 SMB 015 A 137 .214 25.037 126 9.739 9.763 9.751  5 MA  27  26.
6 EVK 012 19.324 23.531 21.428  6 MAA 025 1.608 3.189 2.399 
1 RRT 039 2.056 3.721 2.889  2 SAB 087 27.622 23.882 25.752 
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  Alamar Blue Assay for STIB 806K    806K  Alamar Blue Assay for STIB
Compound IC50 I nd IC50 IC50 IC50C50 IC50  Compou
  (ng/ml) (   /ml) /ml) l) ng/ml) (ng/ml)  (ng  (ng  (ng/m
            erage Average  Av
3 SMB 051 9  C 184 .375 5.231 4.303 9.061 .352 1 MC 39.207 
3 SMB 065 5  B 038 .564 18.907 18.736 9.648 .293 7.471  1810 SM
3 SMB 079 2  B 082 .527 12.496 12.512 21.551 0.274 20.913 0 DW 12
3 SMB 101 6  B 736 .619 26.057 25.338 6.285 .494 6.390 0 MX 24
4 SMB 058  B 767 788 11.496 13.142 23.056 25.116 24.086 0 MX 14.
4 SMB 092 1  B 864 .979 4.986 6.983 19.215 8.619 0 MX 818.917 
5 SMB 032 3  B 084 .765 39.026 896 5.204 .641 4.423  32  35.10 SM
1 57 5  B 003 .099 14.661 13.380 EVK 0 6.457 .612 6.035  1211 SM
16 2  P 075 .505 13.365 14.935  DAP 022 26.596 3.194 24.895 19 DA 16
4 SAB 075 3  P 085 .891 21.021 21.956 2.074 .162 2.618 19 DA 22
5 SMB 093 1  P 089 245 6.089 6.667 24.813 9.672 22.243 19 DA 7.
16 1  P 001 86 7.312 7.586 14.895 6.111 15.503 20 DA 7. DAP 095 
3 K   079 681 17.525 17.603 EG 083 6.661 9.788 8.225 17.19 DAP
3 NAN 027 9  B 066 .174 2.541 3.858 8.377 .513 8.945 8 SA 5
6 SAB 038 1  B 068 487 3.876 3.682 12.973 0.535 11.754 8 SA 3.
8 SMB 021 4  B 072 .293 6.678 7.986 3.978 .348 4.163 8 SA 9
8 SMB 044 1  P 055 233 6.472 7.853 12.774 0.283 11.529 20 DA 9.
7 SAB 004 3  P 059 3.79 13.794 13.792 3.671 .509 20 DA 13.590 
7 SAB 015 1  B 003 .503 6.318 5.411 10.612 0.026 10.319  412 SM
7 97  B 028 .838 1.084 2.461 EVK 0 2.047 2.2 2.124 12 SM  3
7 SAB 079 3  P 023 646 4.414 5.030 3.091 .124 3.108 21 DA  5.
8 EVK 024 2.833 2.558 2.696  9 SAB 021 13.184 13.455 13.320 
8 EVK 030 1.19 2.965 2.078  12 SMB 011 30.071 26.946 28.509 
19 DAP 021 10.33 11.385 10.858  21 DAP 049 7.568 7.162 7.365 
19 DAP 025 1.008 2.655 1.832 2 13.438 9.134 11.286  9 SAB 07
1 FMS 034 9.302 9.808 9.555  9 SAB 076 10.625 4.535 7.580 
1 MCC 112 3.839 1.024 2.432  9 SAB 078 9.408 4.813 7.111 
1 MCC 179 4. 2.354 1.454 904  8 SAB 070 14.434 12.599 13.517 
1 MCC 097 16.801 12.177 15.69 12.409 14.050 14.489 21 DAP 046  
16.432 10.177 1 MCC 128 13.305  10 SAB 037 4.482 5.373 4.928 
1 MCC 148 2.621 3.836 3.229  10 SAB 055 6.265 3.244 4.755 
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Stan ugs dard dr
Boykin compou
1. Raw data for the Alamar Blue® assay 
 
Trypanosoma brucei brucei (STIB 777S / TbAT1 K.
 
 
 
 
 
  A lue or TbA     amar Blue Assay for TbAT1 K.O
nds 
1
O.): 
lamar B Assay f T1 K.O.  Al . 
C  Com IC50 IC50 IC50ompound IC50 IC50 IC50 pound 
  (    ng/m (ng/m (ng/ml)ng/ml) (ng/ml) (ng/ml) ( l) l)  
      Average        Average 
75 14.975 15.787 15.381  9.232 71.908 75.570 828 7
103 1  506 5.782 6.144 8.326 18.764 18.545 832 6.
201 21.147 20.597 20.872  7.211 86.137 81.674 841 7
210 1 1   796 5.074 4.935 8.094 8.416 18.255 846 4.
211 4.312 5.148 4.730  389 6.453 6.421 849 6.
217 2.  8.493 9.941 9.217 899 4.935 3.917 850 
242 8.  851 15.526 15.550 15.538 266 7.496 7.881 
262 4.  1.675 27.14 408 005 4.733 4.369 853 2 1 24.
320 2.545 3.041 2.793  866 23.413 27.865 25.639 
325 2.831 3.461 3.146  8 1.527 0.661 1.094 67 
346 1.187 1.201 1.194  8 0.239 0.215 0.227 77 
351 0.735 0.905 0.820  9 455 26.327 28.891 02 31.
417 3.571 3.627 3.599  9 2.768 2.104 2.436 11 
427 6.148 5.336 5.742  930 20.280 18.78 530 0 19.
484 2.984 3.346 3.165  784 98.170 83.977 935 69.
497 5.929 6.037 5.983  943 4.316 3.502 3.909 
508 4.892 5.332 5.112  127 3.389 3.758 945 4.
544 5.888 6.132 6.010  988 63.518 45.394 54.456 
545 11.798 13.196 12.497  989 3.471 3.777 3.624 
560 2.349 2.893 2.621  994 1.077 1.303 1.190 
609 17.662 19.284 18.473  1012 2.498 2.864 2.681 
690 1.915 2.035 1.975  1016 8.915 9.451 9.183 
746 13.807 13.275 13.541  1017 5.079 4.781 4.930 
763 5.313 6.025 5.669  1019 0.512 0.442 0.477 
773 84.574 59.184 71.879  1023 7.185 6.003 6.594 
820 3.108 2.804 2.956  1044 5.631 4.925 5.278 
 
  ar Blue Assay for TbAT1 K.O. Alam
Drug IC50 IC50 50IC IC50
 /ml (ng/m (ng/ml)  (ng ) l) (ng/ml) 
        Average 
Suramin >100 >10 > 0  0 10 >100 
Diminazene 00 >10 > 0 >1  0 10 >100 
Cymelarsan 2.917 3.364 3. 5 47 3.252 
Q ine 025 81uinapyram >100 81. .043 >87.356 
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Tidwell comp ds 
  Alamar Blue Assay for TbAT1 K.O.     Alamar Blue Assay for TbAT1 K.O. 
Compound IC50 IC50 IC50  Compound IC50 IC50 IC50
  (ng/ml) (ng/ml) (ng/ml)   (ng/ml) (ng/ml) (ng/ml)  
      Average        Average 
1046 >100 8 10 2.778 3.596 3.187 7.380 >93.690  12
1 12.699 18.765 732 1213 0.532 0.696 0.614 049 15.  
1050 7.927 8.241 087 12 4.193 4.689 4.441 8.  14 
1052 7. 4 6.864 7.114  12 13.594  36 20 20.268 16.931
4.251 2.487 369 122 2.551 3.3.  8 531 3.041 1055 
1065 0.136 0.146 141 123 4.762 5.628 5.195 0.  6 
1077 55.628 66.830 .229 123 9.517 9.001 9.259 61  7 
1114 5.538 5.946 742 12 4.733 4.743 4.738 5.  39 
1149 3.861 4.737 299 1242 4.867 6.521 5.694 4.  
1152 0.738 0.624 0.681  1250 0.974 1.662 1.318 
1157 12.066 11.484 11.775  1253 3.565 5.069 4.317 
1159 5.827 5.999 5.91 6.187 5.683 5.935 3  1255 
1164 0.207 0.161 0.184  1258 8.129 6.813 7.471 
1165 0.684 1.752 1.218  1265 4.133 4.033 4.083 
1171 1266 0.397 1.115 0.756  8.879 10.645 9.762 
1172 3.288      2.594 2.941  1271 9.636 9.866 9.751
1173 1272 10.755 11.767 11.261  7.121 6.563 6.842 
1177 4.293 3.043 1283 2.842 2.586 3.668  2.714 
1191 9.451 9.501 9.476  1288 0.485 0.921 0.703 
1192 0.611 0.355 0.483  1340 1.720 0.590 1.155 
1194 1.399 1.875 1.637  1342 8.396 6.894 7.645 
1197 15.106 14.598 14.852  1370 0.567 0.429 0.498 
1206 0.097 0.291 0.194  1371 12.400 11.168 11.784 
oun
 
 
 
 
  r Blu for Tb  lamar Blue Assay for TbAT1 K.O. Alama e Assay AT1 K.O.   A
Co nd  pound 50 50 IC50mpou IC50 IC50 IC50 Com IC IC
   ( /ml) /ml) ng/ml) (ng/ml) ng/ml) (ng/ml)    (ng (ng  (
    Average          Average 
3 023 A 143 100 100 >100 HXC 3.749 4.687 4.218  6 MA > >
5 066 A 085 00 100 >100 BGR 5.858 5.532 5.695  5 MA  >1 >
5 068 O 045 .832 59.756 55.794 BGR 7.415 6.353 6.884  1 KA 51
5 086 L 057 .037 15.299 18.668 BGR 2.619 2.209 2.414  3 ST 22
5 BG >100 R 088 4.687 6.317 5.502  5 MAA 083 >100 >100 
5 094 A 101 .668 100 834 BGR 8.069 7.659 7.864  5 MA 85 > >92.
5 096 A 121 100 100 >100 BGR 8.513 8.121 8.317  5 MA > >
6 012 A 123 ..016 98.342 98.179 BGR 3.983 3.407 3.695  5 MA 98
1 SMB 015  A 137 .177 89.233 86.205 98.561 97.163 97.862  5 MA 83
6 EVK 012 24.937 16.315 20.626  6 MAA 025 27.945 26.717 27.331 
1 RRT 039 28.714 32.682 30.698  2 SAB 087 79.829 90.905 85.367 
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  Alamar Blue Assay for TbAT1 K.O.    K.O.  Alamar Blue Assay for TbAT1
Compound IC50 I nd IC50 IC50 IC50C50 IC50  Compou
  (ng/ml) (   /ml) /ml) l) ng/ml) (ng/ml)  (ng  (ng  (ng/m
            erage Average  Av
3 SMB 051  C 184 .986 4.644 4.315 >100 >100 >100 1 MC 3
3 SMB 065 8  B 038 .720 10.648 11.184 98.613 8.641 93.627 10 SM  11
3 SMB 079  B 082 .318 2.896 3.107 >100 >100 >100 0 DW 3
3 SMB 101 6  B 736 .887 27.669 278 66.198 1.390 63.794 0 MX 20  24.
4 SMB 058  B 767 814 16.370 16.092 >100 >100 >100 0 MX 15.
4 SMB 092  B 864 .932 9.554 9.243 >100 >100 >100 0 MX 8
5 SMB 032 9  B 084 .789 45.379 47.584 87.341 2.963 90.152 10 SM  49
1 57 3  B 003 .527 27.999 32.263 EVK 0 35.825 2.927 34.376 11 SM  36
16  P 075 .298 9.984 12.141  DAP 022 >100 >100 >100 19 DA 14
4 SAB 075 3  P 085 .649 24.311 23.980 25.389 1.549 28.469 19 DA 23
5 SMB 093 1  P 089 .384 14.920 13.652 15.106 9.536 17.321 19 DA 12
16 1  P 001 .356 8.928 9.642  DAP 095 13.398 1.998 12.698 20 DA 10
3 K 39. 36.   079 827 10.611 10.719 EG 083 761 32.849 305 19 DAP 10.
3 NAN 027 4  B 066 .984 1.252 1.118 44.182 1.994 43.088 8 SA 0
6 SAB 038  B 068 .755 1.065 0.910 5.739 6.539 6.139 8 SA 0
8 SMB 021 1  B 072 .887 4.139 4.513 0.724 .020 0.872 8 SA 4
8 SMB 044 1  P 055 .277 6.951 6.614 9.396 0.252 9.824 20 DA 6
7 SAB 004 2  P 059 .247 3.683 3.965 2.538 .812 2.675 20 DA 4
7 SAB 015 6  B 003 .298 2.876 2.587 5.533 .193 5.863 12 SM  2
7 97 1  B 028 .068 6.856 6.962 EVK 0 13.165 4.357 13.761 12 SM  7
7 SAB 079 1  P 023 989 2.085 2.037 2.085 .793 1.939 21 DA  1.
8 EVK 024 38.373 46.283 42.328  9 SAB 021 11.437 10.351 10.894 
8 EVK 030 64.045 53.297 58.671  12 SMB 011 94.338 99.058 96.698 
19 DAP 021 4.308 3.480 3.894  21 DAP 049 10.216 9.448 9.832 
19 DAP 025 1.647 1.987 1.817 72 13.173 10.979 12.076  9 SAB 0
1 FMS 034 8.863 8.329 8.596  9 SAB 076 4.583 4.065 4.324 
1 MCC 112 2.718 2.642 2.680  9 SAB 078 6.672 7.444 7.058 
1 MCC 179 0. 0.566 0.914 740  8 SAB 070 17.746 22.082 19.914 
1 MCC 097 24.591 28.577 26.584  21 DAP 046 6.898 7.360 7.129 
1 MCC 128 3.157 2.609 2.883  10 SAB 037 5.017 4.699 4.858 
1 MCC 148 1.563 2.021 1.792  10 SAB 055 1.968 3.750 2.859 
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Stan rugs dard d
Boy mp
2. Raw data for the L6 Cytotoxicity assay 
 
Rat skeletal myoblast cells (L6 cells): 
 
 
 
 
     
1
kin co ounds 
 
Cytotoxicity Assay for L6 cells Cytotoxicity Assay for L6 cells 
Co IC IC IC50 IC50  Co IC IC50 IC50 IC50mpound 50 50 mpound 50
  (μ μg/m μg/m μg/m     (μg/m μg/m μg/ml) ( g/ml) g/ml) ( l) ( l) ( l) l) ( l) ( μ
        Average          Average 
75 >90 >90 >90 >90  >90 >90 >90 828 >90 
103 >90 >90 >90 >90  >90 >90 >90 832 >90 
201 >90 >90 >90 >90  >90 >90 >90 841 >90 
210 >90 >90 >90 >90  >90 >90 >90 846 >90 
211 >90 >90 >90 >90  >90 >90 >90 849 >90 
217 >90 >90 >90 >90  >90 >90 >90 850 >90 
242 >90 >90 >90 >90  >90 >90 >90 851 >90 
262 8 82 89.43 85.2  >90 >90 >90 4.403 .002 8 8 853 >90 
320 >90 >90 >90 >90  866 >90 >90 >90 >90 
325 >90 >90 >90 >90  >90 >90 >90 867 >90 
346 4. 7 7.911 6.50  >90 >90 >90 195 .394 877 >90 
351 >90 85 >90 88.4  >90 >90 >90 .217  1 902 >90 
417 >90 >90 >90 >90  911 >90 >90 >90 >90 
427 >90 8 >9 89.58.602 0 3  930 >90 >90 >90 >90 
484 >90 >90 >90 >90  >90 >90 >90 935 >90 
497 >90 75 >90 85.2  86. 88.171 >90 8.07 .658  2 943 034 8
508 >90 >90 >90 >90  945 >90 >90 >90 >90 
544 >90 >90 >90 >90  988 >90 >90 >90 >90 
545 6.397 8.195 5.995 6.86  989 >90 >90 >90 >90 
560 >90 >90 >90 >90  994 38.994 39.053 35.488 37.85 
609 >90 >90 >90 >90  1012 >90 >90 >90 >90 
690 >90 >90 >90 >90  1016 >90 >90 >90 >90 
746 50.076 54.92 55.478 53.49  1017 >90 >90 >90 >90 
763 >90 >90 >90 >90  1019 >90 >90 >90 >90 
773 >90 >90 >90 >90  1023 >90 >90 >90 >90 
820 >90 >90 >90 >90  1044 >90 >90 >90 >90 
 
Cytotoxicity Assay for L6 cells   
Drug IC50 IC50 50IC IC50
  l (μg/m (μ ml) (μg/m ) l) g/ (μg/ml) 
        Average 
Suramin >90 >90 >90 >90 
Diminazene 619 4.129 3. 6 4. 52 4.091 
Cymelarsan >90 >90 0 >9 >90 
Q 886 79 84 uinapyramine >90 80. .9 83.623 
Podophylotoxin 0079 0. 79 0.0079 0. 00 0.0079 
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Tidwe omp
  Cytotoxicity Assay for L6 cells    Cytotoxicity Assay for L6 cells 
ll c ounds 
IC50  Compound IC50 IC50 IC50 IC50Compound IC50 IC50 IC50
  (μg/ml) (μg/ml) (μg/ml) (μg/ml)    (μg/ml) (μg/ml) (μg/ml) (μg/ml) 
            Average   Average    
1 >90 >90 0 >9 1210 >90 >90 >90 >90 046 >9 0  
1049 >90 0 >  >90 >90 >90 >90 >9 >90 90 1213 
1050 >90 >90 >90  >90 >90 >90 >90 1214 >90 
1052 36. 401 49.399 .57  >90 >90 898 38. 41 1220 >90 >90 
1055 >90 >90 >9  1 >90 >90 >90 >90 >90 0 228 
1065 >90 90 >  1 >90 >90 >90 >90 > >90 90 236 
1077 >90 >90 >9  1 >90 >90 >90 >90 >90 0 237 
1114 >90 >90 >  >90 >90 >90 >90 >90 90 1239 
1149 >  1242 90 90 >> >90 90 >90 >90 >90 >90 
1152 37.116 30.839 32.518 33.49  1250 >90 >90 >90 >90 
1157 >90 >90 86.521 88.84  1253 >90 >90 >90 >90 
1159 >90 >90 >90 >90 >90 >90 >90 >90  1255 
 1164 >90 >90 >90 >90 1258 >90 >90 >90 >90 
 1165 >90 >90 >90 >90 1265 >90 >90 >90 >90 
1171 69.745 2.83 1266 >90 >90  59.859 58.886 6  >90 >90 
1172 >90        >90 >90 >90  1271 >90 >90 >90 >90
1173 1272 >90 >90 >90 >90  >90 >90 >90 >90 
1177 >90 >90 >90 1283 >90 >90 >90 >90  >90 
1191 >90 >90 >90 >90  1288 >90 >90 >90 >90 
1192 >90 >90 >90 >90  1340 >90 >90 >90 >90 
1194 >90 >90 >90 >90  1342 >90 >90 >90 >90 
1197 >90 >90 >90 >90  1370 >90 >90 >90 >90 
1206 >90 >90 >90 >90  1371 >90 >90 >90 >90 
 
 
 
 
      Cytotoxicity Assay for L6 cells Cytotoxicity Assay for L6 cells 
Co nd I  Com d mpou IC50 IC50 IC50 C50 poun IC50 IC50 IC50 IC50
  ( l) (  (μ ) (μ    (μg/m  (μg/m  (μg/m  (μg/m  μg/m μg/ml) g/ml g/ml) l) l) l) l)
    Average          Average     
3 H 023 >  6 MAA 143 XC >90 >90 >90 90 >90 >90 >90 >90 
5 B 066 >  5 MAA 085 GR >90 >90 >90 90 >90 >90 >90 >90 
5 B 068 >  1 KA 5 GR >90 >90 >90 90 O 04 >90 >90 >90 >90 
5 B 086 >  3 STL 057 GR >90 >90 >90 90 >90 >90 >90 >90 
5 B 088 >  5 MAA 083 GR >90 >90 >90 90 >90 >90 >90 >90 
5 B 094 >  5 MAA 101 GR >90 >90 >90 90 >90 >90 >90 >90 
5 B 096  5 MAA 121 GR >90 >90 >90 >90 >90 >90 >90 >90 
6 B 012 >  5 MAA 123 >90 >90 >90 GR >90 >90 >90 90 >90 
1 SMB 015 >  5 MAA 137 >90 >90 >90 90 >90 >90 >90 >90 
6 EVK 012 >90 >90 >90 >90  6 MAA 025 >90 >90 >90 >90 
1 RRT 039 >90 >90 >90 >90  2 SAB 087 >90 >90 >90 >90 
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  Cytotoxicity Assay for L6 cells     Cytotoxicity Assay for L6 cells 
Compound IC50 50  Co IC ICIC IC50 IC50 mpound 50 IC50 IC50 50
  (μg/ml) ( μ    (μg/ml) (μg/ml) ( g/ml) μg/ml) (μg/ml) (μg/ml) (μg/ml) 
        Average          Average 
3 SMB 051 >90  1 MCC 184 >90 >90 >90 >90 >90 >90 >90 
3 SMB 065 >  10 SMB 038 >90 >90 >90 >90 >90 90 >90 >90 
3 SMB 079 >  0 DWB 082 2 2 2 2>90 >90 >90 90 2.51 8.12 3.58 4.74 
3 SMB 101  0 M  >90 >90 >90 >90 >90 >90 XB 736 >90 >90 
4 SMB 058 >  0 M  3 3 3 3>90 >90 >90 90 XB 767 1.65 3.71 6.08 3.81 
4 SMB 092 >  0 M  >90 >90 >90 >90 >90 90 XB 864 >90 >90 
5 SMB 032 >  10 SMB 084 >90 >90 >90 >90 >90 >90 >90 90 
1 57 >  11 SMB 003 >90 >90 EVK 0 >90 >90 >90 90 >90 >90 
16 >  19 D 5 >90 >90 >90 >90 >90 >90  DAP 022 90 AP 07 >90 
4 SAB 075  19 D 5 >90 >90 >90 >90 >90 >90 AP 08 >90 >90 
5 SMB 093 >  19 D 9 >90 >90 >90 >90 >90 90 AP 08 >90 >90 
16  51  20 D 1 >90 >90  DAP 095 37.58 67.4 48.48 .15 AP 00 >90 >90 
3 83 >  19 D 9 >90 >90 KEG 0 >90 >90 >90 90 AP 07 >90 >90 
3 NAN 027  8 SAB 066 >90 >90 >90 >90 >90 >90 >90 >90 
6 SAB 038 >  8 SAB 068 >90 >90 >90 >90 >90 90 >90 >90 
8 SMB 021 >  8 SAB 072 >90 >90 >90 >90 >90 90 >90 >90 
8 SMB 044 >  20 D 5 >90 >90 >90 >90 >90 90 AP 05 >90 >90 
7 SAB 004 34. 22.  20 DAP >90 >90 >90 >90 13.99 18.94 16 36  059 
7 SAB 015 >  12 SMB 003 >90 >90 >90 >90 >90 90 >90 >90 
7 97 >  12 SMB 028 >90 >90 >90 >90 >90 90 >90 EVK 0 >90 
7 SAB 079 >  21 D 3 >90 >90 >90 >90 >90 90 >90 >90 AP 02
8 EVK 024 >90 >90 >90 >90  9 SAB 021 >90 >90 >90 >90 
8 EVK 030 >90 >90 >90 >90  12 SMB 011 >90 >90 >90 >90 
19 DAP 021 >90 >90 >90 >90  21 DAP 049 >90 >90 >90 >90 
19 DAP 025 >90 >90 >90 >90  9 SAB 072 >90 >90 >90 >90 
1 FMS 034 >90 >90 >90 >9 >90 >90 >90 >90 0  9 SAB 076 
8 EVK 024 >90 >90 >90 >90  9 SAB 021 >90 >90 >90 >90 
8 EVK 030 >90 90  SMB 011 >90 >90  >90 >90 >  12 >90 >90 
19 DAP 021 >90 >90 >90 >90  21 DAP 049 >90 >90 >90 >90 
>90 >90 >90 >90  9 SAB 072 >90 >90 >90 19 DAP 025 >90 
1 FMS 034 >90 >90 >90 >90 >90 >90 >90  9 SAB 076 >90 
1 MCC 112 >90 >90 >90 >90  9 SAB 078 >90 >90 >90 >90 
>90 >90 >90 >90  8 SAB 070 >90 >90 >90 1 MCC 179 >90 
1 MCC 097 >90 >90 >90 >90  21 DAP 046 >90 >90 >90 >90 
1 MCC 128 >90 >90 >90 >90  10 SAB 037 >90 >90 >90 >90 
 >90 >90 >90 >90 >90 >90 >90 1 MCC 148 >90 10 SAB 055 
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13. Raw data for strain sensitivity with the Alamar Blue® assay 
 
 
    Trypanoso a evansi (CAN  / Bra    Trypanosom  evansi bia
 
mar Blue Assay for CAN86/Brazil Al lue A  Colo
m zil):  a86 (Colom ): 
  Ala   amar B ssay for mbia   
 50 IC50 I IC50 IC IIC C50  Compound Compound 50 C50
  (ng/ml) (ng/m (n (ng/ (ng (nl) g/ml)    ml) /ml) g/ml) 
      Average     Av   erage 
Suramin 45.682 42.380 44 in 61.382 58.188 59..031  Suram 785 
Diminazene .758 12.600 12 ene 17.755 14.769 13.11 .179  Diminaz  262 
Cymelarsan 892 1.234 1. rsan 1.473 0.905 1.0. 063 Cymela  189  
Q ine 118 0.180 0. ami 0.157 0.113 0.0.uinapyram 149 Quinapyr ne 135  
2.937 2.225 2. 5 4.146 3.334 3.DB 75 581  DB 7 740 
4.595 4.759 0 3.872 4.278 4.DB 820 4.677  DB 82 075 
3.146 2.652 2. 7 2.311 1.425 1.DB 867 899  DB 86 868 
3.647 4.719 4. 30 6.631 6.447 6.DB 930 183  DB 9 539 
DB 1192 10.211 8.907 9.  92 6.734 9.612 8.559 DB 11 173 
DB 1283 6.084 5.750 5. 83 5.192 5.958 5.917 DB 12 575  
 
 
 
 
    Trypanosom ans zak ):   yp oma evansi (P pines
 
amar Assay azak Alam lue Ass hilip
a ev i (Ka hstan    Tr anos hilip ): 
  Al Blue  for K hstan     ar B ay for P pines 
Compound IC50 IC50 I IC50 IC IC50  Compound 50 C50
  g/ml) (ng/m (n (ng/m (ng/ (n(n l) g/ml)    l) ml) g/ml) 
      Average     Av   erage 
Suramin 59.716 62.034 60 in 50.741 57.003 53..875  Suram 872 
Diminazene .187 13.051 13 ene 11.763 12.509 12.13 .119  Diminaz  136 
Cymelarsan 966 1.440 1. rsan 1.328 1.224 1.0. 203  Cymela  276 
Q ine 073 0.105 0. ami 0.084 0.144 0.uinapyram 0. 089  Quinapyr ne 114 
DB 75 2.279 2.643 2. 5 1.667 0.897 1.461  DB 7 282 
DB 820 5.916 5.348 5. 20 2.953 3.747 3.632  DB 8 350 
DB 867 1.815 2.765 2. 7 1.064 1.546 1.290  DB 86 305 
DB 930 5.341 6.025 5. 0 11.491 9.881 10.683  DB 93 686 
DB 1192 10.562 10.882 10  92 9.833 11.011 10..722 DB 11 422 
DB 1283 5.938 6.620 6.279  DB 1283 9.174 8.114 8.644 
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      Trypanosoma evansi (RoTat 1.2):         Trypanosoma evansi (Vietnam): 
 
  Alamar Blue Assay for RoTat 1.2     Alamar Blue Assay for Vietnam 
Compound IC50 IC50 IC50  Compound IC50 IC50 IC50
  (ng/ml) (ng/ml) (ng/ml)    (ng/ml) (ng/ml) (ng/ml) 
      Average        Average 
Suramin 79.891 72.539 76.215  Suramin 81.638 75.106 78.372 
Diminazene 12.194 12.968 12.581  Diminazene 12.751 12.287 12.519 
Cymelarsan 0.989 1.549 1.269  Cymelarsan 0.963 1.405 1.184 
Quinapyramine 0.167 0.119 0.143  Quinapyramine 0.191 0.139 0.165 
DB 75 2.581 2.735 2.658  DB 75 2.645 2.427 2.536 
DB 820 5.210 4.024 4.617  DB 820 3.975 4.159 4.067 
DB 867 1.437 1.613 1.525  DB 867 1.568 1.358 1.463 
DB 930 3.825 4.365 4.095  DB 930 3.715 4.025 3.870 
DB 1192 9.961 9.807 9.884  DB 1192 10.094 10.552 10.323 
DB 1283 6.198 6.784 6.491  DB 1283 5.581 6.307 5.944 
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In vivo acute efficacy test (mouse model) 14. SOP: 
 
 
Standard parasite strains: None 
U
 
 
Standard conditions: 
 
 
Mice:    M ale mic  22 - 25 g 
 
 
Ca   ac  type II ca
 
 
Mai ce:   
    Pelleted and wat
 
 
Tes dure
N RI fem e,
ges:  M rolon, ges 
ntenan 22 °C and 60 - 70 % relative humidity 
food er ad libitum 
t proce :   
Day 0: All mice in each group (four mice per group), including the 
control group, are infected with a parasite concentration of 
1x104, with the parasite strain being tested. Infection is given 
using an i.p. route, with each mouse receiving 0.25 ml. 
 
Day 3-6: The mice are then treated over four consecutive days, starting 
on day 3 post infection and once a parasitaemia has been 
established. The treatment is also administered using an i.p. 
route. 
 
Day 7: The parasitaemia for all the mice are checked using a tail blood 
examination technique. Thereafter, the parasitaemia is 
monitored twice a week, using the tail blood examination 
technique. 
 
Day 60: Any surviving and aparasitaemic mice are considered cured and 
thus are euthanized on the final day of the experiment. 
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15. Example record sh r the in vivo efficacy test (mo
                                                                                                                                                                                                                                      = Die          reatme
 
eet fo use model) 
                                   D d          T = T nt 
NMRI females   Date : 0 03.05 05.05  11.05       2.05 04.05 06.05           
 
inf. : 29.04.2005 
           
T 0 Days 4 6 12     3 5 7             
  K           D                   
Control R         D                     
  St         D                     
1 KSt             D                 
   Average surviv  = 7.75           al (in days)  
 
                
NMRI females   Date : 03 0  5 23.05 27. 05 6 21.06 28.06 02.05 .05 04.05 5.05 06.05 10.05 17.0 05 30. 07.0 13.06 
 
inf. : 29.04.2005 
           
T 0 Days 24 28 1 53 60 3 4 5 6 7 11 18  3 39 45 
  K   - -  - - T T T T - - -  - - - 
DB 75 R   - -  - - - - T T T T - - -  -
(0.5mg/kg) St   - -  - - - - T T T T - - - -
2 KSt   - - - - - - - T T T T - - - 
   Average survival (in days) = >60           
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Lowest curative doses 
 highlighted in green 
16. Raw data for the in vivo dose-response efficacy test (mouse model) 
 
Trypanosoma evansi (STIB 806K): 
 
 mpound Dose tested (x4) %  survival Average 
are
 
Co
Ide  g u d ) ntity (mg/k mo se)   ( ays
Standard drugs 
Suramin 1 100 >60 
  0.5 75 >51 
  0.25 0 10.75 
Dimin ne 1 75 >43.aze 75 
  0.2 0 8.5 
Cyme n 1 100 >60 larsa
  0.25 100 >60 
  0.2 100 >60 
  0.1  >60 25 100
  0.0625 100 >60 
  0.03125 25 >36.75 
Quinapyramine 1 100 >60 
  0.5 75 >56.75 
  0. >41 25 25 
DB 75 1 100 >60 
  0.5  >60 100
  0.25  >60 100
  0.2 100 >60 
  0.125 >75 55 
  0.0625 >28.50 25 
Boykin 
DB 0.5 0 15  211 
DB 320 1 75 >49.25 
DB 690 1 100 >60 
  0.5 75 >56.25 
DB 1 100 >60  820 
  0.25 100 >60 
  0.2 75 >45.25 
  0.1 >5  25 50 0.25
DB 828 1 0 23.25 
DB  0. 1 850 5 0 5.5 
DB 853 1 0 18.25 
DB 867 1 100 >60 
  0.5 100 >60 
  0.25 75 >53.50 
  0.125 50 >46.00 
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Lowest curative doses 
are highlighted in green 
 Compound Dose tested (x4) %  survival Average 
Identity  (mg/kg mouse)   (days) 
DB 877 1 25 >35 
  0.2 0 12.25 
DB 930 1 100 >60 
  0.5 100 >60 
  0. 25 >37.50 25 
  0. >32.125 25 25 
DB 9  98 0.5 0 26.75 
DB 1012 1 0 12.5 
  0.2 0 8 
DB >   1017 0.5 25 42.50
DB 1019 1 25 >  28.25
DB 1044 0.5 0 16.25 
DB 1046 10.1 0 75 
DB >   1052 1 75 52.75
DB 1055 0.5 0 11.5 
DB 1152 1 0 20.25 
  0.2 0 14.25 
DB >   1171 0.5 25 30.25
D >  B 1172 1 25 38.75
DB 1173 0.5 0 14.5 
DB 1177 0.5 0 12.5 
DB 1191 0.5 0 6.75 
 
DB 1192 0.5 100 >60 
  0.25 50 >50.75 
  0  >  .125 25 28.50
DB 1194 0.5 0 15.75 
DB 1213 0.5 0 26.75 
DB 1220 0.5 0 12.75 
DB 1237 0.5 50 >  46.50
  0.25 0 16 
DB 1253 0.5 0 6.75 
DB 1258 0.5 0 6.75 
DB 1272 0.5 0 18 
DB 1283 1 1  00 >60 
  0.5 100 >60 
  0.  >  25 50 45.50
  0.125 0 22.5 
DB 1288 0.5 0 22.5 
DB 1340 0.5 0 7.5 
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Lowest curative doses 
are highlighted in green 
 Compound Dose tested (x4) %  survival Average 
 Identity (mg/kg mouse)   (days) 
DB 1342 0.5 25 >  33.50
DB 1370 0.5 0 20.75 
DB 1371 0.5 0 14.25 
Tidwell 
3 KE 083 G 1 0 29.25 
4   SAB 075 1 50 >43.25 
  0. 19.5 0 25 
5 MA >29 A 101 1 25 
5 SMB 093 0.5 0 20.25 
8 SAB 066 0.5 50 >38 
9 SAB 021 0.5 0 8.5 
1  2 SMB 003 0.5 0 7.75 
 
 
1  6 DAP 095 1 100 >60 
  0.5 25 >29.25 
  0. 25 >30.25 75 
19 DAP 021 0.5 0 11.75 
19 DAP 025 1 100 >60 
  0.5 75 >56.25 
  0.  25 25 >36 
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17. Protocol:  Preliminary Toxicity Study for DB 75, DB 867 and DB 1192 in goats in the 
Canary Islands. 
 
Mater
 
• e acutainer system - 2 ml (100 pieces) and 5 ml (10 pieces) 
• dorf tubes (for sma transfer) 
• Cryotubes (for plasma storage) 
• s (1000 μl and 100 μl) 
• ponding tips fo pipettes 
• Centrifuge 
 
Experimental procedure: 
 
1) ale Canary goats, weighing between 25 – 30 kg and no less than 6 months old 
rchased from a commercial farm nd transported to the faculty. Once there, 
e housed insi enclosed pens with food and water ad libitum. The goats are 
a week to acc atise to the ne rrounding
 
2) At the start of the toxicity experiment, the goats are divided into three groups of two 
ach group i located to one  the three lead compounds as shown in the 
 
Group  
Number 
mber of  
goats 
Lead  
compound 
Colour on  
timetable chart 
ials: 
Blood collection tub s (v
Eppen  pla
Pipette
Corres r 
Six fem
are pu er a
they ar de 
left for lim w su s. 
goats. E s al  of
table. 
Nu
1 2 DB 75 Green 
2 2 DB 867 Purple 
3 2 DB 1192 Yellow 
 
3) On day 1 of the experiment, a 3 ml blood sample is taken from all 6 goats to 
determine control plasma levels. Each blood sample is inverted 8-10 times to enable 
thorough mixing with lithium heparin (or EDTA) (sprayed on the internal tube walls) 
to prevent coagulation. 
 
4) Once fully mixed, the tubes are placed into a centrifuge and spun at 3000 g for 10 
minutes to separate the blood cells from the plasma. After centrifugation, the plasma 
is removed and placed into a sterile polypropylene cryotube and stored away from 
light at -25 °C. The remaining blood is discarded. 
 
5) On day 2, one goat is taken from group 1 (corresponding to DB 75) and a 2 ml blood 
sample is taken from this goat. This blood sample is also inverted 8-10 times, 
centrifuged at 3000 g for 10 minutes and the plasma removed, placed into a 
polypropylene cryotube and stored away from light at -25 °C. 
 
6) Half an hour later, a 1 ml / 10 kg single compound injection of a 40 mg/ml dose of 
DB 75 is given to this goat. The compound is administered using an intramuscular 
route. Further 2 ml blood samples are taken from the same goat at specific time 
intervals of 15 minutes, 30 minutes, 1 hour, 2 hours, 4 hours, 8 hours, 24 hours and 48 
hours post-injection. 
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step 5. 
 
4, once the final 2ml blood sample has been taken (48 hours), both
7) These eight blood samples are handled in the exact same way as the blood sample in 
8) On day  goats in 
p 1 (corresponding to DB 75) are given a 1 ml / 10 kg compound injection of a 10 
 
9) ond application of a 1 ml / 10 kg 
/ml dose of DB 75 is given to both
grou
mg/ml dose of DB 75. Again the compound is administered using an intramuscular 
route. 
Approximately five minutes BEFORE a sec
compound injection of a 10 mg  goats, 2 hours after 
a 2 ml blood sample is taken from boththe first application was given,  goats in group 
ood samples are taken to determine the trough level of the compound 
within the goats, just before the next compound application is administered. These 
e same as explained in step 5. 
 
1. These bl
blood samples are treated exactly th
10) Similarly, approximately five minutes BEFORE a third application of a 1 ml / 10 kg 
compound injection of a 10 mg/ml dose of DB 75 is given to both goats in group 1, 2 
hours after the second application was given, a 2 ml blood sample is taken from these 
two goats to again determine the trough levels. And similarly to step 9, these blood 
samples are handled in the same way as seen in step 5. 
11)
pound injection of a 10 mg/ml dose of DB 75 is given to both
 
 Approximately five minutes BEFORE a fourth (and final) application of a 1 ml / 10 
kg com  goats, 2 hours 
after the third application was given, a 2 ml blood sample is taken from these two 
goats rmine th gh level. Again the blood sam
desc tep 5. 
 
12) In total, 
 to dete e final trou ples are handled as 
ribed in s
both goats in group 1 have now rec n accumulated com 4 
mg/kg o DB 75 over a 6 hour time period. 
 
13) Further blood samples are taken from e two goats in group 1 at specific 
time intervals of 15 minutes, 30 minutes, 1 hour, 2 hours, 4 hours, 8 hours, 24 hours, 
 
14)
ith the goats in group 3 corresponding with DB 1192.  
 
16) experiments can be visualised in the 
 
 
  
eived a pound dose of 
f 
2 ml  the sam
48 hours, 72 hours and 96 hours after the final (fourth) 1 mg/kg compound 
application. The blood samples are handled as shown in step 5. 
 The procedure steps 5 to 13 are then repeated using the goats in group 2 corresponding 
with DB 867 and then w
 
15) The experiment for group 2 (corresponding with DB 867) starts on day 3, whereas the 
experiment for group 3 (corresponding with DB 1192) begins on day 8. 
 The allocated timing involved in the three toxicity 
timetables for week 1 (days 1 - 7) and week 2 (days 8 - 14). The three different lead
compounds (DB 75, DB 867 and DB 1192) are assigned three different colours 
(green, purple and yellow, respectively) to aid visualisation of the sampling and 
compound administration protocols. 
17) During all three toxicity experiments, all goats must be observed for signs of acute
toxicity, which include tremors, extreme salivation, lacrimation/tearing, abnormal 
urination, rapid onset of diarrhoea, hypotension and possible hypertension. 
Appendix 4: Raw data for Chapter 5 
 
 
Week 1 nday (day 1) es ay Wednesd  3) hursday (da Friday (da  Saturday (d  Sund ) Mo Tu day 2) ay (  T y 4) ay (da(d day y 5) ay 6) y 7
       08.30 
09.00 
T  ake 2ml blood 
sample from goat 1 
for DB 75 
09.40 = 2ml blood 
sample (goat 1-24hr) 
09.24 = 2ml blood 
sample (goat 1-
24hr) 
09.24 = 2ml blood 
sample (goat 1-
48hr) 
  
09.30 
Give single 
4mg/kg injection 
DB  75 (goat 1 only) 
09.40 = 2ml blood 
sample (goat 1-
48hr) 
09.25 + 09.28 = 
Give 1st injection 
(1mg/kg) 2 goats 
  
10.00 
0 09.55 + 1 .10 = 
2m sl blood amples 
(goat 1) 
09.50 + 09.55 = 
Give 1st injection 
(1mg/kg) 2 goats 
   
 
 
 
 
 
10.30 
Take control 
plasma from all 6 
goats (2ml vol.) 
10 l.40 = 2m  blood 
s oample (g at 1-
1hr) 
    
11.00    
11.18 + 11.22 = 
2ml blood sample 
(trough) 2 goats 
  
11.30  
1
Take 2ml sample 
from goat 1 for 
DB867 
09.24 = Give single 
4mg/kg injection 
DB867 (goat 1 only) 
09.39 + 09.54 = 2ml 
blood samples (goat 
1) 
10.24 = 2ml blood 
1hr) sample (goat 1-
 
11.24 = 2ml b1 l.40 = 2m  blood 
s oample (g at 1-
2hr) 
lood 
sample (goat 
11.48 + 11.49 = 
1-2hr) 2ml blood sample 
(trough) 2 goats. 
11.20 + 11.24 = 
Give 2nd injection 
(1mg/kg) 2 goats
  
 
12.00    
11.50 + 11.55 = 
Give 2nd injection    
(1mg/kg) 2 goats 
       12.30 
13.00   
13.23 + 13.26 = 13 lood .24 = 2ml b
sa -4hrmple (goat 1 )  2 e ml blood sampl  trough) 2 goats (
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13.30  
13.42 + 13.44 = 13.40 = 2ml blood 
sample (goat 1-
4hr) 
 2ml blood sample 
(trough) 2 goats. 
13.25 + 13.28 = 
Give 3rd injection   
(1mg/kg) 2 goats 
14.00    
13.45 + 13.50 = 
Give 3rd injection    
(1mg/kg) 2 goats 
14.30        
15.00     
15.23 + 15.26 = 
2ml blood sample 
(trough) 2 goats 
  
15.30     
15.25 + 15.28 =  
Give 4th injection  
(1mg/kg) 2 goats 
15.25 + 15.28 = 15.25 + 15.28 =  
2ml ood  bl2ml blood samples 
samples (2 goats-(2 goats-24hr) 
16.00    
16.05 + 16.10 = 
2ml bl  sample ood
(trough) 2 goats. 
16.15 + 16.20 = 16.15 + 16.20 =  
2ml blood samples 
(2 goats-48hr) 
2ml ood  bl
samples (2 goats-
16.30    
15.40 + 5.43 =  1
2ml blood samples 
(2 goats) 15.55 + 
15.58 = 1ml blood 
samples (2 goats) 
16.15 + 16.20 =  
Give 4th injection    
(1mg/kg) 2 goats 
17.00   17.24 = 2ml blood sample (goat 1-8hr) 
16.15 + 16.20 = 
2ml blood samples 
(2 goats-24hr) 
  
17.30  
17.40 = l blood  2m
samp oat 1-le (g
8hr) 
 
16.25 + 16.28 = 
2ml blood samples 
(2 goats-1hr) 
  
18.00    
17.25 + 17.28 =  
2ml blood samples 
(2 goats-2hr) 
  
18.30    
16.30 + 16.35 = 
2ml blood samples 
(2 goats) 16.45 + 
16.50 = 2ml blood 
samples (2 goats) 
 
17.15 + 17.20 
=2ml lood  b
samples (2 goats-
1hr) 
18.15 + 18.20 =  
2ml blood samples   
(2 goats-2hr) 
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19.00        
19.30     
19.25 + 19.28 = 
2ml bloo  samples d
(2 go 4hr) ats-
  
20.00    
20.15 + 20.20 = 
2ml bloo  samples d
(2 go 4hr) ats-
   
20.30        
21.00        
21.30        
22.00        
22.30        
23.00     
23.25 + 23.28 = 
2ml blood samples 
(2 goats-8hr) 
  
23.30    
23.30 + 23.35 = 
2ml blood samples 
(2 goats-8hr) 
   
00.00        
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Week 2 Monday (day 8) Tuesday (day 9) Wednesday (day 10) Thursday (day 11) Friday (day 12) Saturday (day 13) Sunday (day 14) 
07.45 = 2ml blood Take 2ml blood 07.45 = 2ml blood 08.30 sample from goat 1 
for D 1192 B
sample (goat 1-
24 r) h sample (goat 1-48hr) 
    
09.00  
07.50 + 07.55 = Give 
1st injection (1mg/kg) 
2 s 
   
 goat
 
09.30  
09.48 + 09.53 = 2ml 
blood sample 
(trough) 2 goats.  
   
09.50 + 09.55 = 
2ml blood 
samples 2 goats- (
10.00  
09.50 + 09.55 = Give 
2nd injection 
(1mg/k  2 goats 
    
g)
10.30       
11.00  
11.48 + 11.53 = 2ml 
blood sample 
(trough) 2 goats.  
    
Give single 
4mg/kg jection  in
DB1192 (goat 1 
only) 
08.00 + 8.15 =  0
2ml blood samples 
(goat 1) 
08.45 = l blood  2m
samp oat 1-le (g
1hr) 
09.45 = l blood  2m
samp oat 1-le (g
2hr)  
 
11.45 = l blood  2m
sample (goat 1- 11.50 + 11.55 = Give 
4hr)  11.30 3rd injection 
(1mg/k  2 goats 
    
g)
12.00        
12.30        
13.00   
13.48 + 13.53 = 2ml 
blood sample     
(trough) 2 goats  
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13.30   
13.50 + 13.55 = 
2ml blood samples 
(2 goats-24hr) 
13.50 + 13.55 = 
2ml blood 
samples (2 goats-
13.50 + 13.55 = 2ml 
blood samples (2 
goats-72hr) 
 
14.00       
14.30       
15.00 
15.25 + 15.28 = 
2 s ml bl pleood sam
(2 goats-72hr) 
13.50 + 13.55 = Give 
4th injection 
(1mg/kg) 2 goats 
 
14.05 + 14.10 = 2ml 
blood samples (2 
goats) 14.20 + 14.25 
= 2ml blood samples 
(2 goats) 
 
14.50 + 14.55 = 2ml 15.25 + 15.28 =  b 2 lood samples (
goats-1hr)  2ml blood samples (2 goats-96hr) 
   
15.30 
15.45 = 2ml blood 
sample (goat 1-
8hr) 
 
15.50 + 15.55 = 2ml 
blood samples (  2
goats-2hr) 
    
16.00 
16.15 + 16.20 = 
2ml blood samples 
(2 goats-96hr) 
      
16.30        
17.00        
17.30   
17.50 + 1 .55 = 2ml 7
blood samples (2 
goats-4hr) 
    
18.00        
18.30        
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19.00        
19.30        
20.00        
20.30        
21.00        
21.30   
21.5 2ml 0 + 21.55 = 
blood samples (2 
goat 8hr) s-
    
22.00        
22.30        
23.00        
23.30        
00.00        
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18. Raw data for the in vivo preliminary toxicity test (goat model) 
 
        DB 75 (4 mg/kg): Goat 0823             DB 75 (4 x 1 mg/kg): Goat 0865 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
        DB 867 (4 mg/kg): Goat 0866            DB 867 (4 x 1 mg/kg): Goat 0850 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sample Time  (hrs) 
Concentration 
(ng/ml) 
 
 
 
 
 
Sample Time  (hrs) 
Concentration 
(ng/ml) 
0 0.00 No peak 1st trough 1.97 1030 
15 mins 0.25 3690 2nd trough 3.97 1530 
30 mins 0.50 2910 3rd trough 5.97 1790 
1 hr 1.00 3290 15 mins 6.25 1830 
2 hrs 2.00 3560 30 mins 6.50 1790 
4 hrs 4.00 3290 1 hr 7.00 1810 
8 hrs 8.00 3680 2 hrs 8.00 1570 
24 hrs 24.00 3320 4 hrs 10.00 1610 
48 h .00 0 rs 48 308 8 hrs 14.0 10 0 15
24 hrs 30.00 1590 
48 hrs 54.00 1390 
72 hrs 78.00 1490 
96 hrs 102.00 1060 
Sample Time  rs) 
Concentration 
(ng/ml) (h
Sample Time  (hrs
Concentration 
g/ml) ) (n
0 0.00 No peak 1st trough 1.97 3360 
15 mins 0.25 2260 2nd trough 3.97 3090 
30 mins 0.50 2880 3rd trough 5.97 3070 
1 hr 1.00 1850 15 mins 6.25 2520 
2 hrs 2.00 2420 30 mins 6.50 2970 
4 hrs 4.00 2390 1 hr 7.00 3390 
8 hrs 8.00 1930 2 hrs 8.00 3210 
24 hrs 24.00 2580 4 hrs 10.00 3010 
48 hrs 48.00 2510 8 hrs 14.00 3010 
24 hrs 30.00 3330 
48 hrs 54.0 40 0 33
72 hrs 78.00 3090 
96 hrs 102.00 2680 
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      DB 1192 (4 mg/kg): Goat 0818           DB 1192 (4 x 1 mg/kg): Goat Grey  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sample Time  (hrs) 
Concentration 
(ng/ml) 
Sample Time  (hrs) 
Concentration 
(ng/ml) 
0 0.00 No peak 1  trough st 1.97 265 
15 mins 0.25 1980 2  trough nd 3.97 338 
30 mins 0.50 1840 3  trough rd 5.97 560 
1 hr 1.00 774 15 mins 6.25 585 
2 hrs 2.00 446 30 mins 6.50 762 
4 hrs 4.00 561 1 hr 7.00 631 
8 hrs 8.00 346 2 hrs 8.00 570 
24 hrs 24.00 140 4 hrs 10.00 475 
48 hrs 48.00 193 8 hrs 14.00 352 
24 hrs 30.00 59.1 
48 hrs 54.00 51.4 
72 hrs 78.00 28.7 
96 hrs 102.00 29.7 
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19. Protocol:  “Proof of Concept” Trial for DB 75, DB 867 and DB 1192 in goats 
in the Canary Islands. 
xperimental procedure: 
 
enty  female Canary goats, weighing between 20 – 52 kg and no less than 6 
months are pur rom a commercial fa  tran ted to th ulty. 
nce t they are ed insi e enclosed fly-proof pens with food and water ad 
. The goats are left for a week to acclimatise to the new surroundings. 
ial, the goats are divided into seven groups of three goats 
with four goats in the control group. Each group is a
nd trea t schedu shown  the table below
 
Group  
Numbe  
ber of  Test  
compound 
ment  
 
E
18) Tw -five
 old chased f rmer and spor e fac
O
libitum
here,  hous d
 
19) At the start of the efficacy tr
llocated to a specific com
. 
pound 
a tmen le as in
Num
goats r
Treat
schedule 
1 4 None ne No
2 3 Diminazen /kg e 5 mg
3 3 DB 75 g/kg 2.5 m
4 3 DB 867 /kg  2.5 mg
5 3 DB 1192 2.5 mg/kg 
6 3 DB 75 1.25 mg/kg 
7 3 DB 867 1.25 mg/kg 
8 3 DB 1192 1.25 mg/kg 
 
20) On day 1 of the experiment, a 4 ml blood sample is taken from all 25 goats to 
determine that the goats are not infected.  
 
21) Once the blood samples have been collected, the blood is tested using several 
detection techniques. These include: 
 
a. Microscopic/direct method = Haematocrit technique (Woo) 
b. Serological/Antibody method = CATT/T. evansi technique 
c. DNA detection method = PCR/T. evansi technique 
 
22) Once all goats have been successfully checked for no previous T. evansi infection, all 
25 goats can be infected using T. evansi infected blood isolated from a highly 
parasitaemic camel found positive for T. evansi infection. 
 
23) The goats are infected with a 106 / ml parasite concentration, using an intravenous 
route of application. 
 
24) A previous blood sample taken from the positive camel will be used to count and 
calculate the respective concentration of the trypanosomes within the camel blood. 
Thereafter, the trypanosome suspension will be calculated as required and 
administered to the goats at a total volume of 1 ml / goat. 
 
25) The goats are then regularly checked for the presence of parasitaemia within the 
peripheral blood, using all three detection methods. 
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2 ill 
commence (approximately . 
 
n using an intramuscular route of four applications, spread 
 the corresponding scheduled compound dose depending on the 
28)
 
 
 
20. Agarose gels of goat samples for the PCR / T. evansi method 
 
After experimental infection with T. evansi pound treatment: 
 
6) As soon as all groups of goats become positive for T. evansi infection, treatment w
one month post infection)
27) Treatment will be give
over eight days for
group number. 
 
 After treatment, the goats are checked regularly over the next five months, to 
determine the presence/absence of T. evansi infection and hence the efficacy of the 
test compounds used in this trial. 
 
, yet before com
 
 
 
r   Lane 9. 7390 (BD 75) 
tive control 
Lane 7. 7339 (DB 867)   Lane 14. Ladder 
Lane 1. 1773 (Diminazene)  Lane 8. 7319 (DB 867)  
Lane 2. Ladde
Lane 3. 7396 (Diminazene)   Lane 10. 7324 (DB 75)  
Lane 4. 7388 (Diminazene)   Lane 11. 5406 (DB 75)  
Lane 5. 7372 (DB 867)   Lane 12. Nega
Lane 6. 7341 (DB 867)   Lane 13. Positive control 
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All
the eg
 
 
 
 lanes show a positive reaction for parasite DNA except for the ladder lanes (2 and 14) and 
ative control (lane 12).  n
 
After experimental infection with T. evansi and two weeks after compound treatment: 
 
 
 
Lane 1. Negative control   Lane 10. 7374 (Control)  
Lane 2. Positive control  Lane 11. 7314 (Control)  
Lane 3. Ladder    Lane 12. 1773 (Diminazene)   
Lane 4. 7341 (DB 867)   Lane 13. 7396 (Diminazene)  
Lane 5. 7372 (DB 867)   Lane 14. 7388 (Diminazene)  
Lane 6. 7379 (DB 1192)   Lane 15. 7390 (DB 75) 
Lane 7. 7387 (DB 1192)   Lane 16. 7324 (DB 75)  
Lane 8. 2255 (Control)    Lane 17. 5406 (DB 75) 
 
 
Lanes 2, 6, 7, 8, 9, 10 and 11 are positive for parasite DNA. 
 
Lane 9. 7397 (Control) 
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21. Protocol:  Pharmacokinetic trial for DB 75, DB 867 and DB 1192 in goats in the 
 
Canary Islands. 
xperimental procedure: 
29) Twenty-five female Canary goats, weighing between 20 – 52 kg and no less than 6 
lty. 
ad 
libitum. The goats are left for a week to acclimatise to the new surroundings. 
 
30) At the start of the pharmacokinetic trial, the goats are divided into seven groups of 
three goats with four goats in the control group. Each group is allocated to a specific 
compound and treatment schedule as shown in the table below. 
 
Group  
Number 
Number of  
goats 
Test 
compound 
Treatment  
schedule 
E
 
months old are purchased from a commercial farmer and transported to the facu
Once there, they are housed inside enclosed fly-proof pens with food and water 
1 4 None None 
2 3 Diminazene 5 mg/kg 
3 3 DB 75 2.5 mg/kg 
4 3 DB 867 2.5 mg/kg 
5 3 DB 1192 2.5 mg/kg 
6 3 DB 75 1.25 mg/kg 
7 3 DB 867 1.25 mg/kg 
8 3 DB 1192 1.25 mg/kg 
 
31) On day 4 ml bloo all 25 goats to 
determ t 3000 g for ten 
minutes, the plasm  stored frozen 
at -80 °
 
32) Once a sfull  check fection, all 
25 goats can be infected using T. evansi  a highly 
parasit o T. eva
 
33) The go 6 / ml parasite concentration, using an intravenous 
route o
 
34) A previous blood sam  the pos
calculate the respective concentration of the trypanosomes within the camel blood. 
Thereafter, the trypanosome suspension will be calculated as required and 
administered to the goats at a total volume of 1 ml / goat.  
r T. evansi infection, compound 
treatment will commence (approximately one month post infection). 
 
36) Treatment will be given using an intramuscular route of four applications, spread 
over eight days for the corresponding scheduled compound dose depending on the 
group number. 
 1 of the experiment, a d sample is taken from 
ine that the goats are not infected. The sample is centrifuged a
a removed and placed into plastic cryotubes and then
C. 
ll goats have been succes y ed for no previous T. evansi in
 infected blood isolated from
aemic camel found positive f r nsi infection. 
ats are infected with a 10
f application. 
ple taken from itive camel will be used to count and 
 
35) As soon as all groups of goats become positive fo
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37) Blood samples will be collected from each of the goats, shortly before the ne
. This will provid
xt 
compound injection is applied e data on the trough levels for each 
compound tested for each goat. 
 final compound injection has been applied, blood samples will be 
 
39)
000 g for 
 
40) ity of North Carolina, 
Chapel Hill, HPLC and 
dete  concen pound he plasma en. 
 
 
38) After the fourth and
taken from each goat at the following time points: 0.5, 1, 2, 4, 8, 24, 48, 96 and 192 
hours post-treatment. 
 All blood samples taken will be immediately placed on ice and thereafter transported 
to the laboratory for plasma preparation. The samples will be centrifuged at 3
ten minutes, the plasma removed and placed into plastic cryotubes for storage at -80 
°C. 
 Thereafter, the plasma samples will be shipped to the Univers
 USA, where they will be analys
trat  com
ed using MS techniques to 
 akrmine the ion of  present in t samples t
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22.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DB 75 (1.25 mg/kg):      DB 867 (2.5 mg/kg): 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Samp /ml) 
 Raw data for the in vivo pharmacokinetic trial (goat model) 
Diminazene (5 mg/kg):     DB 75 (2.5 mg/kg): 
 
le Time  (hrs) 
Concentration 
(ng
 
 
 
 
 
 
 
Sample (hrs) (ng/ml) 
Time  Concentration 
2nd trough 95.97 1750 
3rd trough 143.97 1577 
30 mins 144.50 2530 
2nd trough 95.97 900 
3rd trough 143.97 840 
30 mins 144.50 8637 
1 hr 145.00 6017  1 hr 145.00 2110 
2 hrs 146.00 2227 
4 hrs 148.00 2193 
8 hrs 152.00 212
2 hrs 146.00 5420 
4 hrs 148.00 2893 
8 hrs 152.00 2093 0 
24 hrs 168.00 1258 24 hrs 168.00 1630 
48 hrs 192.00 965 48 hrs 192.00 1706 
96 hrs 240.00 861 96 hrs 240.00 2140 
192 hrs 336.00 568 192 hrs 336.00 1600 
Sample Time  (hrs) 
Concentration 
(ng/ml) Sample 
Time  
(hrs) 
Concentration 
(ng/ml) 
2nd trough 95.97 1915 2nd trough 95.97 1610 
3rd trough 143.97 2380 3rd trough 143.97 1847 
30 mins 144.50 2890 30 mins 144.50 3310 
1 hr 145.00 3115 1 hr 145.00 3263 
2 hrs 146.00 2740 2 hrs 146.00 2813 
4 hrs 148.00 2090 4 hrs 148.00 2673 
8 hrs 152.00 2475 8 hrs 152.00 2390 
24 hrs 168.00 1835 24 hrs 168.00 2140 
48 hrs 192.00 2070 48 hrs 192.00 1910 
96 hrs 240.00 2375 96 hrs 240.00 1793 
192 hrs 336.00 1540 192 hrs 336.00 1683 
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Appendix 6: Raw data for Chapter 7 
 
 
 
 
DB 867 (1.25 mg/kg):            DB 1192 (2.5 mg/kg): 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DB 1192 (1.25 mg/kg): 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sample Time  (hrs) 
Concentration 
(ng/ml) 
Sample Time  (hrs) 
Concentration 
(ng/ml) 
2nd trough 95.97 1877 2nd trough 95.97 28 
3rd trough 143.97 2257 3rd trough 143.97 46 
30 mins 144.50 3663 30 mins 144.50 1563 
1 hr 145.00 3340 1 hr 145.00 1020 
2 hrs 146.00 2933 2 hrs 146.00 474 
4 hrs 148.00 2723 4 hrs 148.00 278 
8 hrs 152.00 2533 8 hrs 152.00 203 
24 hrs 168.00 2310 24 hrs 168.00 78 
48 hrs 192.00 2067 48 hrs 192.00 40 
96 hrs 240.00 1960 96 hrs 240.00 23 
192 hrs 336.00 1637 192 hrs 336.00 10 
Sample Time  (hrs) 
Concentration 
(ng/ml) 
2nd trough 95.97 17 
3rd trough 143.97 19 
30 mins 144.50 836 
1 hr 145.00 738 
2 hrs 146.00 170 
4 hrs 148.00 108 
8 hrs 152.00 69 
24 hrs 168.00 23 
48 hrs 192.00 18 
96 hrs 240.00 18 
192 hrs 336.00 9 
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